
<html lang="en"     class="pb-page"  data-request-id="26c2fb55-7c64-4846-832a-4f099e62738c"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;article:article:10.1021/acs.jmedchem.0c00100;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2020.63.issue-18;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Discovery of GS-9688 (Selgantolimod) as a Potent and Selective Oral Toll-Like Receptor 8 Agonist for the Treatment of Chronic Hepatitis B" /></meta><meta name="dc.Creator" content="Richard L.  Mackman" /></meta><meta name="dc.Creator" content="Michael  Mish" /></meta><meta name="dc.Creator" content="Gregory  Chin" /></meta><meta name="dc.Creator" content="Jason K.  Perry" /></meta><meta name="dc.Creator" content="Todd  Appleby" /></meta><meta name="dc.Creator" content="Vangelis  Aktoudianakis" /></meta><meta name="dc.Creator" content="Sammy  Metobo" /></meta><meta name="dc.Creator" content="Peter  Pyun" /></meta><meta name="dc.Creator" content="Congrong  Niu" /></meta><meta name="dc.Creator" content="Stephane  Daffis" /></meta><meta name="dc.Creator" content="Helen  Yu" /></meta><meta name="dc.Creator" content="Jim  Zheng" /></meta><meta name="dc.Creator" content="Armando G.  Villasenor" /></meta><meta name="dc.Creator" content="Jeff  Zablocki" /></meta><meta name="dc.Creator" content="Jason  Chamberlain" /></meta><meta name="dc.Creator" content="Haolun  Jin" /></meta><meta name="dc.Creator" content="Gary  Lee" /></meta><meta name="dc.Creator" content="Kimberley  Suekawa-Pirrone" /></meta><meta name="dc.Creator" content="Rex  Santos" /></meta><meta name="dc.Creator" content="William E.  Delaney, IV" /></meta><meta name="dc.Creator" content="Simon P.  Fletcher" /></meta><meta name="dc.Description" content="Toll-like receptor 8 (TLR8) recognizes pathogen-derived single-stranded RNA fragments to trigger innate and adaptive immune responses. Chronic hepatitis B (CHB) is associated with a dysfunctional i..." /></meta><meta name="Description" content="Toll-like receptor 8 (TLR8) recognizes pathogen-derived single-stranded RNA fragments to trigger innate and adaptive immune responses. Chronic hepatitis B (CHB) is associated with a dysfunctional i..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="May 14, 2020" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c00100" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2020 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00100" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c00100" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00100" /></link>
        
    
    

<title>Discovery of GS-9688 (Selgantolimod) as a Potent and Selective Oral Toll-Like Receptor 8 Agonist for the Treatment of Chronic Hepatitis B | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c00100" /></meta><meta property="og:title" content="Discovery of GS-9688 (Selgantolimod) as a Potent and Selective Oral Toll-Like Receptor 8 Agonist for the Treatment of Chronic Hepatitis B" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00100/20200918/images/large/jm0c00100_0015.jpeg" /></meta><meta property="og:description" content="Toll-like receptor 8 (TLR8) recognizes pathogen-derived single-stranded RNA fragments to trigger innate and adaptive immune responses. Chronic hepatitis B (CHB) is associated with a dysfunctional immune response, and therefore a selective TLR8 agonist may be an effective treatment option. Structure-based optimization of a dual TLR7/8 agonist led to the identification of the selective TLR8 clinical candidate (R)-2-((2-amino-7-fluoropyrido[3,2-d]pyrimidin-4-yl)amino)-2-methylhexan-1-ol (GS-9688, (R)-7). Potent TLR8 agonism (IL-12p40 EC50 = 220 nM) and &gt;100-fold TLR7 selectivity (IFN-α EC50 &gt; 50 μM) was observed in human peripheral blood mononuclear cells (PBMCs). The TLR8-ectodomain:(R)-7 complex confirmed TLR8 binding and a direct ligand interaction with TLR8 residue Asp545. Oral (R)-7 had good absorption and high first pass clearance in preclinical species. A reduction in viral markers was observed in HBV-infected primary human hepatocytes treated with media from PBMCs stimulated with (R)-7, supporting the clinical development of (R)-7 for the treatment of CHB." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c00100"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00100">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c00100&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c00100&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c00100&amp;href=/doi/10.1021/acs.jmedchem.0c00100" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 18</span><span class="cit-fg-pageRange">, 10188-10203</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/18" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c00415" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Drug Annotation</span><a href="/doi/10.1021/acs.jmedchem.0c00259" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of GS-9688 (Selgantolimod) as a Potent and Selective Oral Toll-Like Receptor 8 Agonist for the Treatment of Chronic Hepatitis B</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Richard L. Mackman</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Richard L. Mackman</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Phone: 650 522 5258. Email: <a href="/cdn-cgi/l/email-protection#afddc6ccc7ceddcb81c2ceccc4c2cec1efc8c6c3cacecb81ccc0c2"><span class="__cf_email__" data-cfemail="9ae8f3f9f2fbe8feb4f7fbf9f1f7fbf4dafdf3f6fffbfeb4f9f5f7">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Richard+L.++Mackman">Richard L. Mackman</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-8861-7205" title="Orcid link">http://orcid.org/0000-0001-8861-7205</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Michael Mish</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Michael Mish</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Michael++Mish">Michael Mish</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Gregory Chin</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Gregory Chin</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Gregory++Chin">Gregory Chin</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jason K. Perry</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jason K. Perry</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jason+K.++Perry">Jason K. Perry</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-5492-0652" title="Orcid link">http://orcid.org/0000-0001-5492-0652</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Todd Appleby</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Todd Appleby</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Todd++Appleby">Todd Appleby</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Vangelis Aktoudianakis</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Vangelis Aktoudianakis</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Vangelis++Aktoudianakis">Vangelis Aktoudianakis</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Sammy Metobo</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sammy Metobo</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sammy++Metobo">Sammy Metobo</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Peter Pyun</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Peter Pyun</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Peter++Pyun">Peter Pyun</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Congrong Niu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Congrong Niu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Congrong++Niu">Congrong Niu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Stephane Daffis</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Stephane Daffis</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Stephane++Daffis">Stephane Daffis</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Helen Yu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Helen Yu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Helen++Yu">Helen Yu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jim Zheng</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jim Zheng</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jim++Zheng">Jim Zheng</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Armando G. Villasenor</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Armando G. Villasenor</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Armando+G.++Villasenor">Armando G. Villasenor</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jeff Zablocki</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jeff Zablocki</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jeff++Zablocki">Jeff Zablocki</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jason Chamberlain</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jason Chamberlain</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jason++Chamberlain">Jason Chamberlain</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Haolun Jin</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Haolun Jin</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Haolun++Jin">Haolun Jin</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Gary Lee</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Gary Lee</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Gary++Lee">Gary Lee</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Kimberley Suekawa-Pirrone</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kimberley Suekawa-Pirrone</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kimberley++Suekawa-Pirrone">Kimberley Suekawa-Pirrone</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Rex Santos</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Rex Santos</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Rex++Santos">Rex Santos</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">William E. Delaney IV</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">William E. Delaney, IV</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=William+E.++Delaney%2C++IV">William E. Delaney, IV</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Simon P. Fletcher</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Simon P. Fletcher</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Simon+P.++Fletcher">Simon P. Fletcher</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00100&amp;href=/doi/10.1021%2Facs.jmedchem.0c00100" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 18</span><span class="cit-pageRange">, 10188–10203</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">May 14, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>18 January 2020</li><li><span class="item_label"><b>Published</b> online</span>14 May 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 24 September 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c00100" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00100</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D10188%26pageCount%3D16%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DRichard%2BL.%2BMackman%252C%2BMichael%2BMish%252C%2BGregory%2BChin%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D18%26contentID%3Dacs.jmedchem.0c00100%26title%3DDiscovery%2Bof%2BGS-9688%2B%2528Selgantolimod%2529%2Bas%2Ba%2BPotent%2Band%2BSelective%2BOral%2BToll-Like%2BReceptor%2B8%2BAgonist%2Bfor%2Bthe%2BTreatment%2Bof%2BChronic%2BHepatitis%2BB%26numPages%3D16%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D10203%26publicationDate%3DSeptember%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c00100"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2947</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">16</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c00100" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of GS-9688 (Selgantolimod) as a Potent and Selective Oral Toll-Like Receptor 8 Agonist for the Treatment of Chronic Hepatitis B&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Richard&quot;,&quot;last_name&quot;:&quot;L. Mackman&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;Mish&quot;},{&quot;first_name&quot;:&quot;Gregory&quot;,&quot;last_name&quot;:&quot;Chin&quot;},{&quot;first_name&quot;:&quot;Jason&quot;,&quot;last_name&quot;:&quot;K. Perry&quot;},{&quot;first_name&quot;:&quot;Todd&quot;,&quot;last_name&quot;:&quot;Appleby&quot;},{&quot;first_name&quot;:&quot;Vangelis&quot;,&quot;last_name&quot;:&quot;Aktoudianakis&quot;},{&quot;first_name&quot;:&quot;Sammy&quot;,&quot;last_name&quot;:&quot;Metobo&quot;},{&quot;first_name&quot;:&quot;Peter&quot;,&quot;last_name&quot;:&quot;Pyun&quot;},{&quot;first_name&quot;:&quot;Congrong&quot;,&quot;last_name&quot;:&quot;Niu&quot;},{&quot;first_name&quot;:&quot;Stephane&quot;,&quot;last_name&quot;:&quot;Daffis&quot;},{&quot;first_name&quot;:&quot;Helen&quot;,&quot;last_name&quot;:&quot;Yu&quot;},{&quot;first_name&quot;:&quot;Jim&quot;,&quot;last_name&quot;:&quot;Zheng&quot;},{&quot;first_name&quot;:&quot;Armando&quot;,&quot;last_name&quot;:&quot;G. Villasenor&quot;},{&quot;first_name&quot;:&quot;Jeff&quot;,&quot;last_name&quot;:&quot;Zablocki&quot;},{&quot;first_name&quot;:&quot;Jason&quot;,&quot;last_name&quot;:&quot;Chamberlain&quot;},{&quot;first_name&quot;:&quot;Haolun&quot;,&quot;last_name&quot;:&quot;Jin&quot;},{&quot;first_name&quot;:&quot;Gary&quot;,&quot;last_name&quot;:&quot;Lee&quot;},{&quot;first_name&quot;:&quot;Kimberley&quot;,&quot;last_name&quot;:&quot;Suekawa-Pirrone&quot;},{&quot;first_name&quot;:&quot;Rex&quot;,&quot;last_name&quot;:&quot;Santos&quot;},{&quot;first_name&quot;:&quot;William&quot;,&quot;last_name&quot;:&quot;E. Delaney&quot;},{&quot;first_name&quot;:&quot;Simon&quot;,&quot;last_name&quot;:&quot;P. Fletcher&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;05&quot;,&quot;day&quot;:&quot;14&quot;,&quot;issue&quot;:&quot;18&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;10188-10203&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c00100&quot;},&quot;abstract&quot;:&quot;Toll-like receptor 8 (TLR8) recognizes pathogen-derived single-stranded RNA fragments to trigger innate and adaptive immune responses. Chronic hepatitis B (CHB) is associated with a dysfunctional immune response, and therefore a selective TLR8 agonist may be an effective treatment option. Structure-based optimization of a dual TLR7/8 agonist led to the identification of the selective TLR8 clinical candidate (R)-2-((2-amino-7-fluoropyrido[3,2-d]pyrimidin-4-yl)amino)-2-methylhexan-1-ol (GS-9688, (R)-7). Potent TLR8 agonism (IL-12p40 EC50 = 220 nM) and &gt;100-fold TLR7 selectivity (IFN-α EC50 &gt; 50 μM) was observed in human peripheral blood mononuclear cells (PBMCs). The TLR8-ectodomain:(R)-7 complex confirmed TLR8 binding and a direct ligand interaction with TLR8 residue Asp545. Oral (R)-7 had good absorption and high first pass clearance in preclinical species. A reduction in viral markers was observed in HBV-infected primary human hepatocytes treated with media from PBMCs stimulated with (R)-7, supporting the cl&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00100&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00100" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00100&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00100" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00100&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00100" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00100&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00100&amp;href=/doi/10.1021/acs.jmedchem.0c00100" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c00100" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c00100" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c00100%26sid%3Dliteratum%253Aachs%26pmid%3D32407112%26genre%3Darticle%26aulast%3DMackman%26date%3D2020%26atitle%3DDiscovery%2Bof%2BGS-9688%2B%2528Selgantolimod%2529%2Bas%2Ba%2BPotent%2Band%2BSelective%2BOral%2BToll-Like%2BReceptor%2B8%2BAgonist%2Bfor%2Bthe%2BTreatment%2Bof%2BChronic%2BHepatitis%2BB%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D18%26spage%3D10188%26epage%3D10203%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (6)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292589" title="Agonists">Agonists</a>,</li><li><a href="/action/doSearch?ConceptID=291439" title="Genetics">Genetics</a>,</li><li><a href="/action/doSearch?ConceptID=292444" title="Molecular structure">Molecular structure</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/18" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/jmcmar.2020.63.issue-18/20200924/jmcmar.2020.63.issue-18.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00100/20200918/images/medium/jm0c00100_0015.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00100/20200918/images/large/jm0c00100_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00100&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Toll-like receptor 8 (TLR8) recognizes pathogen-derived single-stranded RNA fragments to trigger innate and adaptive immune responses. Chronic hepatitis B (CHB) is associated with a dysfunctional immune response, and therefore a selective TLR8 agonist may be an effective treatment option. Structure-based optimization of a dual TLR7/8 agonist led to the identification of the selective TLR8 clinical candidate (<i>R</i>)-2-((2-amino-7-fluoropyrido[3,2-<i>d</i>]pyrimidin-4-yl)amino)-2-methylhexan-1-ol (GS-9688, (<i>R</i>)-<b>7</b>). Potent TLR8 agonism (IL-12p40 EC<sub>50</sub> = 220 nM) and >100-fold TLR7 selectivity (IFN-α EC<sub>50</sub> > 50 μM) was observed in human peripheral blood mononuclear cells (PBMCs). The TLR8-ectodomain:(<i>R</i>)-<b>7</b> complex confirmed TLR8 binding and a direct ligand interaction with TLR8 residue Asp545. Oral (<i>R</i>)-<b>7</b> had good absorption and high first pass clearance in preclinical species. A reduction in viral markers was observed in HBV-infected primary human hepatocytes treated with media from PBMCs stimulated with (<i>R</i>)-<b>7</b>, supporting the clinical development of (<i>R</i>)-<b>7</b> for the treatment of CHB.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_63746" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_63746" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Toll-like receptors (TLRs) are a family of membrane-bound molecular pattern recognition receptors that play a central role in the detection of molecular fragments from microorganisms. Activation of the TLRs leads to the initiation of innate and adaptive immune responses.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Human TLR8 is located on the endosomal membrane of a subset of immune cells, notably myeloid dendritic cells, monocytes, macrophages, and neutrophils, and recognizes single-stranded RNA (ssRNA) fragments.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> A closely related toll-like receptor, TLR7 is also located on the endosome membrane, and similarly recognizes ssRNA, but in contrast to TLR8, is predominantly expressed in plasmacytoid dendritic cells and B cells. Importantly, this orthogonal cell-specific expression pattern drives disparate immune responses upon either TLR7 or TLR8 receptor activation. TLR7 agonism predominantly induces the production of interferon-α (IFN-α), whereas TLR8 agonism stimulates the production of a variety of immunomodulatory and pro-inflammatory cytokines including interleukin-12 (IL-12), IL-18, and tumor necrosis factor-α (TNF-α).</div><div class="NLM_p">Chronic hepatitis B (CHB) is a major global health care challenge and one of the main causes of chronic liver disease, cirrhosis, and hepatocellular carcinoma. An estimated two billion people worldwide have been acutely infected with hepatitis B (HBV), of which >250 million have developed CHB, and an estimated 887 000 die annually from complications associated with CHB.<a onclick="showRef(event, 'ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref3 ref4">(3,4)</a> CHB is characterized by a dysfunctional or exhausted immune response, and therefore it is hypothesized that TLR8 activation with a small molecule agonist could stimulate a host immune response and lead to an effective new treatment option for CHB.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> In vitro, TLR8 small-molecule agonists have been shown to stimulate a CD8<sup>+</sup> T cell response to HBsAg, a viral protein secreted from HBV-infected hepatocytes, and the TLR8-induced immunomodulatory cytokine, IL-12, has also been shown to rescue the antiviral function of exhausted HBV-specific CD8<sup>+</sup> T cells.<a onclick="showRef(event, 'ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref6 ref7">(6,7)</a> IL-12 and IL-18 also strongly activate cytolytic and noncytolytic functions of natural killer cells and mucosal-associated invariant T-cells.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> In addition, TLR8 strongly induces TNF-α, which has been shown to drive intrahepatic CD8<sup>+</sup> T cell expansion and inhibit HBV in an adenovirus mouse model.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Finally, TLR8 induced cytokines, including IFN-γ, IL-1β, and TNF-α, have direct antiviral properties against HBV in vitro.<a onclick="showRef(event, 'ref10 ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref10 ref11 ref12">(10−12)</a> Taken together, these data show that TLR8 engages multiple arms of the immune system and produces antiviral cytokines that have been shown to inhibit HBV in vitro and in vivo.</div><div class="NLM_p">Our aim was to design an oral, selective small-molecule agonist of TLR8 with good absorption and high first-pass hepatic clearance as a rational approach to induce effective presystemic antiviral immunity in CHB patients. Activation of TLR8 expressing immune cells in the gut following oral administration would be expected to result in the secretion of immune mediators into the portal vein that will, in turn, stimulate immune cells in the liver, the organ of HBV infection. In addition, intestinal absorption of the agonist and drug exposure in the liver should lead to direct effects on intrahepatic TLR8-expressing immune cells. Provided the compound demonstrates high first-pass hepatic clearance in hepatocytes, systemic exposure of the agonist would be minimized, thereby reducing undesirable side effects from systemic TLR8 agonism. TLR7 agonism with oral small-molecule agents has also been hypothesized to be beneficial for CHB treatment and led to the discovery of vesatolimod from this group.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> The design of a selective TLR8 agonist would therefore afford the flexibility to modulate both pathways independently and allow for a combination approach if applicable. This is especially important because the relative contributions of oral TLR7 and TLR8 agonism, and their disparate immune responses to the treatment of CHB, or indeed, tolerability limitations, were largely unknown at the time.</div><div class="NLM_p">The cocrystal X-ray structure of TLR8 ectodomain with the dual TLR7/TLR8 agonist 3M-002 (<b>1</b>, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) was recently reported and enabled a rational approach to design novel TLR8-selective agonists.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Compound <b>1</b> has marginal selectivity for TLR8 and is structurally related to the TLR7 agonist imiquimod, which was approved in the 1990s for the treatment of genital warts.<a onclick="showRef(event, 'ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref15 ref16">(15,16)</a> In contrast, compounds <b>2</b> and <b>3</b> (VTX-2337) that contain the 2-aminoquinoline or 2-aminobenzazepine bicyclic cores have increased selectivity for TLR8.<a onclick="showRef(event, 'ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref17 ref18">(17,18)</a> These scaffolds illustrate that the tricyclic core of <b>1</b> can be truncated to a quinoline or benzoazepine bicyclic heterocycle and yet retain TLR8 potency. During the course of this program, additional novel TLR8 agonists were reported in the literature including the monocyclic 2,4-diaminopyrimidines <b>4</b> and <b>5</b>.<a onclick="showRef(event, 'ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref19 ref20">(19,20)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00100/20200918/images/medium/jm0c00100_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00100/20200918/images/large/jm0c00100_0001.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. TLR8 agonists.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00100/20200918/images/large/jm0c00100_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00100&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The pyrido[3,2-<i>d</i>]pyrimidine heterocycle and its preparation was familiar to this group due to its earlier inclusion in compounds that demonstrated promising anti-HCV activity.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> On the basis of the same heterocycle, <b>6a</b> was identified as a moderately potent dual TLR7/8 agonist lead. Optimization of the C-4 and C-7 substituents on the heterocycle led to the identification of the TLR8 selective clinical candidate (<i>R</i>)-<b>7</b> (GS-9688, selgantolimod). The structure–activity relationships that led to the identification of (<i>R</i>)-<b>7</b> as a selective TLR8 agonist are described in addition to the preclinical pharmacokinetic properties that demonstrate presystemic exposure and minimal oral bioavailability due to high first pass clearance. The inhibition of viral parameters in hepatitis B infected primary human hepatocytes (PHH), combined with the previously reported antiviral efficacy in the woodchuck model of CHB, support the development of (<i>R</i>)-<b>7</b> as an orally delivered, first in class, selective TLR8 agonist for the treatment of CHB.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(22)</a></div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_61826" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_61826" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">A high throughput multiplex assay was developed that quantified the levels of IL-12p40 (TLR8 cytokine) and IFN-α (TLR7 cytokine) in the supernatant of human PBMCs. Provided IL-12p40 induction was >50% of the TLR8 selective control compound <b>3</b>, a concentration for 50% maximal induction (EC<sub>50</sub>) of this cytokine was calculated from the computationally fitted dose response curve. IFN-α induction values were calculated in a similar manner using the TLR7 agonist, vesatolimod, as the positive control. A single PBMC donor was used consistently during the SAR iteration to reduce assay variability. Human embryonic kidney (HEK) 293 reporter cell lines stably expressing human TLR8 or TLR7 have also been reported in the literature as a primary screening tool for the identification of TLR7 or TLR8 selective agonists.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> However, an advantage of the robust high throughput PBMC assay developed here is that both TLR7 and TLR8 responses could be assessed in the same assay using nontransformed cells that do not overexpress the TLR receptors. Therefore, a more biologically relevant functional selectivity window could be calculated based on the respective IL-12p40 and IFN-α responses in a single assay.</div><div class="NLM_p">The active TLR8 homodimer has two equivalent agonist binding sites at the interface of the ectodomain monomers. A common feature for all the TLR8 agonists shown in <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a> is the presence of a weakly basic heterocyclic nitrogen, with a range of p<i>K</i><sub>a</sub> values, e.g., p<i>K</i><sub>a</sub> = 6.3 and 7.3 for <b>1</b> and <b>3</b>, respectively. In the low pH ∼ 4–6 environment of the endosomal compartment, where TLR8 is functional, this weakly basic group is protonated. The cocrystal X-ray structure of the TLR8-ectodomain homodimer:<b>1</b> complex indicates the weakly basic group forms an ionic interaction with Asp543 of one TLR8 monomer (Chain A, <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A). The lipophilic propyl chain extends into a narrow but deep hydrophobic pocket formed by residues Gly572 and Val573 from chain A, and Phe346, Tyr348, Gly376, Val378, Ile403, and Phe405 from chain B of the second TLR8 monomer. All of the compounds in <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a> have a lipophilic group that likely occupies this pocket, illustrating its importance for binding of small-molecule agonists. The lipophilic pocket of TLR7 based on homology modeling was expected to be very similar to that of TLR8. Thus, the major structural differences between TLR7 and TLR8 within the ligand binding site are residues Gly351 (chain B) and Asp545 (chain A), located at the front of the pocket (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A). These residues correspond to Gln354 and Leu557, respectively, in TLR7. Lead <b>6a</b> was modeled into the binding site of TLR8 to establish the same charged interaction with Asp543, and orientate the <i>N</i>-alkyl side chain into the lipophilic pocket (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>B). The model suggested that the α-carbon of the alkyl side chain was the most proximal atom from which to explore substitutions directed toward the front of the pocket in an attempt to engage Asp545 of TLR8. It was reasoned that polar groups could lead to a water mediated or direct hydrogen bond to Asp545 in TLR8, but would be unfavorable toward TLR7, due to presence of the lipophilic Leu557 side chain, thereby generating TLR8 selectivity.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00100/20200918/images/medium/jm0c00100_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00100/20200918/images/large/jm0c00100_0002.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A) TLR8-ectodomain:<b>1</b> X-ray complex with protons added to the ligand by modeling. Lighter green shading indicates chain A surface of one TLR8 monomer and darker green is chain B of the second TLR8 monomer. (B) Model of <b>6a</b>. (C) Model of (<i>R</i>)-<b>6d</b> with a bridging water hydrogen bond to Asp545. (D) Model of (<i>R</i>)-<b>6d</b> with a direct hydrogen bond to Asp545. (E) Cross section view of (<i>R</i>)-<b>6d</b> occupying the lipophilic pocket from model shown in panel D. (F) Model of (<i>S</i>)-<b>6d</b> with a bridging water hydrogen bond to Asp545. All modeled compounds in B–F were docked into the TLR8 X-ray structure. PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3W3M">3W3M</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00100/20200918/images/large/jm0c00100_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00100&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p"><a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a> illustrates the preparation of a variety of C-4 modified pyrido[3,2-<i>d</i>]pyrimidine compounds starting from the commercially available 2,4-dichloropyrido[3,2-<i>d</i>]pyrimidine <b>8</b>. Nucleophilic addition of butan-1-ol or amines <b>11a</b>–<b>h</b> at C-4 was followed by addition of 2,4-dimethoxybenzyl (Dmb) amine at C-2 to afford the intermediates <b>9</b> and <b>12a</b>–<b>h</b>. Acid deprotection of the Dmb group afforded the target compounds <b>10</b> and <b>6a</b>–<b>f</b>. Ester <b>12g</b> was reduced to the alcohol before Dmb removal to yield (<i>R</i>)-<b>6g</b>, and ester <b>12h</b> was first hydrolyzed to the acid followed by Dmb removal to afford (<i>R</i>)-<b>6h</b>. The amides (<i>R</i>)-<b>6i</b> and (<i>R</i>)-<b>6j</b> were generated from the above acid intermediate using a HATU mediated coupling prior to Dmb removal.</div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00100/20200918/images/medium/jm0c00100_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00100/20200918/images/large/jm0c00100_0006.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of <i>N</i><sup>4</sup>- and <i>O</i><sup>4</sup>-Substituted Pyrido[3,2-<i>d</i>]pyrimidin-2-amines<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00100/20200918/images/large/jm0c00100_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00100&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) butan-1-ol, NaH (60% disp), 71%; (ii) 2,4-dimethoxybenzyl(Dmb)-NH<sub>2</sub>, iPr<sub>2</sub>NEt, 100 °C, 37%; (iii) TFA, 9%; (iv) amine <b>11a</b>–<b>h</b>, iPr<sub>2</sub>NEt; rt, (100 °C for (<i>R</i>)-<b>11e</b>); (v) Dmb-NH<sub>2</sub>, iPr<sub>2</sub>NEt, 100–135 °C, 52% for <b>12g</b>, 68% for <b>12h</b>; (vi) TFA, 11–73% over 3 steps; (vii) LAH; (viii) TFA, 5% over 2 steps; (ix) KOH(aq), MeOH, quant; (x) TFA, quant; (xi) HATU, iPr<sub>2</sub>NEt, NMP, ammonia (14%) or methylamine (18%); (xii) TFA, 22–42%.</p></p></figure><div class="NLM_p">The induction of IL-12p40 (TLR8 cytokine) and IFN-α (TLR7 cytokine) in PBMCs for compounds <b>6a</b>–<b>j</b> is reported in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>. The lack of TLR activity for <i>O</i><sup>4</sup>-linked analogue <b>10</b> established that the corresponding amine linkage in <b>6a</b> was critical, and the similar potency of the α-branched analogue, <b>6b</b>, indicated that α-carbon branching was tolerated by both TLRs. Further extension of the α-branching group by the addition of a hydroxyl group resulted in 5-fold improved TLR8 potency and 5-fold selectivity for (<i>S</i>)-<b>6c</b> toward TLR8, while the corresponding (<i>R</i>)-<b>6c</b> isomer was 10-fold less potent toward TLR8. A significant advance was observed for isomers (<i>R</i>)-<b>6d</b> and (S)-<b>6d</b> that extend the α-alkyl chain to four carbons from the branch point. The (<i>S</i>)-<b>6d</b> isomer had comparable potency and selectivity to the shorter chain analogue (<i>S</i>)-<b>6c</b>, but the (<i>R</i>)-<b>6d</b> isomer was >20-fold more potent than (<i>R</i>)-<b>6c</b> toward TLR8 and had no TLR7 mediated IFN-α induction up to 50 μM, leading to the first selective TLR8 agonist in the series. Extending the α-alkyl chain with another methylene, analogue (<i>R</i>)-<b>6g</b>, reduced potency while extending the hydroxyl group further from the branch point by one methylene, analogue (<i>R</i>)-<b>6e</b>, was also less potent. Modification of the hydroxyl in (<i>R</i>)-<b>6d</b> to an amine, (<i>R</i>)-<b>6f</b>, or other groups capable of hydrogen bond donation, e.g., <b>6h</b>–<b>j</b>, afforded only weak activity. Taken together, the SAR established that the length and <i>R</i> stereochemistry of the lipophilic side chain in (<i>R</i>)-<b>6d</b>, together with the hydroxyl group were all required for optimal TLR8 potency and selectivity.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. TLR Activity of <i>N</i><sup>4</sup>- and <i>O</i><sup>4</sup>-Substituted Pyrido[3,2-<i>d</i>]pyrimidin-2-amines</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00100/20200918/images/medium/jm0c00100_0010.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00100/20200918/images/medium/jm0c00100_0011.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">Average of <i>n</i> ≥ 2 results.</p></div></div><div></div></div><div class="NLM_p">Modeling was used in an attempt rationalize the TLR8 potency SAR and also the differential selectivity toward TLR7 of the two isomers (<i>R</i>)-<b>6d</b> and (<i>S</i>)-<b>6d</b>. One pose for the (<i>R</i>)-<b>6d</b> analogue in TLR8 (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>C) suggested the hydroxyl was interacting via a water molecule with Asp545 and the <i>N</i><sup>4</sup>-alkyl group was rotated 180° relative to its orientation in <b>6a</b>. A second pose (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>D) maintained the orientation of the <i>N</i><sup>4</sup>-alkyl group relative to <b>6a</b> but led to the displacement of the bridging water molecule and the formation of a direct hydrogen bond to Asp545. Both possibilities were considered, but it was not until an X-ray cocrystal structure of compound (<i>R</i>)-<b>7</b> was solved that the direct hydrogen bond model was deemed to be correct (vide infra). <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>E shows a cross section of the lipophilic pocket with the four-carbon chain of (<i>R</i>)-<b>6d</b> fully occupying the space in the lipophilic pocket. The total distance from the end of the four-carbon chain to the hydroxyl group is ideal to occupy the lipophilic pocket while also enabling the hydroxyl group to interact with Asp545. However, the shorter three-carbon (<i>R</i>)-<b>6c</b> and longer five-carbon (<i>R</i>)-<b>6g</b> lengths are suboptimal. The 5-fold weaker activity of (<i>R</i>)-<b>6e</b>, which has an identical length to (<i>R</i>)-<b>6d</b>, is presumed to be a combination of incomplete occupancy of the lipophilic pocket from the α-branch point and the greater entropic penalty of the more flexible hydroxyethyl group that forms the key interaction with Asp545. The (<i>S</i>)-<b>6d</b> isomer was modeled in TLR8 in a pose similar to <b>6a</b> and is presumed to derive its TLR8 potency from a similar water mediated interaction with Asp545 (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>F). However, the fact that (<i>S</i>)-<b>6d</b> and indeed the shorter (<i>S</i>)-<b>6c</b> analogue had comparable TLR7 and TLR8 potency is harder to rationalize but does suggest that other binding poses are present in the TLR7 binding site that allow these <i>S</i>-isomers to generate favorable interactions with Leu557 despite the presence of the hydroxyl group. More extensive X-ray studies using TLR7 and TLR8 constructs will be required to tease out the binding modes of the <i>S</i> isomers in TLR7, the feasibility of which has now increased given the recent publication of TLR7 X-ray small-molecule complex structures.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a></div><div class="NLM_p">The pyrido[3,2-<i>d</i>]pyrimidine heterocycle forms a π-stacking interaction with the aromatic ring of Phe405 (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>B), so it was of interest to explore the effects of alternate heterocycle cores. The corresponding quinazolines of both <b>6d</b> isomers, (<i>R</i>)-<b>14</b> and (<i>S</i>)-<b>14</b>, and quinoline isomers, (<i>R</i>)-<b>16</b> and (<i>S</i>)-<b>16</b>, were therefore prepared according to <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>. The quinazoline analogues have recently been shown to be TLR8 selective in HEK reporter assays.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Commercial <b>13</b> was converted to isomers <b>14</b> via a BOP mediated coupling with the amine isomers <b>11d</b>, while the corresponding quinolines <b>16</b> were prepared in a palladium cross coupling of quinoline <b>15</b> with amine isomers <b>11d</b>.</div><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00100/20200918/images/medium/jm0c00100_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00100/20200918/images/large/jm0c00100_0007.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of <i>N</i><sup>4</sup>-Substituted Quinazoline-2-amines, <b>14</b>, and Quinoline-2-amines, <b>16</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00100/20200918/images/large/jm0c00100_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00100&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) DMF, DBU, BOP, <b>11d</b>, 62–71%; (ii) Pd(dba)<sub>2</sub>, NaO<sup>t</sup>Bu, (<i>R</i>)-BINAP, <b>11d</b>, 135 °C, 7–16%.</p></p></figure><div class="NLM_p">The quinazoline isomers <b>14</b> had parallel SAR to their corresponding pyrido[3,2-<i>d</i>]pyrimidin-2-amines, albeit 2-fold less potent in each case toward TLR8 (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). In contrast removal of the additional nitrogen in the core, quinolines <b>16</b>, resulted in complete loss of activity. The measured p<i>K</i><sub>a</sub> for (<i>R</i>)-<b>6d</b> was 7.0, 8.2 for quinazoline (<i>R</i>)-<b>14</b>, and calculated to be even higher for the quinoline (<i>R</i>)-<b>16</b>,<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> thus protonation state in the endosome was not the cause of lower activity. This loss of activity for the quinoline (<i>R</i>)-<b>16</b> is also surprising in light of the observation that quinoline <b>2</b> is a potent TLR8 agonist and suggests that the 2-aminoquinoline core binds differently to these other cores in the TLR8 pocket, leading to suboptimal positioning of the <i>N</i><sup>4</sup>-group into the lipophilic pocket.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. TLR Activity of <i>N</i><sup>4</sup>-Substituted Quinazolin-2-amines and Quinolin-2-amines</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00100/20200918/images/medium/jm0c00100_0012.gif" alt="" id="fx3" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">Average of <i>n</i> ≥ 2 results.</p></div></div><div></div></div><div class="NLM_p">Cytotoxicity screening of the TLR8 selective lead (<i>R</i>)-<b>6d</b> indicated a narrow cell-based toxicity index, ∼10-fold (MT-4 CC<sub>50</sub>/IL-12p40 EC<sub>50</sub>) in the rapidly proliferating MT-4 cell line due to “off-target” effects. Continued optimization was therefore conducted and focused on exploring substitution at the remaining α-carbon position leading to α,α-substituted analogues. In the models of (<i>R</i>)-<b>6d</b> (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>C,D), there is a small unoccupied space near the unsubstituted α-site. To support this effort, several chiral α,α-substituted amino acid esters and alcohols were required and their preparation is described in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>. The amino acid esters <b>18a</b>,<b>b</b> and <b>18g</b> were generated from commercially available unnatural amino acids through esterification of the acid followed by protecting group removal as needed. The tertiary amino alcohol (<i>S</i>)-<b>18c</b> was derived from the acid (<i>S</i>)-<b>19</b> via a borane reduction and alcohols (<i>R</i>)-<b>18c</b>–<b>f</b> by stereospecific synthesis from the 5,6-dihydro-2<i>H</i>-1,4-oxazin-2-one intermediate (<i>R</i>)-<b>20</b>.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> The oxazin-2-one route not only facilitated control of stereochemistry but also allowed for rapid generation of amino alcohols with modified alkyl chains, e.g., (<i>R</i>)-<b>18f</b>.</div><figure id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00100/20200918/images/medium/jm0c00100_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00100/20200918/images/large/jm0c00100_0008.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Stereoselective Synthesis of α,α-Substituted Amino Acid Esters and Alcohols<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00100/20200918/images/large/jm0c00100_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00100&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) TMSCHN<sub>2</sub>, MeOH, quant; (ii) piperidine, THF, 85% over 2 steps; (iii) BH<sub>3</sub>·THF; (iv) BF<sub>3</sub>·OEt<sub>2</sub>, −78 °C, RMgCl, 60–76%; (v) LiBH<sub>4</sub>, 0 °C-rt, quant; (vi) Pd(OH)<sub>2</sub>/C, EtOH, HCl, H<sub>2</sub>, 70–75 °C, quant.</p></p></figure><div class="NLM_p">The subsequent coupling of the α,α-substituted amines to the pyrido[3,2-<i>d</i>]pyrimidine-2-core <b>8</b> is described in <a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>. Unlike the mono α-substituted series, the more hindered α,α-substituted amines typically required elevated temperatures in the nucleophilic substitution reaction. In examples where Dmb protecting groups were present, their removal proceeded as described previously, along with any ester or carbon–carbon double bond reductions, to afford <b>23a</b>–<b>e</b>. The same methods were also applicable to the nucleophilic substitution on the 7-F and 7-Cl heterocycle intermediates, <b>25</b> and <b>27</b>, respectively. 7-Chloro intermediate <b>28</b> could also be converted to the 7-methyl analogue (<i>R</i>)-<b>30</b> using methylboronic acid in a Suzuki cross coupling. Finally, preparation of (<i>S</i>)-<b>7</b> illustrates an alternative approach to 7-fluoro analogues via a simple two-step method from readily available fluoropicolinic acid <b>31</b>.</div><figure id="sch4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00100/20200918/images/medium/jm0c00100_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00100/20200918/images/large/jm0c00100_0009.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of <i>N</i><sup>4</sup>-α,α-Substituted Pyrido[3,2-<i>d</i>]pyrimidin-2-amines<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00100/20200918/images/large/jm0c00100_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00100&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) amine <b>18a</b>–<b>g</b>, iPr<sub>2</sub>NEt, 80 °C; (ii) Dmb-NH<sub>2</sub>, iPr<sub>2</sub>NEt (K<sub>2</sub>CO<sub>3</sub> for (<i>R</i>)-<b>23e</b> and (<i>R</i>)-<b>26a</b>), 85–120 °C, 17–66% over 2 steps; (iii) LAH, 29–100%, (over 2 steps, (<i>R</i>)-<b>23a</b> (45%) and (<i>R</i>)-<b>30</b> (82%); over 3 steps (<i>S</i>)-<b>23c</b> (26%) and (<i>R</i>)-<b>23d</b> (7%)); (iv) Pd/C, H<sub>2</sub>; (v) TFA, 7%-quant; (vi) Pd(Ph<sub>3</sub>)<sub>4</sub>, ZnCN<sub>2</sub>, DMF, 115 °C, quant; (vii) K<sub>2</sub>CO<sub>3</sub>, H<sub>2</sub>O<sub>2</sub>, 0 °C, 97% over 2 steps; (viii) (COCl<sub>2</sub>)<sub>3</sub>, 110 °C, 90%; (ix) PCl<sub>5</sub>, POCl<sub>3</sub>, 110 °C, 75%; (x) fermentation; (xi) CH<sub>3</sub>B(OH)<sub>2</sub>, Pd(Ph<sub>3</sub>)<sub>4</sub>, K<sub>3</sub>PO<sub>4</sub>, 150 °C; (xii) ClC(═NH)-NH<sub>2</sub>, (CH<sub>3</sub>)<sub>2</sub>SO<sub>2</sub>, 160 °C, 24%; (xiii) NMP, BOP, DBU, (<i>S</i>)-<b>18c</b>, 20%.</p></p></figure><div class="NLM_p">The α,α-substituted analogues <b>23a</b>–<b>e</b> were evaluated across a wide range of assays including TLR8 potency and selectivity, cytotoxicity index CC<sub>50</sub> (MT-4 CC<sub>50</sub>/IL-12p40 EC<sub>50</sub>), p<i>K</i><sub>a</sub>, log <i>D</i>, Caco-2 cell permeability, and in vitro microsomal metabolism (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). The α-methyl analogue (<i>R</i>)-<b>23c</b>, not only improved the TLR8 potency by 5-fold compared to the corresponding mono α-substituted analogue (<i>R</i>)-<b>6d</b> but also retained >80-fold selectivity over TLR7 and improved the MT-4 cytotoxicity window to 182-fold. The <i>S</i> isomer, (<i>S</i>)-<b>23c</b>, was >10-fold less active toward TLR8 than (<i>R</i>)-<b>23c</b> and less selective over TLR7 reinforcing the preference for the <i>R</i> isomer series. Like the previous mono α-substituted series, extending the α-alkyl chain analogues, (<i>R</i>)-<b>23d</b>/<b>e</b>, or shortening, (<i>R</i>)-<b>23a</b>, was less potent although the one methylene extended (<i>R</i>)-<b>23d</b> was only 3-fold less potent. The achiral analogue <b>23b</b> was devoid of activity, suggesting the second α-substitutent needs to be sterically small, consistent with the modeling prediction.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. <i>N</i><sup>4</sup>-α,α-Substituted Pyrido[3,2-<i>d</i>]pyrimidin-2-amines</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00100/20200918/images/medium/jm0c00100_0013.gif" alt="" id="fx4" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00100/20200918/images/medium/jm0c00100_0014.gif" alt="" id="fx5" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">Average of <i>n</i> ≥ 2 results.</p></div><div class="footnote" id="t3fn2"><sup><sup>b</sup></sup><p class="last">Cytotoxicity (CC<sub>50</sub>) index, defined as MT-4 CC<sub>50</sub>/IL-12p40 PBMC EC<sub>50</sub>.</p></div><div class="footnote" id="t3fn3"><sup><sup>c</sup></sup><p class="last">AB, apical to basolateral; BA, basolateral to apical.</p></div><div class="footnote" id="t3fn4"><sup><sup>d</sup></sup><p class="last">MS, microsomes; r, rat; d, dog; c, cyno; h, human; CL pred., predicted clearance.</p></div></div><div></div></div><div class="NLM_p">Turning attention to the pharmacokinetic properties, the low molecular weight, moderate log <i>D</i>, and good solubility in aqueous media resulted in excellent passive permeability in caco-2 cells for both (<i>R</i>)- and (<i>S</i>)-<b>23c</b> with no apparent efflux ratio (efflux ratio = BA/AB). High first-pass clearance was predicted using microsomal incubations for both <b>23c</b> isomers from multiple preclinical species. Metabolite identification studies in hepatocytes indicated extensive heterocycle core metabolism, which raised the concern that some of the oxidized core metabolites could be immunologically active in vivo, leading to a convoluted in vivo profile. Therefore, in an attempt to suppress core metabolism, the core was modified at several positions, of which the most favorable was 7-substitution, analogues (<i>R</i>)-<b>7</b> (7-F), (<i>R</i>)-<b>29</b> (7-Cl), and (<i>R</i>)-<b>30</b> (7-Me), respectively. The p<i>K</i><sub>a</sub> of the heterocycle nitrogen was lowered by only 0.5 units for the 7-F and 7-Cl analogues to a range of 6.3–7.1, higher than the endosome, and therefore not expected to impact potency (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). Indeed, all three analogues demonstrated comparable potency to the 7-unsubstituted analogue (<i>R</i>)-<b>23c</b>, but TLR8 selectivity improved to >185-fold, and the CC<sub>50</sub> index in the MT-4 cell line was >77-fold. No significant changes in permeability or the predicted clearance across species was noted except for a lower predicted human clearance of the C7-methyl analogue (<i>R</i>)-<b>30</b>. The risk of potentially lower first pass clearance for this analogue was sufficient to rule it out of contention for selection. Metabolite identification following incubation of (<i>R</i>)-<b>7</b> in human hepatocytes indicated that core oxidation had indeed been suppressed, and the most dominant metabolites were lipophilic chain oxidation, hydroxyl oxidation to the acid, and glucuronidation. Although the specific site of oxidation on the lipophilic chain was not rigorously identified, the SAR for small changes along this chain was extremely narrow, and even small changes such as fluorine led to weaker activity (data not shown). Although it was extremely unlikely oxidation along the four-carbon chain would result in an active metabolite, the terminal hydroxyl (<i>R</i>)-<b>26a</b> was prepared and tested as one potential metabolite to verify lack of TLR7/8 activity (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). The acid (<i>R</i>)-<b>26b</b> was also prepared and found to be inactive to both TLRs, as was the <i>O</i>-glucuruonide (<i>R</i>)-<b>26c</b> that was structurally confirmed by NMR following isolation from microbial fermentation mixtures. Compound (<i>R</i>)-<b>7</b> sufficiently derisked the potential metabolite concerns and was more potent than (<i>R</i>)-<b>29</b>, so it was selected for in vivo evaluation. In each nonclinical species, high clearance and low oral bioavailability was observed consistent with the in vitro prediction of high first pass metabolism (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). A bile duct cannulated study in rat detected minimal parent compound in bile and urine, confirming metabolism was the dominant mechanism of clearance in rat. Oral absorption was confirmed through analysis of portal vein samples in dog and cynomolgus monkey following oral dosing, and these data indicated at least 28% absorption in dog and ∼100% in cynomolgus monkey. Taken together, the in vitro predictions of good oral absorption and high first-pass clearance were confirmed in vivo in the nonclinical species. The predicted first-pass clearance of (<i>R</i>)-<b>7</b> in humans is high, close to that of liver blood flow, so (<i>R</i>)-<b>7</b> was expected to be a well-absorbed high clearance compound in humans meeting the desired target profile (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>).</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Mean Plasma Pharmacokinetic Parameters of (<i>R</i>)-7 Following IV and Oral Administration</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center" char="±">IV<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th><th class="rowsep1 colsep0" colspan="3" align="center" char="±">Oral<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">species</th><th class="colsep0 rowsep0" align="center" char="±">CL (L/h/kg)</th><th class="colsep0 rowsep0" align="center" char="±"><i>V</i><sub>ss</sub> (L/kg)</th><th class="colsep0 rowsep0" align="center" char="±"><i>t</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center" char="±">AUC<sub>inf</sub> (nM·h)</th><th class="colsep0 rowsep0" align="center" char="±"><i>C</i><sub>max</sub> (nM)</th><th class="colsep0 rowsep0" align="center" char="±"><i>F</i> (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Sprague–Dawley rat</td><td class="colsep0 rowsep0" align="char" char="±">1.8 ± 0.2</td><td class="colsep0 rowsep0" align="char" char="±">1.1 ± 0.0</td><td class="colsep0 rowsep0" align="char" char="±">1.45 ± 0.12</td><td class="colsep0 rowsep0" align="char" char="±">827 ± 540</td><td class="colsep0 rowsep0" align="char" char="±">517 ± 224</td><td class="colsep0 rowsep0" align="char" char="±">8.8 ± 5.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">beagle dog</td><td class="colsep0 rowsep0" align="char" char="±">1.2 ± 0.13</td><td class="colsep0 rowsep0" align="char" char="±">1.01 ± 0.13</td><td class="colsep0 rowsep0" align="char" char="±">1.32 ± 0.18</td><td class="colsep0 rowsep0" align="char" char="±">11.8 ± 7.3</td><td class="colsep0 rowsep0" align="char" char="±">9.7 ± 7.7</td><td class="colsep0 rowsep0" align="char" char="±">0.8 ± 0.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">cynomolgus monkey</td><td class="colsep0 rowsep0" align="char" char="±">6.2 ± 1.8</td><td class="colsep0 rowsep0" align="char" char="±">2.1 ± 1.5</td><td class="colsep0 rowsep0" align="char" char="±">0.67 ± 0.07</td><td class="colsep0 rowsep0" align="char" char="±">4.7 ± 4.2</td><td class="colsep0 rowsep0" align="char" char="±">1.2 ± 0.5</td><td class="colsep0 rowsep0" align="char" char="±">0.3 ± 0.2</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">30 min intravenous infusion to Sprague–Dawley (SD) rats (1 mg/kg), beagle dogs (0.25 mg/kg), and cynomolgus monkeys (0.1 mg/kg) (mean ± SD, <i>n</i> = 3).</p></div><div class="footnote" id="t4fn2"><sup><sup>b</sup></sup><p class="last">Oral administration to SD rats (5 mg/kg), beagle dogs (0.5 mg/kg) and cynomolgus monkeys (3 mg/kg), formulation was 2% ethanol, 40% PEG 300 and 58% 0.01 N HCl.</p></div></div></div><div class="NLM_p">Evidence for direct binding of (<i>R</i>)-<b>7</b> to TLR8 was attained by solving the TLR8-ectodomain:(<i>R</i>)-<b>7</b> cocrystal structure (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). The structure indicates that the compound binds with a direct hydrogen bond to Asp545, the basic group interacts with Asp543, and the lipophilic <i>N</i><sup>4</sup>-alkyl chain occupies the narrow lipophilic pocket. However, Asp545 shifted slightly relative to the published structure of <b>1</b> to provide a more optimal direct hydrogen bond to the hydroxyl group of (<i>R</i>)-<b>7</b>. This supports the premise that the Asp545 interaction is the key driver of TLR8 potency and selectivity. The α-methyl group is directed to the top of the binding site and nicely occupies the space proximal to Tyr348, Val378, and Gly351, which results in increased binding potency.</div><figure id="fig3" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00100/20200918/images/medium/jm0c00100_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00100/20200918/images/large/jm0c00100_0003.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Single cocrystal structure of TLR8-ectodomain:(<i>R</i>)-<b>7</b> complex. PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6WML">6WML</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00100/20200918/images/large/jm0c00100_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00100&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The broader selectivity profile of (<i>R</i>)-<b>7</b> toward immune receptors was assessed in reporter gene assays using HEK293 cells, stably expressing individual human TLRs or other innate immune receptors. The minimum effective concentration (MEC) of (<i>R</i>)-<b>7</b> that resulted in a 3-fold increase above background was 49 nM for human TLR8 (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). In contrast, the MEC for human TLR7 was 5197 nM, further supporting a mechanism of selective engagement of (<i>R</i>)-<b>7</b> on human TLR8 over human TLR7. Moreover, (<i>R</i>)-<b>7</b> did not stimulate HEK293 cells stably expressing other human TLRs including TLR2, TLR3, TLR4, TLR5, TLR9, and other receptors including Nod-like receptors (NLRs: NOD1 and NOD2), RIG-I -like receptors (RLRs; RIG-I and MDA5), or C-type lectin receptors (CLRs; Dectin1a, Dectin 1b, and Mincle) (data not shown). This data, taken together with the structural data, supports the direct and selective engagement and activation of TLR8 by (<i>R</i>)-<b>7</b>.</div><figure id="fig4" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00100/20200918/images/medium/jm0c00100_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00100/20200918/images/large/jm0c00100_0004.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. TLR8 and TLR7 HEK293 reporter assay response to (<i>R</i>)-<b>7</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00100/20200918/images/large/jm0c00100_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00100&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In HBV-infected PHH viral RNAs are transcribed from the viral genome (covalent closed circular DNA, cccDNA), leading to the expression of the viral proteins, e.g., HBeAg and HBsAg. Direct stimulation of HBV infected PHH with (<i>R</i>)-<b>7</b> did not result in any antiviral effects consistent with the lack of robust TLR8 expression in human hepatocytes (data not shown). In an indirect experiment, designed to assess the antiviral effect of TLR8 induced immune mediators generated in PBMCs, HBV-infected PHH were treated with media from human PBMCs stimulated with (<i>R</i>)-<b>7</b> ((<i>R</i>)-<b>7</b>-CM). Exposure of HBV-infected PHH to (<i>R</i>)-<b>7</b>-CM over 10 days resulted in a decrease in HBV DNA, HBV RNA, HBeAg, and HBsAg levels by >50% relative to no compound control (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>). However, (<i>R</i>)-<b>7-</b>CM did not reduce levels of cccDNA, demonstrating that, in this in vitro system, TLR8-induced cytokines are insufficient to induce noncytolytic degradation of cccDNA (data not shown).</div><figure id="fig5" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00100/20200918/images/medium/jm0c00100_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00100/20200918/images/large/jm0c00100_0005.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Antiviral activity in HBV-infected PHH treated with (<i>R</i>)-<b>7</b>-CM.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00100/20200918/images/large/jm0c00100_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00100&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The woodchuck hepatitis virus (WHV) is a hepadnavirus closely related to HBV, and therefore the woodchuck model has been used to evaluate TLR agonists.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> The TLR7 agonist vesatolimod (GS-9620) demonstrated anti-WHV activity in the woodchuck model, prompting this program to conduct a similar model to evaluate oral (<i>R</i>)-<b>7</b> following local IACUC guidelines. The results from oral dosing of (<i>R</i>)-<b>7</b> have recently been published and will only be summarized here.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(22)</a> Once weekly oral dosing of (<i>R</i>)-<b>7</b> at 3 mg/kg for 8 weeks reduced serum WHV DNA and WHBsAg to below the limit of detection in three out of six treated woodchucks. These responses were not conclusively associated with baseline levels of WHV DNA or WHBsAg. The responses were sustained following cessation of dosing in these three animals. Strikingly, >95% reductions in intrahepatic WHV RNA, WHV DNA, and WHV cccDNA were also observed in these three sustained antiviral responders. Pharmacokinetic sampling was limited during the study to a single time point at 0.5 h following dosing. There was a trend to higher exposures in the responding animals in this study, but this trend was not reproduced in a larger follow-on study.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(22)</a> The lack of a clear correlation between systemic drug exposure and efficacy suggests that the response is not driven from systemic activation of TLR8 but, more likely, presystemic gut and liver TLR8 activation. Understanding the molecular basis for the differential responses in woodchucks is now the focus of future experiments.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(22)</a> In conclusion, this striking result observed in several woodchucks strongly supports the potential for (<i>R</i>)-<b>7</b> to be an effective new agent for the treatment of CHB.</div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i12">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_61460" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_61460" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">The clinical compound (<i>R</i>)-<b>7</b> is an orally active selective TLR8 agonist that was discovered through structure guided evolution of the C-4 substituent on an initial pyrido[3,2-<i>d</i>]pyrimid-2-amine lead. (<i>R</i>)-<b>7</b> demonstrated EC<sub>50</sub> = 220 nM for induction of IL-12p40 in cryopreserved human PBMCs and >100-fold selectivity for TLR8 against TLR7 in PBMCs and HEK293 cells. In vivo, (<i>R</i>)-<b>7</b> demonstrated good oral absorption properties across several preclinical species and a high first-pass clearance that limited systemic exposure levels. Treatment of HBV-infected PHH with cytokines obtained from (<i>R</i>)-<b>7</b>-stimulated PBMCs decreased the levels of HBV DNA and RNA in addition to other viral proteins. These findings combined with the promising in vivo efficacy in the woodchuck model of CHB, supports the potential of (<i>R</i>)-<b>7</b> to be an effective new treatment option for CHB. (<i>R</i>)-<b>7</b> is currently in multiple phase 2 studies for the treatment of CHB.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_28846" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_28846" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">All organic compounds were synthesized at Gilead Sciences, Inc. (Foster City, CA) unless otherwise noted. Commercially available solvents and reagents were used as received without further purification. Nuclear magnetic resonance (NMR) spectra were recorded on a Varian Mercury Plus 400 MHz at room temperature, with tetramethylsilane as an internal standard. Proton nuclear magnetic resonance spectra are reported in parts per million (ppm) on the δ scale and are referenced from the residual protium in the NMR solvent (CHCl<sub>3</sub>-<i>d</i><sub>1</sub>: δ 7.26; MeOH-<i>d</i><sub>4</sub>: δ 3.31; DMSO-<i>d</i><sub>6</sub>: δ 2.50; CH<sub>3</sub>CN-<i>d</i><sub>3</sub>: δ 1.94). Data is reported as follows: chemical shift (multiplicity [s = singlet, d = doublet, t = triplet, q = quartet, p = pentet, h = heptet, m = multiplet, br = broad, app = apparent], coupling constants (<i>J</i>) in hertz, integration). See <a href="/doi/suppl/10.1021/acs.jmedchem.0c00100/suppl_file/jm0c00100_si_002.pdf" class="ext-link">Supporting Information</a> for NMR spectra of final compounds. Preparative normal phase silica gel chromatography was carried out using a Teledyne ISCO CombiFlash Companion instrument with silica gel cartridges. Preparative HPLC purification is described in the experimental method. Purities of the final compounds were determined by analytical high-performance liquid chromatography (HPLC), and were greater than 95% unless otherwise noted (see <a href="/doi/suppl/10.1021/acs.jmedchem.0c00100/suppl_file/jm0c00100_si_002.pdf" class="ext-link">Supporting Information</a> for HPLC spectra and methods). LC/MS was conducted on a Thermo Finnigan MSQ Std using electrospray positive and negative [M + 1]<sup>+</sup> and [M – 1]<sup>−</sup>, and a Dionex Summit HPLC system (model P680A HPG) equipped with a Gemini 5 μ C18 110A column (30 mm × 4.60 mm), eluting with CH<sub>3</sub>CN containing 0.1% formic acid, and water containing 0.1% formic acid; 0–1.8 min 2–100% CH<sub>3</sub>CN, 1.8–1.85 min 100%–2% CH<sub>3</sub>CN, and 1.85–2.00 min 2% CH<sub>3</sub>CN at 1800 μL/min.</div><div class="NLM_p"><b>CAUTION</b>: The compounds generated using these methods are potent immunomodulators and should be handled with appropriate personal protective equipment practices, including double glove, lab coat disposable arm bands, and disposable footwear booties. A full mask respirator should be used when handling the solid form of the compounds in amounts exceeding 10 mg.</div><div class="NLM_p">The synthesis, characterization data, and associated references for the amines <b>11e</b>–<b>g</b> and <b>18a</b>–<b>g</b> are provided in <a href="/doi/suppl/10.1021/acs.jmedchem.0c00100/suppl_file/jm0c00100_si_002.pdf" class="ext-link">Supporting Information</a>.</div><div id="sec4_1_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> <i>N</i><sup>4</sup>-Butylpyrido[3,2-<i>d</i>]pyrimidine-2,4-diamine (<b>6a</b>)</h3><div class="NLM_p last">Compound <b>8</b> (CAS no. 39551-54-7, Astatech, Inc., Bristol, PA) (50 mg, 0.25 mmol) in THF (2 mL) was treated with butan-1-amine <b>11a</b> (0.03 mL, 0.28 mmol) and <i>N</i>,<i>N</i>-diisopropylethylamine (0.13 mL, 0.75 mmol). The mixture was stirred for 30 min, and then Dmb-NH<sub>2</sub> (0.19 mL, 1.25 mmol) and <i>N</i>,<i>N</i>-diisopropylethylamine (0.13 mL, 0.75 mmol) were added. The mixture was heated at 100 °C for 16 h, cooled to rt, diluted with EtOAc (20 mL), washed with water (20 mL) and brine (20 mL), and then concentrated under reduced pressure. The residue was subjected to silica gel chromatography eluting with 0–100% EtOAc–hexanes to provide <b>12a</b>. LC/MS (<i>m</i>/<i>z</i>) 368.14 [M + 1]. <b>12a</b> was treated with TFA (3 mL), stirred for 30 min, diluted with water and MeOH, and then stirred for a further 60 min. The mixture was then concentrated under reduced pressure and the residue coevaporated with MeOH (3×). The solid was collected by filtration to provide <b>6a</b> (51 mg, 62%) as a TFA salt. <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ 8.59 (dd, <i>J</i> = 4.4, 1.4 Hz, 1H), 7.82 (dd, <i>J</i> = 8.5, 1.4 Hz, 1H), 7.72 (dd, <i>J</i> = 8.4, 4.4 Hz, 1H), 3.66 (t, <i>J</i> = 7.3 Hz, 2H), 1.76–1.64 (m, 2H), 1.43 (dq, <i>J</i> = 14.7, 7.4 Hz, 2H), 0.98 (t, <i>J</i> = 7.4 Hz, 3H). LC/MS (<i>m</i>/<i>z</i>) 218.1 [M + 1].</div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> <i>N</i><sup>4</sup>-(Pentan-2-yl)pyrido[3,2-<i>d</i>]pyrimidine-2,4-diamine (<b>6b</b>)</h3><div class="NLM_p last">The same procedure as <b>6a</b>, except replacing <b>11a</b> with (±)-pentan-2-amine <b>11b</b> provided <b>6b</b> (63 mg, 73%) as a TFA salt. <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ 8.61 (dd, <i>J</i> = 4.4, 1.4 Hz, 1H), 7.84 (dd, <i>J</i> = 8.5, 1.4 Hz, 1H), 7.74 (dd, <i>J</i> = 8.5, 4.4 Hz, 1H), 4.60–4.45 (m, 1H), 1.74 (dtd, <i>J</i> = 13.5, 8.3, 6.7 Hz, 1H), 1.68–1.55 (m, 1H), 1.41 (app h, <i>J</i> = 7.5 Hz, 2H), 1.32 (d, <i>J</i> = 6.6 Hz, 3H), 0.95 (t, <i>J</i> = 7.4 Hz, 3H). LC/MS (<i>m</i>/<i>z</i>) 232.1 [M + 1].</div></div><div id="sec4_1_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> (<i>R</i>)-2-((2-Aminopyrido[3,2-<i>d</i>]pyrimidin-4-yl)amino)pentan-1-ol ((<i>R</i>)-<b>6c</b>)</h3><div class="NLM_p last">The same procedure as <b>6a</b>, except replacing <b>11a</b> with (<i>R</i>)-2-aminopentan-1-ol (<i>R</i>)-<b>11c</b> provided (<i>R</i>)-<b>6c</b> (40 mg, 36%) as a TFA salt. <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ 8.64 (dd, <i>J</i> = 4.4, 1.4 Hz, 1H), 7.83 (dd, <i>J</i> = 8.5, 1.5 Hz, 1H), 7.76 (dd, <i>J</i> = 8.5, 4.4 Hz, 1H), 4.55 (dq, <i>J</i> = 7.4, 5.4 Hz, 1H), 3.78–3.69 (m, 2H), 1.77–1.65 (m, 2H), 1.52–1.36 (m, 2H), 0.98 (t, <i>J</i> = 7.3 Hz, 3H). LC/MS (<i>m</i>/<i>z</i>) 248.1 [M + 1].</div></div><div id="sec4_1_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> (<i>S</i>)-2-((2-Amino-[3,2-<i>d</i>]pyrimidin-4-yl)amino)pentan-1-ol ((<i>S</i>)-<b>6c</b>)</h3><div class="NLM_p last">The same procedure as <b>6a</b>, except replacing <b>11a</b> with (<i>S</i>)-2-aminopentan-1-ol (<i>S</i>)-<b>11c</b> provided (<i>S</i>)-<b>6c</b> (3 mg, 11%) as a TFA salt, with the exception that, after the addition of the Dmb-NH<sub>2</sub>, the mixture was heated at 135 °C in a microwave reactor for 30 min, and the final compound (<i>S</i>)-<b>6c</b> was subjected to purification via reverse phase preparative HPLC (10–70% CH<sub>3</sub>CN in water with 0.1% TFA using a Hydro-RP column over a 20 min gradient). <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ 8.37 (dd, <i>J</i> = 4.2, 1.5 Hz, 1H), 7.62 (dd, <i>J</i> = 8.5, 1.5 Hz, 1H), 7.52 (dd, <i>J</i> = 8.5, 4.2 Hz, 1H), 4.37 (dq, <i>J</i> = 10.1, 5.0 Hz, 1H), 3.69 (d, <i>J</i> = 4.9 Hz, 2H), 1.78–1.62 (m, 2H), 1.44 (dq, <i>J</i> = 14.5, 6.9 Hz, 2H), 0.97 (t, <i>J</i> = 7.3 Hz, 3H). LC/MS (<i>m</i>/<i>z</i>) 248.2 [M + 1].</div></div><div id="sec4_1_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> (<i>R</i>)-2-((2-Aminopyrido[3,2-<i>d</i>]pyrimidin-4-yl)amino)hexan-1-ol ((<i>R</i>)-<b>6d</b>)</h3><div class="NLM_p last">The same procedure as <b>6a</b>, except replacing <b>11a</b> with (<i>R</i>)-2-aminohexan-1-ol (<i>R</i>)-<b>11d</b> provided (<i>R</i>)-<b>6d</b> (50 mg, 55%) as a TFA salt. <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ 8.64 (dd, <i>J</i> = 4.3, 1.5 Hz, 1H), 7.82 (dd, <i>J</i> = 8.5, 1.5 Hz, 1H), 7.77 (dd, <i>J</i> = 8.5, 4.3 Hz, 1H), 4.53 (m, 1H), 3.73 (d, <i>J</i> = 5.3 Hz, 2H), 1.85–1.59 (m, 2H), 1.39 (m, 4H), 0.91 (m, 3H). LC/MS (<i>m</i>/<i>z</i>) 262.2 [M + 1].</div></div><div id="sec4_1_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> (<i>S</i>)-2-((2-Aminopyrido[3,2-<i>d</i>]pyrimidin-4-yl)amino)hexan-1-ol ((<i>S</i>)-<b>6d</b>)</h3><div class="NLM_p last">The same procedure as <b>6a</b>, except replacing <b>11a</b> with (<i>S</i>)-2-aminohexan-1-ol (<i>S</i>)-<b>11d</b> provided (<i>S</i>)-<b>6d</b> (46 mg, 50%) as a TFA salt. <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ 8.63 (dd, <i>J</i> = 4.4, 1.4 Hz, 1H), 7.84 (dd, <i>J</i> = 8.5, 1.4 Hz, 1H), 7.76 (dd, <i>J</i> = 8.5, 4.4 Hz, 1H), 4.53 (m, 1H), 3.73 (d, <i>J</i> = 5.3 Hz, 2H), 1.87–1.61 (m, 2H), 1.52–1.31 (m, 4H), 1.01–0.85 (m, 3H). LC/MS (<i>m</i>/<i>z</i>) 262.2 [M + 1].</div></div><div id="sec4_1_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> (<i>R</i>)-3-((2-Aminopyrido[3,2-<i>d</i>]pyrimidin-4-yl)amino)heptan-1-ol ((<i>R</i>)-<b>6e</b>)</h3><div class="NLM_p last">The same procedure as <b>6a</b>, except replacing <b>11a</b> with (<i>R</i>)-3-aminoheptan-1-ol (<i>R</i>)-<b>11e</b> and heating at 100° for 1 h prior to the Dmb-NH<sub>2</sub> addition provided (<i>R</i>)-<b>6e</b> (19 mg, 19%) as a TFA salt. <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ 8.63 (dd, <i>J</i> = 4.4, 1.5 Hz, 1H), 7.82 (dd, <i>J</i> = 8.5, 1.5 Hz, 1H), 7.76 (dd, <i>J</i> = 8.5, 4.4 Hz, 1H), 4.65–4.62 (m, 1H), 3.72–3.59 (m, 2H), 1.99–1.83 (m, 2H), 1.81–1.66 (m, 2H), 1.46–1.29 (m, 4H), 0.97–0.82 (m, 3H). LC/MS (<i>m</i>/<i>z</i>) 276.1 [M + 1].</div></div><div id="sec4_1_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> (<i>R</i>)-<i>N</i><sup>4</sup>-(1-Aminohexan-2-yl)pyrido[3,2-<i>d</i>]pyrimidine-2,4-diamine ((<i>R</i>)-<b>6f</b>)</h3><div class="NLM_p last">The same procedure as <b>6a</b>, except replacing <b>11a</b> with (<i>R</i>)-<b>11f</b> and heating the reaction after the Dmb-NH<sub>2</sub> addition at 125 °C for 24 h, provided (<i>R</i>)-<b>6f</b> (6 mg, 40%) as a TFA salt. <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ 8.68 (dd, <i>J</i> = 4.4, 1.4 Hz, 1H), 7.89 (dd, <i>J</i> = 8.5, 1.5 Hz, 1H), 7.81 (dd, <i>J</i> = 8.5, 4.4 Hz, 1H), 7.24 (d, <i>J</i> = 8.3 Hz, 1H), 6.62 (d, <i>J</i> = 2.4 Hz, 1H), 6.55 (dd, <i>J</i> = 8.3, 2.4 Hz, 1H), 3.70–3.51 (m, 1H), 1.74 (ddh, <i>J</i> = 21.4, 14.1, 7.5 Hz, 2H), 1.63–1.30 (m, 4H), 0.98 (t, <i>J</i> = 7.1 Hz, 3H). LC/MS (<i>m</i>/<i>z</i>) 261.1 [M + 1].</div></div><div id="sec4_1_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> (<i>R</i>)-2-((2-Aminopyrido[3,2-<i>d</i>]pyrimidin-4-yl)amino)heptan-1-ol ((<i>R</i>)-<b>6g</b>)</h3><div class="NLM_p last">Compound <b>8</b> (89 mg, 0.44 mmol) in THF (5 mL) was treated with <i>N</i>,<i>N</i>-diisopropylethylamine (0.26 mL, 1.76 mmol) and (<i>R</i>)-<b>11g</b> (71 mg, 0.44 mmol). The reaction was stirred for 1 h, and then the mixture was treated with Dmb-NH<sub>2</sub> (0.17 mL, 1.1 mmol) and heated at 120 °C overnight. The reaction mixture was then partitioned between EtOAc (50 mL) and H<sub>2</sub>O (50 mL). The organic layer was separated, dried, and concentrated under reduced pressure. The residue was subjected to silica gel chromatography eluting with 0–100% EtOAc–hexanes to provide the Dmb-intermediate <b>12g</b> (82 mg, 52%). LC/MS (<i>m</i>/<i>z</i>) 454.6 [M + 1]. <b>12g</b> (169 mg, 0.37 mmol) was dissolved in THF (5 mL) and treated with 1 M lithium aluminum hydride in Et<sub>2</sub>O (1.1 mL, 1.1 mmol). The reaction mixture was stirred at rt for 2 h and then quenched with water. The mixture was extracted with EtOAc (3×), the organics combined, dried, and concentrated under reduced pressure. The crude product (∼20 mg) was used without further purification. LC/MS (<i>m</i>/<i>z</i>) 426.4 [M + 1]. The crude product was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (2 mL) and TFA (0.5 mL) and the mixture stirred for 3 h. The reaction mixture was concentrated under reduced pressure and the residue subjected to reverse phase preparative HPLC (10–70% CH<sub>3</sub>CN in water with 0.1% TFA using a Hydro-RP column over a 20 min gradient) to provide (<i>R</i>)-<b>6g</b> (0.7 mg, 5%) as a TFA salt. <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ 8.65 (dd, <i>J</i> = 4.3, 1.6 Hz, 1H), 7.92–7.66 (m, 2H), 4.66–4.43 (m, 1H), 3.73 (d, <i>J</i> = 5.3 Hz, 2H), 1.81–1.57 (m, 2H), 1.51–1.20 (m, 6H), 0.89 (t, <i>J</i> = 7.0 Hz, 3H). LC/MS (<i>m</i>/<i>z</i>) 276.4 [M + 1].</div></div><div id="sec4_1_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> (<i>R</i>)-2-((2-Aminopyrido[3,2-<i>d</i>]pyrimidin-4-yl)amino)hexanoic Acid ((<i>R</i>)-<b>6h</b>)</h3><div class="NLM_p">Compound <b>8</b> (500 mg, 2.50 mmol) in THF (10 mL) was treated with <span class="smallcaps smallerCapital">d</span>-norleucine, methyl ester hydrochloride (<i>R</i>)-<b>11h</b> (455 mg, 2.50 mmol, Combi-Blocks, Inc., San Diego, CA), and <i>N</i>,<i>N</i>-diisopropylethylamine (1.3 mL, 7.50 mmol). The mixture was stirred for 3.5 min, and then Dmb-NH<sub>2</sub> (1.9 mL, 12.5 mmol), <i>N</i>,<i>N</i>-diisopropylethylamine (1.3 mL, 7.50 mmol), and THF (5 mL) were added. The mixture was heated to 100 °C for 16 h, cooled to room temperature, diluted with EtOAc (50 mL), washed with water (50 mL) and brine (50 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure. The residue was subjected to silica gel chromatography eluting with 0–100% EtOAc–hexanes to provide methyl (<i>R</i>)-2-((2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-<i>d</i>]pyrimidin-4-yl)amino)hexanoate <b>12h</b> (750.7 mg, 68%). <sup>1</sup>H NMR (400 MHz, CHCl<sub>3</sub>-<i>d</i><sub>1</sub>) δ 8.33 (dd, <i>J</i> = 4.2, 1.5 Hz, 1H), 7.68 (d, <i>J</i> = 7.6 Hz, 1H), 7.43 (dd, <i>J</i> = 8.5, 4.2 Hz, 1H), 7.28 (s, 1H), 6.46 (d, <i>J</i> = 2.3 Hz, 1H), 6.41 (dd, <i>J</i> = 8.2, 2.4 Hz, 1H), 4.88 (q, <i>J</i> = 7.3 Hz, 1H), 4.59 (d, <i>J</i> = 6.0 Hz, 2H), 3.85 (s, 3H), 3.79 (s, 3H), 3.75 (s, 3H), 2.04–1.95 (m, 1H), 1.88 (dq, <i>J</i> = 14.8, 7.6 Hz, 1H), 1.40 (m, 4H), 0.91 (t, <i>J</i> = 7.1 Hz, 3H). LC/MS (<i>m</i>/<i>z</i>) 440.19 [M + 1].</div><div class="NLM_p">Methyl (<i>R</i>)-2-((2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-<i>d</i>]pyrimidin-4-yl)amino)hexanoate <b>12h</b> (750.7 mg, 1.71 mmol) in THF (3.6 mL) and MeOH (3.6 mL) was treated with 1 M aq KOH (3.6 mL), and the mixture stirred for 4 h. The reaction was neutralized with 1 M aq HCl and then concentrated under reduced pressure to provide (<i>R</i>)-2-((2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-<i>d</i>]pyrimidin-4-yl)amino)hexanoic acid (992.0 mg, 100%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.34 (d, <i>J</i> = 4.1 Hz, 1H), 7.77 (s, 1H), 7.61 (d, <i>J</i> = 6.5 Hz, 1H), 7.53 (dd, <i>J</i> = 8.5, 4.2 Hz, 1H), 7.10 (m, 1H), 6.53 (d, <i>J</i> = 2.3 Hz, 1H), 6.42 (dd, <i>J</i> = 7.9, 2.0 Hz, 1H), 4.65 (m, 1H), 4.44 (m, 2H), 3.81 (s, 3H), 3.71 (s, 3H), 1.90 (m, 2H), 1.30 (m, 4H), 0.84 (m, 3H). LC/MS (<i>m</i>/<i>z</i>) 426.16 [M + 1].</div><div class="NLM_p last">(<i>R</i>)-2-((2-((2,4-Dimethoxybenzyl)amino)pyrido[3,2-<i>d</i>]pyrimidin-4-yl)amino)hexanoic acid (10.9 mg, 0.02 mmol) was treated with TFA (3 mL) and the mixture stirred for 2.5 h. The reaction was concentrated under reduced pressure and then the residue coevaporated with MeOH (3 × 20 mL). The residue was suspended in MeOH and filtered. The solution was concentrated under reduced pressure to provide (<i>R</i>)-<b>6h</b> (17.3 mg, 100%) as a TFA salt. <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ 8.67 (dd, <i>J</i> = 4.4, 1.4 Hz, 1H), 7.89 (dd, <i>J</i> = 8.5, 1.5 Hz, 1H), 7.79 (dd, <i>J</i> = 8.5, 4.4 Hz, 1H), 4.97 (dd, <i>J</i> = 8.4, 5.0 Hz, 1H), 2.23–2.08 (m, 1H), 2.08–1.96 (m, 1H), 1.47–1.37 (m, 4H), 0.93 (t, <i>J</i> = 7.1 Hz, 3H). LC/MS (<i>m</i>/<i>z</i>) 276.12 [M + 1].</div></div><div id="sec4_1_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> (<i>R</i>)-2-((2-Aminopyrido[3,2-<i>d</i>]pyrimidin-4-yl)amino)hexanamide ((<i>R</i>)-<b>6i</b>)</h3><div class="NLM_p">(<i>R</i>)-2-((2-((2,4-Dimethoxybenzyl)amino)pyrido[3,2-<i>d</i>]pyrimidin-4-yl)amino)hexanoic acid (50 mg, 0.12 mmol, see example (<i>R</i>)-<b>6h</b>) in NMP (6 mL) was treated with 0.5 M ammonia in 1,4-dioxane (1.2 mL, 0.6 mmol), <i>N</i>,<i>N</i>-diisopropylethylamine (1.2 mL, 6.89 mmol), and HATU (174.2 mg, 0.46 mmol). The mixture was stirred for 3.5 h, and then the mixture was subjected to reverse phase preparative HPLC (10–70% CH<sub>3</sub>CN in water with 0.1% TFA on a Synergi 4 μ Polar-RP 80A Axia over a 20 min gradient) to provide (<i>R</i>)-2-((2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-<i>d</i>]pyrimidin-4-yl)amino)hexanamide (7.4 mg, 14%). LC/MS (<i>m</i>/<i>z</i>) 425.13 [M + 1].</div><div class="NLM_p last">(<i>R</i>)-2-((2-((2,4-Dimethoxybenzyl)amino)pyrido[3,2-<i>d</i>]pyrimidin-4-yl)amino)hexanamide (7.4 mg, 0.02 mmol) was treated with TFA (3 mL) and the mixture stirred for 4.5 h. The reaction was concentrated under reduced pressure and coevaporated with MeOH (3 × 20 mL). The residue was subjected to reverse phase preparative HPLC (10–60% CH<sub>3</sub>CN in water with 0.1% TFA on a Synergi 4 μ Polar-RP 80A Axia over a 20 min gradient) to provide (<i>R</i>)-<b>6i</b> (1.5 mg, 22%) as a TFA salt. <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ 8.69 (dd, <i>J</i> = 4.3, 1.5 Hz, 1H), 7.85 (dd, <i>J</i> = 8.5, 1.5 Hz, 1H), 7.80 (dd, <i>J</i> = 8.5, 4.3 Hz, 1H), 2.17–2.03 (m, 1H), 2.03–1.90 (m, 1H), 1.50–1.35 (m, 4H), 0.93 (t, <i>J</i> = 6.9 Hz, 3H). LC/MS (<i>m</i>/<i>z</i>) 275.17 [M + 1].</div></div><div id="sec4_1_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> (<i>R</i>)-2-((2-Aminopyrido[3,2-<i>d</i>]pyrimidin-4-yl)amino)-<i>N</i>-methylhexanamide ((<i>R</i>)-<b>6j</b>)</h3><div class="NLM_p">(<i>R</i>)-2-((2-((2,4-Dimethoxybenzyl)amino)pyrido[3,2-<i>d</i>]pyrimidin-4-yl)amino)hexanoic acid (100 mg, 0.24 mmol, see example (<i>R</i>)-<b>6h</b>) in NMP (10 mL)) was treated with 2 M methylamine in THF (0.25 mL, 0.5 mmol), <i>N</i>,<i>N</i>-diisopropylethylamine (0.20 mL, 1.17 mmol), and HATU (138 mg, 0.36 mmol). The mixture was stirred for 2.5 h and then subjected to reverse phase preparative HPLC (20–60% CH<sub>3</sub>CN in water with 0.1% TFA on a Synergi 4 μ Polar-RP 80A Axia over a 20 min gradient) to provide (<i>R</i>)-2-((2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-<i>d</i>]pyrimidin-4-yl)amino)-<i>N</i>-methylhexanamide (22.6 mg, 18%). LC/MS (<i>m</i>/<i>z</i>) 439.15 [M + 1].</div><div class="NLM_p last">(<i>R</i>)-2-((2-((2,4-Dimethoxybenzyl)amino)pyrido[3,2-<i>d</i>]pyrimidin-4-yl)amino)-<i>N</i>-methylhexanamide (22.6 mg, 0.05 mmol) was treated with TFA (3 mL) and the mixture stirred for 3.5 h. The reaction was concentrated under reduced pressure and then coevaporated with MeOH (3 × 20 mL). The residue was subjected to reverse phase preparative HPLC (10–60% CH<sub>3</sub>CN in water with 0.1% TFA on a Synergi 4 μ Polar-RP 80A Axia over a 20 min gradient) to provide (<i>R</i>)-<b>6j</b> (8.8 mg, 42%) as a TFA salt. <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ 8.68 (dd, <i>J</i> = 4.4, 1.5 Hz, 1H), 7.87 (dd, <i>J</i> = 8.5, 1.5 Hz, 1H), 7.80 (dd, <i>J</i> = 8.5, 4.3 Hz, 1H), 4.82 (dd, <i>J</i> = 8.3, 5.5 Hz, 1H), 2.77 (s, 3H), 2.14–2.00 (m, 1H), 2.00–1.86 (m, 1H), 1.52–1.32 (m, 4H), 0.94 (t, <i>J</i> = 7.0 Hz, 3H). LC/MS (<i>m</i>/<i>z</i>) 289.23 [M + 1].</div></div><div id="sec4_1_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> (<i>S</i>)-2-((2-Amino-7-fluoropyrido[3,2-<i>d</i>]pyrimidin-4-yl)amino)-2-methylhexan-1-ol ((<i>S</i>)<b>-7</b>)</h3><div class="NLM_p last">Compound <b>32</b> (140 mg, 78 mmol) and (<i>S</i>)-<b>18c</b> (125 mg, 0.95 mmol) in NMP (7.5 mL) were treated with 1,8-diazabicyclo[5.4.0]undec-7-ene (0.35 mL, 2.4 mmol) followed by (benzotriazol-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate (419 mg, 0.95 mmol). The mixture was stirred for 16 h and then subjected to reverse phase preparative HPLC (10–50% CH<sub>3</sub>CN in water with 0.1% TFA on a Gemini 10 μ C18 110A Axia over a 20 min gradient) to provide (<i>S</i>)-<b>7</b> (45 mg, 20%) as a TFA salt. <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ 8.55 (d, <i>J</i> = 2.4 Hz, 1H), 7.63 (dd, <i>J</i> = 8.7, 2.5 Hz, 1H), 3.97 (d, <i>J</i> = 11.2 Hz, 1H), 3.71 (d, <i>J</i> = 11.2 Hz, 1H), 2.15–2.04 (m, 1H), 1.98–1.87 (m, 1H), 1.54 (s, 3H), 1.41–1.31 (m, 4H), 0.92 (t, <i>J</i> = 6.9 Hz, 3H). <sup>19</sup>F NMR (377 MHz, MeOH-<i>d</i><sub>4</sub>) δ −118.22 (d, <i>J</i> = 8.7 Hz). LC/MS (<i>m</i>/<i>z</i>) 294.1 [M + 1].</div></div><div id="sec4_1_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> (<i>R</i>)-2-((2-Amino-7-fluoropyrido[3,2-<i>d</i>]pyrimidin-4-yl)amino)-2-methylhexan-1-ol ((<i>R</i>)-<b>7</b>)</h3><div class="NLM_p">Compound <b>25</b> (9.5 g, 43.6 mmol) and (<i>R</i>)-<b>18c</b> (5.5 g, 41.9 mmol) in 2-methyl THF (400 mL) was treated with <i>N</i>,<i>N</i>-diisopropylethylamine (29 mL, 167.7 mmol) and the mixture heated at reflux for 4 h. The reaction was cooled to rt, and solids removed by filtration. The eluant was concentrated under reduced pressure and the residue diluted in EtOAc (300 mL) and H<sub>2</sub>O (300 mL). The organics were separated and then washed with brine (100 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure to ∼75 mL. To this concentrated solution, hexanes (200 mL) was slowly added via addition funnel with stirring to induce precipitation. The resulting solid product was filtered and air-dried to provide (<i>R</i>)-2-((2-chloro-7-fluoropyrido[3,2-<i>d</i>]pyrimidin-4-yl)amino)-2-methylhexan-1-ol (7.7 g, 58.7%) as a tan solid. The mother liquor was subjected to silica gel chromatography eluting with 0–100% EtOAc-hexanes to provide additional product (3.3 g, 25.2%). <sup>1</sup>H NMR (400 MHz, CHCl<sub>3</sub>-<i>d</i><sub>1</sub>) δ 8.56 (d, <i>J</i> = 2.6 Hz, 1H), 7.74 (dd, <i>J</i> = 8.8, 2.2 Hz, 1H), 7.50 (d, <i>J</i> = 13.5 Hz, 1H), 3.86 (d, <i>J</i> = 12.1 Hz, 1H), 3.81 (d, <i>J</i> = 12.1 Hz, 1H), 1.95 (ddd, <i>J</i> = 13.6, 11.8, 4.4 Hz, 1H), 1.82 (ddd, <i>J</i> = 13.7, 11.9, 4.2 Hz, 1H), 1.46 (s, 3H), 1.44–1.23 (m, 4H), 0.93 (t, <i>J</i> = 7.1 Hz, 3H). <sup>19</sup>F NMR (377 MHz, CHCl<sub>3</sub>-<i>d</i><sub>1</sub>) δ −116.77. LC/MS (<i>m</i>/<i>z</i>) 313.3 [M + 1].</div><div class="NLM_p">(<i>R</i>)-2-((2-Chloro-7-fluoropyrido[3,2-<i>d</i>]pyrimidin-4-yl)amino)-2-methylhexan-1-ol (5.9 g, 18.9 mmol) in 2-methyl THF (200 mL) was treated with Dmb-NH<sub>2</sub> (7.0 mL, 46.6 mmol) and <i>N</i>,<i>N</i>-diisopropylethylamine (10.0 mL, 57.4 mmol). The reaction vessel was then sealed and heated at 110 °C for 8 h. The mixture was then allowed to cool to rt, diluted with EtOAc (500 mL), washed with water (500 mL) and brine (300 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The residue was subjected to silica gel chromatography eluting with 0–100% EtOAc–hexanes to provide (<i>R</i>)-2-((2-((2,4-dimethoxybenzyl)amino)-7-fluoropyrido[3,2-<i>d</i>]pyrimidin-4-yl)amino)-2-methylhexan-1-ol (7.02 g, 84%). <sup>1</sup>H NMR (400 MHz, CHCl<sub>3</sub>-<i>d</i><sub>1</sub>) δ 8.13 (d, <i>J</i> = 2.5 Hz, 1H), 7.33 (s, 1H), 7.28 (s, 1H), 7.10 (s, 1H), 6.46 (d, <i>J</i> = 2.4 Hz, 1H), 6.42 (dd, <i>J</i> = 8.2, 2.4 Hz, 1H), 4.56 (d, <i>J</i> = 5.8 Hz, 2H), 3.84 (s, 3H), 3.79 (s, 3H), 3.76 (s, 2H), 1.91 (m, 1H), 1.74 (m, 2H), 1.39 (s, 3H), 1.48–1.28 (m, 4H), 0.91 (t, <i>J</i> = 7.0 Hz, 4H). <sup>19</sup>F NMR (377 MHz, CHCl<sub>3</sub>-<i>d</i><sub>1</sub>) δ −121.34. LC/MS (<i>m</i>/<i>z</i>) 444.2 [M + 1].</div><div class="NLM_p last">(<i>R</i>)-2-((2-((2,4-Dimethoxybenzyl)amino)-7-fluoropyrido[3,2-<i>d</i>]pyrimidin-4-yl)amino)-2-methylhexan-1-ol (9.5 g, 21.4 mmol) was dissolved in TFA (200 mL) and the mixture stirred for 3 h. The mixture was concentrated under reduced pressure, and the residue was diluted with MeOH (80 mL) and the mixture stirred for 16 h. The mixture was filtered and the solids rinsed with MeOH (3 × 20 mL). The eluant was concentrated under reduced pressure and the residue coevaporated with toluene and dried under vacuum. The solid was then dissolved in Et<sub>2</sub>O (300 mL), washed with satd NaHCO<sub>3</sub> solution (3 × 100 mL) and brine (100 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure to provide (<i>R</i>)-<b>7</b> (5.5 g, 88%). <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ 8.25 (d, <i>J</i> = 2.6 Hz, 1H), 7.26 (dd, <i>J</i> = 10.1, 2.6 Hz, 1H), 3.92 (d, <i>J</i> = 11.3 Hz, 1H), 3.73 (d, <i>J</i> = 11.3 Hz, 1H), 2.16–2.03 (m, 1H), 1.87–1.76 (m, 1H), 1.46 (s, 3H), 1.43–1.26 (m, 4H), 0.91 (t, <i>J</i> = 7.0 Hz, 3H). <sup>19</sup>F NMR (377 MHz, MeOH-<i>d</i><sub>4</sub>) δ −123.39 (d, <i>J</i> = 10.0 Hz). LC/MS (<i>m</i>/<i>z</i>) 294.1 [M + 1].</div></div><div id="sec4_1_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> 4-Butoxypyrido[3,2-<i>d</i>]pyrimidin-2-amine (<b>10</b>)</h3><div class="NLM_p">Compound <b>8</b> (50 mg, 0.25 mmol, CAS no. 39551-54-7, Astatech, Inc., Bristol, PA) in THF (2 mL) was treated with butan-1-ol (0.03 mL, 0.28 mmol) and NaH 60% oil dispersion (12 mg, 0.3 mmol). The reaction mixture was stirred for 6 h and then diluted with EtOAc (50 mL), washed with water (50 mL) and brine (50 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure. The residue was subjected to silica gel chromatography eluting with 0–100% EtOAc–hexanes to provide 4-butoxy-2-chloropyrido[3,2-<i>d</i>]pyrimidine (42 mg, 71%). LC/MS (<i>m</i>/<i>z</i>) 237.91 [M + 1]. The 4-butoxy-2-chloropyrido[3,2-<i>d</i>]pyrimidine (42 mg, 0.18 mmol) in THF (10 mL) was then treated with Dmb-NH<sub>2</sub> (0.19 mL, 1.25 mmol) and <i>N</i>,<i>N</i>-diisopropylethylamine (0.13 mL, 0.75 mmol) and the mixture heated at 100 °C for 16 h. The reaction was cooled to rt, diluted with EtOAc (20 mL), washed with water (20 mL) and brine (20 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure. The residue was subjected to silica gel chromatography eluting with 0–40% EtOAc–hexanes to provide <b>9</b> (24 mg, 37%). LC/MS (<i>m</i>/<i>z</i>) 369.07 [M + 1].</div><div class="NLM_p last">Compound <b>9</b> (24 mg, 0.07 mmol) was treated with TFA (3 mL) and the mixture stirred for 1 h. The mixture was diluted with water and MeOH and stirred for 1 h before concentration under reduced pressure. The residue was coevaporated with MeOH (3 × 20 mL), suspended in MeOH, and filtered. The eluant was concentrated under reduced pressure and the residue subjected to reverse phase preparative HPLC (10–70% CH<sub>3</sub>CN in water with 0.1% TFA on a Synergi 4 μ Polar-RP 80A Axia over a 20 min gradient) to provide <b>10</b> (2 mg, 9%) as a TFA salt. <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ 8.75 (dd, <i>J</i> = 4.4, 1.4 Hz, 1H), 7.99 (dd, <i>J</i> = 8.6, 1.4 Hz, 1H), 7.89 (dd, <i>J</i> = 8.6, 4.3 Hz, 1H), 4.73 (t, <i>J</i> = 6.6 Hz, 2H), 1.99–1.89 (m, 2H), 1.62–1.52 (m, 2H), 1.03 (t, <i>J</i> = 7.4 Hz, 3H). LC/MS (<i>m</i>/<i>z</i>) 218.95 [M + 1].</div></div><div id="sec4_1_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> (<i>R</i>)-2-((2-Aminoquinazolin-4-yl)amino)hexan-1-ol ((<i>R</i>)-<b>14</b>)</h3><div class="NLM_p last">Compound <b>13</b> (20 mg, 0.12 mmol) and (benzotriazol-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate (66.0 mg, 0.15 mmol) were suspended in DMF (1.3 mL) and treated with 1,8-diazabicyclo[5.4.0]undec-7-ene (0.05 mL, 0.27 mmol). The mixture was stirred for 4.5 h, (<i>R</i>)-<b>11d</b> (39 mg, 0.27 mmol) was added, and after 16 h, the reaction mixture was subjected to reverse phase preparative HPLC (10%–70% CH<sub>3</sub>CN in water with 0.1% TFA on a Synergi 4 μ Polar-RP 80A Axia over a 20 min gradient) to provide (<i>R</i>)-<b>14</b> (33.2 mg, 71%) as a TFA salt. <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ 8.23–8.21 (m, 1H), 7.80–7.76 (m, 1H), 7.50–7.33 (m, 2H), 4.71–4.56 (m, 1H), 3.80–3.61 (m, 2H), 1.81–1.64 (m, 2H), 1.47–1.31 (m, 4H), 0.92 (m, 3H). LC/MS (<i>m</i>/<i>z</i>) 261.1 [M + 1].</div></div><div id="sec4_1_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> (<i>S</i>)-2-((2-Aminoquinazolin-4-yl)amino)hexan-1-ol ((<i>S</i>)-<b>14</b>)</h3><div class="NLM_p last">The same procedure as (<i>R</i>)-<b>14</b>, except with addition of (<i>S</i>)-<b>11d</b> provided (<i>S</i>)-<b>14</b> (29 mg, 62%) as a TFA salt. <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ 8.23–8.21 (m, 1H), 7.80–7.76 (m, 1H), 7.45–7.39 (m, 2H), 4.71–4.56 (m, 1H), 3.80–3.61 (m, 2H), 1.81–1.64 (m, 2H), 1.47–1.31 (m, 4H), 0.92 (m, 3H). LC/MS (<i>m</i>/<i>z</i>) 261.1 [M + 1].</div></div><div id="sec4_1_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> (<i>R</i>)-2-((2-Aminoquinolin-4-yl)amino)hexan-1-ol ((<i>R</i>)-<b>16</b>)</h3><div class="NLM_p last">Compound <b>15</b> (50 mg, 0.28 mmol), (<i>R</i>)-<b>11d</b> (82.01 mg, 0.7 mmol), bis(dibenzylideneacetone)palladium(0) (8.08 mg, 0.01 mmol), sodium <i>tert</i>-butoxide (53.8 mg, 0.56 mmol), and (<i>R</i>)-(+)-2,2′-bis(diphenylphosphino)-1,1′-binaphthyl (9.11 mg, 0.01 mmol) were added to 1,4-dioxane (4 mL) and the mixture heated in a sealed vial at 135 °C for 4 h. The reaction was then diluted with minimal water and MeOH, filtered, and then subjected to reverse phase preparative HPLC (5–50% CH<sub>3</sub>CN in water with 0.1% TFA on a Synergi 4 μ Polar-RP 80A Axia over a 20 min gradient) to provide (<i>R</i>)-<b>16</b> (12 mg, 16%) as a TFA salt. <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ 8.30–8.27 (m, 1H), 7.83–7.79 (m, 1H), 7.63–7.60 (m, 1H), 7.54–7.50 (m, 1H), 6.48 (s, 1H), 4.57 (dd, <i>J</i> = 10.8, 3.2 Hz, 1H), 4.45 (dd, <i>J</i> = 10.7, 6.1 Hz, 1H), 3.84–3.78 (m, 1H), 1.93–1.86 (m, 2H), 1.62–1.35 (m, 4H), 0.99 (t, <i>J</i> = 7.0 Hz, 3H). LC/MS (<i>m</i>/<i>z</i>) 260.0 [M + 1].</div></div><div id="sec4_1_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> (<i>S</i>)-2-((2-Aminoquinolin-4-yl)amino)hexan-1-ol ((<i>S</i>)-<b>16</b>)</h3><div class="NLM_p last">The same procedure as (<i>R</i>)-<b>16</b>, except with the addition of (<i>S</i>)-<b>11d</b> (82.01 mg, 0.7 mmol) provided (<i>S</i>)-<b>16</b> (5.1 mg, 7%) as a TFA salt. <sup>1</sup>H (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ 8.30–8.28 (m, 1H), 7.83–7.79 (m, 1H), 7.66–7.58 (m, 1H), 7.54–7.50 (m, 1H), 6.47 (s, 1H), 4.57 (dd, <i>J</i> = 10.8, 3.2 Hz, 1H), 4.45 (dd, <i>J</i> = 10.7, 6.1 Hz, 1H), 3.84–3.79 (m, 1H), 1.95–1.84 (m, 2H), 1.62–1.35 (m, 4H), 0.99 (t, <i>J</i> = 7.0 Hz, 3H). LC/MS (<i>m</i>/<i>z</i>) 260.0 [M + 1].</div></div><div id="sec4_1_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> (<i>R</i>)-2-((2-Aminopyrido[3,2-<i>d</i>]pyrimidin-4-yl)amino)-2-methylpentan-1-ol ((<i>R</i>)-<b>23a</b>)</h3><div class="NLM_p">Compound <b>8</b> (540 mg, 2.71 mmol) was treated with dioxane (15 mL), followed by <i>N</i>,<i>N</i>-diisopropylethylamine (1.9 mL, 10.8 mmol) and (<i>R</i>)-<b>18a</b> (486 mg, 2.71 mmol). The reaction mixture was stirred at 80 °C for 15 min, then additional <b>8</b> (250 mg, 1.25 mmol) was added. The mixture was stirred at 80 °C overnight then treated with Dmb-NH<sub>2</sub> (0.80 mL, 5.0 mmol) and the mixture heated at 120 °C overnight. The reaction mixture was partitioned between EtOAc (50 mL) and H<sub>2</sub>O (50 mL), the organic layer separated, dried over MgSO<sub>4</sub>, and concentrated under reduced pressure. The residue was subjected to silica gel chromatography eluting with 0–100% EtOAc–hexanes to provide methyl (<i>R</i>)-2-((2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-<i>d</i>]pyrimidin-4-yl)amino)-2-methylpent-4-enoate (634 mg, 54%). LC/MS (<i>m</i>/<i>z</i>) 438.2 [M + 1].</div><div class="NLM_p">Methyl (<i>R</i>)-2-((2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-<i>d</i>]pyrimidin-4-yl)amino)-2-methylpent-4-enoate (634 mg, 1.44 mmol) was treated with THF (20 mL) and 1 M lithium aluminum hydride in Et<sub>2</sub>O (3.6 mL, 3.6 mmol). The reaction mixture was stirred for 2 h and then quenched with water (100 mL) and extracted with EtOAc (100 mL). The organic layer was separated, dried over MgSO<sub>4</sub>, and concentrated under reduced pressure. The residue was subjected to silica gel chromatography eluting with 0–100% EtOAc–hexanes to provide (<i>R</i>)-<b>22a</b> (168 mg, 28%). LC/MS (<i>m</i>/<i>z</i>) 410.2 [M + 1].</div><div class="NLM_p last">(<i>R</i>)-<b>22a</b> (35 mg, 0.09 mmol) was treated with Pd/C (60 mg) and EtOH (5 mL) and then stirred under H<sub>2</sub> for 24 h. The mixture was filtered and the eluant concentrated under reduced pressure. The residue was treated with CH<sub>2</sub>Cl<sub>2</sub> (2 mL) and TFA (0.5 mL) and the mixture stirred for 3 h. The reaction mixture was concentrated under reduced pressure and subjected to reverse phase preparative HPLC (10–70% CH<sub>3</sub>CN in water with 0.1% TFA using a Hydro-RP column) to provide (<i>R</i>)-<b>23a</b> (9.7 mg, 45%) as a TFA salt. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.85–7.61 (m, 2H), 7.42–7.25 (m, 3H), 6.05 (s, 1H), 3.65 (d, <i>J</i> = 8.6 Hz, 1H), 3.55 (d, <i>J</i> = 8.6 Hz, 1H), 1.71–1.41 (m, 4H), 1.45 (s, 3H), 0.90–0.75 (m, 3H). LC/MS (<i>m</i>/<i>z</i>) 262.1 [M + 1].</div></div><div id="sec4_1_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> 2-((2-Aminopyrido[3,2-<i>d</i>]pyrimidin-4-yl)amino)-2-butylhexan-1-ol (<b>23b</b>)</h3><div class="NLM_p">Compound <b>18b</b> (109 mg, 0.42 mmol) in THF (10 mL) was treated with <b>8</b> (94 mg, 0.47 mmol) and <i>N</i>,<i>N</i>-diisopropylethylamine (0.15 mL, 0.76 mmol) and the mixture heated at 80 °C for 20 h. Dmb-NH<sub>2</sub> (0.25 mL, 1.66 mmol) was added, and the mixture was heated at 100 °C for 24 h. The reaction mixture was cooled to rt, diluted with EtOAc (50 mL), washed with water (50 mL) and brine (50 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure. The residue was subjected to silica gel chromatography eluting with 0–100% EtOAc–hexanes to provide methyl 2-butyl-2-((2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-<i>d</i>]pyrimidin-4-yl)amino)hexanoate (64.4 mg, 52%). LC/MS (<i>m</i>/<i>z</i>) 496.27 [M + 1].</div><div class="NLM_p">Methyl 2-butyl-2-((2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-<i>d</i>]pyrimidin-4-yl)amino)hexanoate (64.4 mg) in THF (10 mL) at 0 °C was treated with 1 M lithium aluminum hydride in Et<sub>2</sub>O (0.9 mL, 0.9 mmol) and the mixture stirred for 3 h and allowed to warm to rt. The reaction was quenched with water (1 mL), followed by 2 M aq NaOH (0.1 mL), and the slurry that formed was filtered, rinsed with EtOAc, and the filtrate concentrated under reduced pressure. The residue was subjected to silica gel chromatography eluting with 20–100% EtOAc–hexanes to provide 2-butyl-2-((2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-<i>d</i>]pyrimidin-4-yl)amino)hexan-1-ol <b>22b</b> (21.1 mg, 35%). <sup>1</sup>H NMR (400 MHz, CHCl<sub>3</sub>-<i>d</i><sub>1</sub>) δ 8.26 (dd, <i>J</i> = 4.2, 1.5 Hz, 1H), 7.67 (d, <i>J</i> = 8.3 Hz, 1H), 7.41 (dd, <i>J</i> = 8.5, 4.2 Hz, 1H), 7.35–7.17 (m, 2H), 6.46 (d, <i>J</i> = 2.4 Hz, 1H), 6.41 (dd, <i>J</i> = 8.2, 2.4 Hz, 1H), 4.55 (d, <i>J</i> = 5.7 Hz, 2H), 3.83 (s, 3H), 3.80 (s, 2H), 3.78 (s, 3H), 1.79 (tt, <i>J</i> = 13.6, 9.9 Hz, 4H), 1.45–1.19 (m, 8H), 0.91 (t, <i>J</i> = 7.0 Hz, 6H). LC/MS (<i>m</i>/<i>z</i>) 468.22 [M + 1].</div><div class="NLM_p last"><b>22b</b> (21.1 mg, 0.05 mmol) was treated with TFA (3 mL) and the mixture stirred for 1 h. The reaction mixture was diluted with MeOH (10 mL), stirred for 1 h, and then concentrated under reduced pressure. The residue was coevaporated with MeOH (3 × 20 mL), resuspended in MeOH, and filtered. The filtrate was concentrated under reduced pressure to provide <b>23b</b> (21.3 mg, 100%) as a TFA salt. <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ 8.61 (dd, <i>J</i> = 4.4, 1.4 Hz, 1H), 7.85 (dd, <i>J</i> = 8.5, 1.4 Hz, 1H), 7.76 (dd, <i>J</i> = 8.5, 4.4 Hz, 1H), 3.90 (s, 2H), 2.03–1.95 (m, 4H), 1.39–1.31 (m, 8H), 0.92 (t, <i>J</i> = 6.9 Hz, 6H). LC/MS (<i>m</i>/<i>z</i>) 318.15 [M + 1].</div></div><div id="sec4_1_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> (<i>R</i>)-2-((2-Aminopyrido[3,2-<i>d</i>]pyrimidin-4-yl)amino)-2-methylhexan-1-ol ((<i>R</i>)-<b>23c</b>)</h3><div class="NLM_p last">Compound <b>8</b> (50 mg, 0.25 mmol) in THF (10 mL) was treated with (<i>R</i>)-<b>18c</b> (50 mg, 0.38 mmol) and <i>N</i>,<i>N</i>-diisopropylethylamine (0.13 mL, 0.75 mmol). The mixture was stirred at 80 °C for 18 h, and then Dmb-NH<sub>2</sub> (0.19 mL, 1.25 mmol) was added. The mixture was heated at 100 °C for 18 h, cooled to rt, diluted with EtOAc, washed with water and brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and then filtered and concentrated under reduced pressure. The residue was subjected to silica gel chromatography eluting with 0–100% EtOAc–hexanes to provide (<i>R</i>)-2-((2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-<i>d</i>]pyrimidin-4-yl)amino)-2-methylhexan-1-ol (18 mg, 17%). LC/MS (<i>m</i>/<i>z</i>) 426.2 [M + 1]. The (<i>R</i>)-2-((2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-<i>d</i>]pyrimidin-4-yl)amino)-2-methylhexan-1-ol (18 mg) was treated with TFA (3 mL) and the mixture stirred for 2 h. The reaction mixture was concentrated under reduced pressure and the residue subjected to reverse phase preparative HPLC (10%–70% CH<sub>3</sub>CN in water with 0.1% TFA on a Synergi 4 μ Polar-RP 80A Axia over a 20 min gradient) to provide (<i>R</i>)-<b>23c</b> (10 mg, 60%) as a TFA salt. <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ 8.63 (dd, <i>J</i> = 4.2, 1.6 Hz, 1H), 7.82 (dd, <i>J</i> = 8.5, 1.6 Hz, 1H), 7.78 (dd, <i>J</i> = 8.5, 4.2 Hz, 1H), 3.98 (d, <i>J</i> = 11.2 Hz, 1H), 3.73 (d, <i>J</i> = 11.2 Hz, 1H), 2.16–2.03 (m, 1H), 2.01–1.85 (m, 1H), 1.55 (s, 3H), 1.42–1.32 (m, 4H), 0.93 (t, <i>J</i> = 6.8 Hz, 3H). LC/MS (<i>m</i>/<i>z</i>) 276.1 [M + 1].</div></div><div id="sec4_1_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> (<i>S</i>)-2-((2-Aminopyrido[3,2-<i>d</i>]pyrimidin-4-yl)amino)-2-methylhexan-1-ol ((<i>S</i>)-<b>23c</b>)</h3><div class="NLM_p last">The same procedure as (<i>R</i>)-<b>23c</b> (50 mg), except with the addition of (<i>S</i>)-<b>18c</b> (250 mg, 1.38 mmol, Astatech, Inc., Bristol, PA) provided (<i>S</i>)-<b>23c</b> (25 mg, 26% overall yield) as a TFA salt. <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ 8.61 (dd, <i>J</i> = 4.4, 1.4 Hz, 1H), 7.85 (dd, <i>J</i> = 8.5, 1.4 Hz, 1H), 7.76 (dd, <i>J</i> = 8.5, 4.4 Hz, 1H), 3.98 (d, <i>J</i> = 11.3 Hz, 1H), 3.73 (d, <i>J</i> = 11.3 Hz, 1H), 2.17–2.05 (m, 1H), 1.98–1.85 (m, 1H), 1.55 (s, 3H), 1.40–1.32 (m, 4H), 0.92 (t, <i>J</i> = 6.9 Hz, 3H). LC/MS (<i>m</i>/<i>z</i>) 276.1 [M + 1].</div></div><div id="sec4_1_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> (<i>R</i>)-2-((2-Amino-7-fluoropyrido[3,2-<i>d</i>]pyrimidin-4-yl)amino)-2-methylheptan-1-ol ((<i>R</i>)-<b>23d</b>)</h3><div class="NLM_p last">The same procedure as (<i>R</i>)-<b>23c</b> (50 mg), except with the addition of (<i>R</i>)-<b>18d</b> (135 mg, 0.74 mmol) provided (<i>R</i>)-<b>23d</b> (9.3 mg, 7%) as a TFA salt. <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ 8.63 (dd, <i>J</i> = 4.3, 1.5 Hz, 1H), 7.86–7.80 (m, 1H), 7.77 (dd, <i>J</i> = 8.5, 4.3 Hz, 1H), 3.98 (d, <i>J</i> = 11.2 Hz, 1H), 3.72 (d, <i>J</i> = 11.2 Hz, 1H), 2.16–2.04 (m, 1H), 1.92 (tt, <i>J</i> = 11.1, 4.9 Hz, 1H), 1.55 (s, 3H), 1.42–1.28 (m, 6H), 0.93–0.85 (m, 3H). LC/MS (<i>m</i>/<i>z</i>) 290.2 [M + 1].</div></div><div id="sec4_1_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> (<i>R</i>)-2-((2-Aminopyrido[3,2-<i>d</i>]pyrimidin-4-yl)amino)-2-methyloctan-1-ol ((<i>R</i>)-<b>23e</b>)</h3><div class="NLM_p">(<i>R</i>)-<b>18e</b> (75 mg, 0.38 mmol) and <b>8</b> (76 mg, 0.38 mmol) in THF (2.5 mL) were treated with <i>N</i>,<i>N</i>-diisopropylethylamine (0.2 mL, 1.15 mmol) and the mixture stirred at 80 °C for 24 h. The reaction was cooled to ambient temperature, diluted with EtOAc (25 mL), washed with water (25 mL) and brine (25 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, then filtered and concentrated under reduced pressure. The residue was subjected to silica gel chromatography eluting with 0–50% EtOAc–hexanes to provide (<i>R</i>)-2-((2-chloropyrido[3,2-<i>d</i>]pyrimidin-4-yl)amino)-2-methyloctan-1-ol (85.6 mg, 69%). LC/MS (<i>m</i>/<i>z</i>) 323.11 [M + 1].</div><div class="NLM_p">(<i>R</i>)-2-((2-Chloropyrido[3,2-<i>d</i>]pyrimidin-4-yl)amino)-2-methyloctan-1-ol (86 mg, 0.27 mmol) in 2-MeTHF (3.0 mL) was treated with K<sub>2</sub>CO<sub>3</sub> (77 mg, 0.55 mmol) followed by Dmb-NH<sub>2</sub> (0.09 mL, 0.55 mmol) and the mixture stirred at 85 °C for 18 h. The reaction was cooled to ambient temperature, diluted with EtOAc (25 mL), washed with water (20 mL) and brine (20 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, then filtered and concentrated under reduced pressure. The residue was subjected to silica gel chromatography eluting with 20–100% EtOAc–hexanes to provide (<i>R</i>)-2-((2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-<i>d</i>]pyrimidin-4-yl)amino)-2-methyloctan-1-ol (64.6 mg, 54%). <sup>1</sup>H NMR (400 MHz, CHCl<sub>3</sub>-<i>d</i><sub>1</sub>) δ 8.27 (dd, <i>J</i> = 4.2, 1.4 Hz, 1H), 7.69 (d, <i>J</i> = 8.4 Hz, 1H), 7.42 (dd, <i>J</i> = 8.4, 4.2 Hz, 1H), 7.29 (d, <i>J</i> = 8.2 Hz, 1H), 7.24 (s, 1H), 6.46 (d, <i>J</i> = 2.3 Hz, 1H), 6.42 (dd, <i>J</i> = 8.2, 2.4 Hz, 1H), 4.57 (d, <i>J</i> = 5.8 Hz, 2H), 3.84 (s, 3H), 3.79 (s, 3H), 3.76 (s, 2H), 2.00–1.90 (m, 1H), 1.79–1.68 (m, 1H), 1.39 (s, 3H), 1.31–1.26 (m, 8H), 0.87 (t, <i>J</i> = 7.7 Hz, 3H). LC/MS (<i>m</i>/<i>z</i>) 454.20 [M + 1].</div><div class="NLM_p last">(<i>R</i>)-2-((2-((2,4-Dimethoxybenzyl)amino)pyrido[3,2-<i>d</i>]pyrimidin-4-yl)amino)-2-methyloctan-1-ol (57 mg, 0.13 mmol) was treated with TFA (3 mL), the mixture stirred for 3.5 h, and then concentrated under reduced pressure. The residue was coevaporated with MeOH (3 × 20 mL), then suspended in MeOH and filtered. The filtrate was stirred for 16 h and then concentrated under reduced pressure to provide (<i>R</i>)-<b>23e</b> (48 mg, 91%) as a TFA salt. <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ 8.60 (dd, <i>J</i> = 4.4, 1.4 Hz, 1H), 7.85 (dd, <i>J</i> = 8.5, 1.4 Hz, 1H), 7.76 (dd, <i>J</i> = 8.5, 4.4 Hz, 1H), 3.98 (d, <i>J</i> = 11.2 Hz, 1H), 3.73 (d, <i>J</i> = 11.3 Hz, 1H), 2.15–2.04 (m, 1H), 1.97–1.86 (m, 1H), 1.54 (s, 3H), 1.36–1.27 (m, 8H), 0.87 (t, <i>J</i> = 6.6 Hz, 3H). LC/MS (<i>m</i>/<i>z</i>) 304.15 [M + 1].</div></div><div id="sec4_1_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> 2,4-Dichloro-7-fluoropyrido[3,2-<i>d</i>]pyrimidine (<b>25</b>)</h3><div class="NLM_p">3-Amino-2-bromo-5-fluoropyridine <b>24</b> (25 g, 131 mmol, Astatech, Inc., Bristol, PA) was treated with ZnCN<sub>2</sub> (16.9 g, 144 mmol), Pd(Ph<sub>3</sub>)<sub>4</sub> (11.3 g, 9.8 mmol) in DMF (200 mL), and heated at 115 °C. The mixture was stirred for 6 h and then allowed to cool and concentrated under reduced pressure to a solid. The solid was washed with EtOAc (2×) and filtered. The organic layers were combined, washed water (3×), satd aq NH<sub>4</sub>Cl, dried over MgSO<sub>4</sub>, filtered, and concentrated under reduced pressure to provide crude 3-amino-5-fluoropicolinonitrile (19.8 g, quant). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.86 (d, <i>J</i> = 2.4 Hz, 1H), 7.01 (dd, <i>J</i> = 11.0, 2.5 Hz, 1H), 6.55 (s, 2H). <sup>19</sup>F NMR (377 MHz, DMSO-<i>d</i><sub>6</sub>) δ −119.65 (d, <i>J</i> = 11.0 Hz).</div><div class="NLM_p">The crude 3-amino-5-fluoropicolinonitrile (2.6 g, 19.0 mmol) in DMSO (10 mL) was cooled to 0 °C and treated with K<sub>2</sub>CO<sub>3</sub> (524 mg, 3.8 mmol) followed by slow addition of H<sub>2</sub>O<sub>2</sub> (2.3 mL, 22.8 mmol, 30% water). The cooling bath was removed and the reaction mixture stirred for 1 h. The reaction mixture was diluted with water (100 mL), extracted with EtOAc (3 × 100), and the combined organic layers washed with water (3 × 500), satd aq NH<sub>4</sub>Cl (500 mL), dried over MgSO<sub>4</sub>, filtered, and concentrated under reduced pressure. The crude residue of 3-amino-5-fluoropicolinamide (2.59 g, 85%) was used without further purification. LC/MS (<i>m</i>/<i>z</i>) 155.9 [M + 1].</div><div class="NLM_p">Crude 3-amino-5-fluoropicolinamide (1 g, 6.4 mmol) in dioxane (20 mL) was treated with triphosgene (1.9 g, 6.4 mmol) and the mixture heated to 110 °C for 30 min. The reaction mixture was allowed to cool, concentrated under reduced pressure, and the residue washed with CH<sub>2</sub>Cl<sub>2</sub> and Et<sub>2</sub>O, and air-dried to provide 7-fluoropyrido[3,2-<i>d</i>]pyrimidine-2,4-diol (1.03 g, 90%). LC/MS (<i>m</i>/<i>z</i>) 182.0 [M + 1].</div><div class="NLM_p last">7-Fluoropyrido[3,2-<i>d</i>]pyrimidine-2,4-diol (13.7 g, 75.6 mmol) was treated with phosphorus pentachloride (63.0 g, 302.6 mmol) and phosphorus(V) oxychloride (63g, 303 mmol, 4 equiv) and heated to 110 °C under a under reflux condenser for 8 h. The reaction mixture was concentrated under reduced pressure and azeotroped with toluene. The resultant solid was treated with EtOAc (500 mL) and ice–water (500 mL). The organic layer was separated and washed with saturated NaHCO<sub>3</sub> solution (500 mL), water (500 mL) and satd aq NH<sub>4</sub>Cl (500 mL), and dried over MgSO<sub>4</sub>, filtered, and concentrated under reduced pressure to provide <b>25</b> (12.3 g, 75%). <sup>1</sup>H NMR (400 MHz, CHCl<sub>3</sub>-<i>d</i><sub>1</sub>) δ 9.01 (d, <i>J</i> = 2.6 Hz, 1H), 7.94 (dd, <i>J</i> = 7.9, 2.7 Hz, 1H). <sup>19</sup>F NMR (377 MHz, CHCl<sub>3</sub>-<i>d</i><sub>1</sub>) δ −111.79 (d, <i>J</i> = 7.9 Hz). LC/MS (<i>m</i>/<i>z</i>) 213.9 [M + 1 + (OMe)-Cl]<sup>+</sup>.</div></div><div id="sec4_1_27" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> (<i>R</i>)-2-((2-Amino-7-fluoropyrido[3,2-<i>d</i>]pyrimidin-4-yl)amino)-2-methylhexane-1,6-diol ((<i>R</i>)-<b>26a</b>)</h3><div class="NLM_p">Compound <b>25</b> (289 mg, 1.32 mmol) and (<i>R</i>)-<b>18f</b> (240 mg, 1.32 mmol) in 2,4-dioxane (13 mL) was treated with <i>N</i>,<i>N</i>-diisopropylethylamine (0.7 mL, 3.96 mmol) and the mixture stirred at 80 °C for 4 h. The reaction mixture was cooled, diluted with EtOAc (500 mL), washed with brine (400 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, and then filtered and concentrated under reduced pressure to provide (<i>R</i>)-2-((2-chloro-7-fluoropyrido[3,2-<i>d</i>]pyrimidin-4-yl)amino)-2-methylhexane-1,6-diol that was used without further purification. LC/MS (<i>m</i>/<i>z</i>) 329.07 [M + 1]. The residue in 2-MeTHF (8.5 mL) was treated with K<sub>2</sub>CO<sub>3</sub> (369 mg, 2.64 mmol), followed by Dmb-NH<sub>2</sub> (0.4 mL, 2.64 mmol), and stirred at 85 °C for 18 h. The reaction mixture was cooled, filtered, concentrated under reduced pressure, and the residue subjected to silica gel chromatography eluting with 20–100% EtOAc–hexanes to provide (<i>R</i>)-2-((2-((2,4-dimethoxybenzyl)amino)-7-fluoropyrido[3,2-<i>d</i>]pyrimidin-4-yl)amino)-2-methylhexane-1,6-diol (410 mg, 66% over two steps). <sup>1</sup>H NMR (400 MHz, CHCl<sub>3</sub>-<i>d</i><sub>1</sub>) δ 8.14 (s, 1H), 7.35 (d, <i>J</i> = 8.9 Hz, 1H), 7.27 (s, 1H), 6.47 (d, <i>J</i> = 2.3 Hz, 1H), 6.42 (dd, <i>J</i> = 8.2, 2.4 Hz, 1H), 4.57 (d, <i>J</i> = 5.8 Hz, 2H), 3.85 (s, 3H), 3.79 (s, 3H), 3.79–3.73 (m, 2H), 3.65 (t, <i>J</i> = 5.9 Hz, 2H), 2.03–1.89 (m, 1H), 1.89–1.78 (m, 1H), 1.65–1.47 (m, 4H), 1.47–1.33 (m, 3H). LC/MS (<i>m</i>/<i>z</i>) 460.22 [M + 1].</div><div class="NLM_p last">(<i>R</i>)-2-((2-((2,4-Dimethoxybenzyl)amino)-7-fluoropyrido[3,2-<i>d</i>]pyrimidin-4-yl)amino)-2-methylhexane-1,6-diol (53 mg, 0.12 mmol) was treated with TFA (3 mL) and the mixture stirred for 1 h. The reaction mixture was concentrated under reduced pressure and coevaporated with MeOH (3 × 20 mL). The residue was suspended in MeOH, filtered, and stirred overnight. The mixture was subjected to reverse phase preparative HPLC (Synergi 4u Polar-RP 80A, Axia; 20% aq CH<sub>3</sub>CN–50% aq CH<sub>3</sub>CN, over 20 min gradient) to provide (<i>R</i>)-<b>26a</b> (19.8 mg, 55%) as a white solid. <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ 8.23 (d, <i>J</i> = 2.3 Hz, 1H), 7.25 (dd, <i>J</i> = 10.2, 2.5 Hz, 1H), 3.94 (d, <i>J</i> = 11.2 Hz, 1H), 3.73 (d, <i>J</i> = 11.3 Hz, 1H), 3.54 (t, <i>J</i> = 6.4 Hz, 2H), 2.17–2.07 (m, 1H), 1.90–1.80 (m, 1H), 1.55 (p, <i>J</i> = 6.9 Hz, 2H), 1.47 (s, 3H), 1.45–1.24 (m, 2H). <sup>19</sup>F NMR (377 MHz, MeOH-<i>d</i><sub>4</sub>) δ −123.39 (d, <i>J</i> = 10.2 Hz). LC/MS (<i>m</i>/<i>z</i>) 310.14 [M + 1].</div></div><div id="sec4_1_28" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> (<i>R</i>)-2-((2-Amino-7-fluoropyrido[3,2-<i>d</i>]pyrimidin-4-yl)amino)-2-methylhexanoic Acid ((<i>R</i>)-<b>26b</b>)</h3><div class="NLM_p last">Compound <b>25</b> (200 mg, 0.92 mmol) in THF (10 mL) was treated with (<i>R</i>)-<b>18g</b> (250 mg, 1.4 mmol) and <i>N,N</i>-diisopropylethylamine (1.3 mL, 7.50 mmol) and the mixture heated at 80 °C for 4 h. Dmb-NH<sub>2</sub> (1.9 mL, 12.5 mmol), <i>N</i>,<i>N</i>-diisopropylethylamine (1.3 mL, 7.50 mmol), and THF (5 mL) were then added, and the mixture was heated at 110 °C for 16 h. The reaction mixture was analyzed by LC/MS to confirm amine addition and loss of the ester group. The reaction mixture was cooled, diluted with EtOAc (50 mL), washed with water (50 mL) and brine (50 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure to provide (<i>R</i>)-2-((2-((2,4-dimethoxybenzyl)amino)-7-fluoropyrido[3,2-<i>d</i>]pyrimidin-4-yl)amino)-2-methylhexanoic acid (300 mg, 66%). LC/MS (<i>m</i>/<i>z</i>) 458.19 [M + 1]. (<i>R</i>)-2-((2-((2,4-Dimethoxybenzyl)amino)-7-fluoropyrido[3,2-<i>d</i>]pyrimidin-4-yl)amino)-2-methylhexanoic acid was treated with TFA (3 mL) and the mixture stirred for 2.5 h. The reaction mixture was concentrated under reduced pressure and coevaporated with MeOH (3 × 20 mL). The residue was suspended in MeOH, filtered, and the eluant concentrated under reduced pressure to provide (<i>R</i>)-<b>26b</b> (8 mg, 29%) as a TFA salt. <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ 9.10 (s, 1H), 8.59 (d, <i>J</i> = 2.4 Hz, 1H), 7.64 (dd, <i>J</i> = 8.7, 2.5 Hz, 1H), 3.98–3.84 (m, 2H), 3.85–3.63 (m, 2H), 2.61 (ddd, <i>J</i> = 13.6, 11.6, 4.9 Hz, 1H), 2.06 (ddd, <i>J</i> = 13.7, 11.3, 5.1 Hz, 1H), 1.81 (s, 3H), 1.44–1.07 (m, 5H), 0.88 (t, <i>J</i> = 7.2 Hz, 3H). LC/MS (<i>m</i>/<i>z</i>) 308.17 [M + 1].</div></div><div id="sec4_1_29" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> (2<i>R</i>,3<i>R</i>,4<i>R</i>,5<i>S</i>,6<i>R</i>)-6-(((<i>R</i>)-2-((2-Amino-7-fluoropyrido[3,2-<i>d</i>]pyrimidin-4-yl)amino)-2-methylhexanoyl)oxy)-3,4,5-trihydroxytetrahydro-2<i>H</i>-pyran-2-carboxylic Acid ((<i>R</i>)-<b>26c</b>)</h3><div class="NLM_p last">Produced by Hypha Discovery, Uxbridge, United Kingdom, using microbial (actinomycete) fermentation of (<i>R</i>)-<b>7</b> followed by reverse phase preparative HPLC purification to provide the glucuronide (<i>R</i>)-<b>26c</b>. <sup>1</sup>H NMR (499 MHz, CH<sub>3</sub>CN-<i>d</i><sub>3</sub>) δ 7.71 (dd, <i>J</i> = 5.1, 2.6 Hz, 1H), 7.60 (s, 1H), 6.78 (dd, <i>J</i> = 10.6, 2.6 Hz, 1H), 6.46 (d, <i>J</i> = 11.4 Hz, 1H), 5.93 (s, 2H), 4.56–4.29 (m, 2H), 3.65 (ddd, <i>J</i> = 44.0, 28.8, 8.8 Hz, 2H), 3.09 (dd, <i>J</i> = 16.3, 9.9 Hz, 1H), 2.56 (d, <i>J</i> = 9.0 Hz, 1H), 2.43 (d, <i>J</i> = 9.5 Hz, 1H), 1.59–1.42 (m, 1H), 1.37 (t, <i>J</i> = 12.5 Hz, 1H), 0.92 (d, <i>J</i> = 6.9 Hz, 2H), 0.70 (dd, <i>J</i> = 14.3, 8.6 Hz, 3H), 0.45 (d, <i>J</i> = 7.7 Hz, 1H), 0.29 (td, <i>J</i> = 7.0, 4.2 Hz, 2H). LC/MS (<i>m</i>/<i>z</i>) 470.0 [M + 1].</div></div><div id="sec4_1_30" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> (<i>R</i>)-2-((7-Chloro-2-((2,4-dimethoxybenzyl)amino)pyrido[3,2-<i>d</i>]pyrimidin-4-yl)amino)-2-methylhexan-1-ol (<b>28</b>)</h3><div class="NLM_p last">Compound <b>27</b><a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(28)</a> (50 mg, 0.21 mmol) and (<i>R</i>)-<b>18c</b> (45 mg, 0.45 mmol) in THF (5 mL) was treated with <i>N</i>,<i>N</i>-diisopropylethylamine (0.16 mL, 0.90 mmol), and the mixture was then heated at 80 °C for 24 h. The reaction was cooled, diluted with EtOAc (50 mL), washed with water (50 mL) and brine (50 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure. The residue was subjected to silica gel chromatography eluting with 0–100% EtOAc–hexanes to provide a yellow solid. The yellow solid was dissolved in THF (5 mL) and treated with Dmb-NH<sub>2</sub> (0.25 mL, 1.51 mmol) and <i>N</i>,<i>N</i>-diisopropylethylamine (0.16 mL, 0.90 mmol) and the mixture heated at 100 °C for 16 h. The reaction was cooled, diluted with EtOAc (100 mL), washed with water (100 mL) and brine (100 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure. The residue was subjected to silica gel chromatography eluting with 20–100% EtOAc–hexanes to provide <b>28</b> (71.1 mg, 52% over 2 steps). <sup>1</sup>H NMR (400 MHz, CHCl<sub>3</sub>-<i>d</i><sub>1</sub>) δ 8.12 (d, <i>J</i> = 2.5 Hz, 1H), 7.33 (s, 1H), 7.28 (d, <i>J</i> = 8.1 Hz, 1H), 7.09 (s, 1H), 6.46 (d, <i>J</i> = 2.4 Hz, 1H), 6.42 (dd, <i>J</i> = 8.2, 2.4 Hz, 1H), 5.29 (s, 1H), 4.56 (d, <i>J</i> = 5.8 Hz, 2H), 3.84 (s, 3H), 3.79 (s, 3H), 3.75 (s, 2H), 1.94 (m, 1H), 1.74 (m, 1H), 1.38 (s, 3H), 1.50–1.20 (m, 4H), 0.91 (t, <i>J</i> = 7.1 Hz, 3H). LC/MS (<i>m</i>/<i>z</i>) 460.29 [M + 1].</div></div><div id="sec4_1_31" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> (<i>R</i>)-2-((2-Amino-7-chloropyrido[3,2-<i>d</i>]pyrimidin-4-yl)amino)-2-methylhexan-1-ol ((<i>R</i>)-<b>29</b>)</h3><div class="NLM_p last">Compound <b>28</b> (11 mg, 0.02 mmol) was treated with TFA (3 mL) and the mixture stirred for 3.5 h. The reaction mixture was concentrated under reduced pressure and coevaporated with MeOH (3 × 20 mL). The residue was suspended in MeOH, filtered, and the eluant stirred a further 16 h. The mixture was concentrated under reduced pressure to provide (<i>R</i>)-<b>29</b> (10.6 mg, 100%) as a TFA salt. <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ 8.59 (d, <i>J</i> = 2.1 Hz, 1H), 8.25 (s, 1H), 7.91 (d, <i>J</i> = 2.1 Hz, 1H), 3.97 (d, <i>J</i> = 11.3 Hz, 1H), 3.71 (d, <i>J</i> = 11.3 Hz, 1H), 2.15–2.04 (m, 1H), 1.97–1.87 (m, 1H), 1.54 (s, 3H), 1.37–1.33 (m, 4H), 0.92 (t, <i>J</i> = 7.0 Hz, 3H). LC/MS (<i>m</i>/<i>z</i>) 310.12 [M + 1].</div></div><div id="sec4_1_32" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> (<i>R</i>)-2-((2-Amino-7-methylpyrido[3,2-<i>d</i>]pyrimidin-4-yl)amino)-2-methylhexan-1-ol ((<i>R</i>)-<b>30</b>)</h3><div class="NLM_p">Compound <b>28</b> (26.1 mg, 0.057 mmol), methylboronic acid (14.6 mg, 0.22 mmol), tetrakis(triphenylphosphine)palladium(0) (16.9 mg, 0.12 mmol), potassium phosphate tribasic (27.4 mg, 0.13 mmol) in 1,4-dioxane (2.2 mL), and water (2.2 mL) was heated to 150 °C in a microwave reactor for 30 min. The reaction was diluted with water (20 mL), extracted with EtOAc (3 × 20 mL), and the combined organics washed with water (50 mL) and brine (50 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The residue was subjected to silica gel chromatography eluting with 15–100% EtOAc–hexanes to provide (<i>R</i>)-2-((2-((2,4-dimethoxybenzyl)amino)-7-methylpyrido[3,2-<i>d</i>]pyrimidin-4-yl)amino)-2-methylhexan-1-ol (31.4 mg). H NMR (400 MHz, CHCl<sub>3</sub>-<i>d</i><sub>1</sub>) δ 7.74–7.62 (m, 2H), 7.29 (d, <i>J</i> = 7.5 Hz, 1H), 6.47 (d, <i>J</i> = 2.4 Hz, 1H), 6.42 (dd, <i>J</i> = 8.3, 2.4 Hz, 1H), 4.57 (d, <i>J</i> = 5.8 Hz, 2H), 3.85 (s, 3H), 3.79 (s, 3H), 3.78–3.66 (m, 2H), 2.03–1.88 (m, 1H), 1.81–1.68 (m, 1H), 1.58 (s, 3H), 1.39 (s, 3H), 1.36–1.21 (m, 4H), 0.90 (t, <i>J</i> = 7.4 Hz, 3H). LC/MS (<i>m</i>/<i>z</i>) 440.31 [M + 1].</div><div class="NLM_p last">(<i>R</i>)-2-((2-((2,4-Dimethoxybenzyl)amino)-7-methylpyrido[3,2-<i>d</i>]pyrimidin-4-yl)amino)-2-methylhexan-1-ol (31.4 mg) was treated with TFA (3 mL) and the mixture stirred for 30 min. The reaction mixture was concentrated under reduced pressure and coevaporated with MeOH (3 × 20 mL). The residue was subjected to reverse phase preparative HPLC (30–70% CH<sub>3</sub>CN in water with 0.1% TFA on a Synergi 4 μ Polar-RP 80A Axia over a 20 min gradient), and the product was isolated was suspended in MeOH. The mixture was filtered and the eluant stirred for 16 h, and then the mixture concentrated under reduced pressure to provide (<i>R</i>)-<b>30</b> (18.8 mg, 82% over two steps) as a TFA salt. <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ 8.47 (d, <i>J</i> = 1.7 Hz, 1H), 7.64 (dd, <i>J</i> = 1.9, 1.0 Hz, 1H), 3.97 (d, <i>J</i> = 11.2 Hz, 1H), 3.72 (d, <i>J</i> = 11.2 Hz, 1H), 2.51 (s, 3H), 2.15–2.04 (m, 1H), 1.96–1.85 (m, 1H), 1.54 (s, 3H), 1.42–1.31 (m, 4H), 0.92 (t, <i>J</i> = 6.9 Hz, 3H). LC/MS (<i>m</i>/<i>z</i>) 290.19 [M + 1].</div></div><div id="sec4_1_33" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> 2-Amino-7-fluoropyrido[3,2-<i>d</i>]pyrimidin-4-ol (<b>32</b>)</h3><div class="NLM_p last">Methyl 3-amino-5-fluoropicolinate <b>31</b> (830 mg, 4.88 mmol), chloroformamidine hydrochloride (1.1 g, 9.8 mmol), and dimethyl sulfone (4.6 g, 48.8 mmol) were charged into a sealed pressure tube and the mixture stirred and heated to 160 °C for 1 h. The reaction mixture was allowed to cool, water (50 mL) was added, and the solution stirred for 30 min. Solids were removed by filtration, and the eluant was subjected to reverse phase preparative HPLC (2–5% CH<sub>3</sub>CN in water with 0.1% TFA on a Hydro-RP column over a 20 min gradient). Solvents were removed under reduced pressure and the residue azeotroped with MeOH (2×) and CH<sub>2</sub>Cl<sub>2</sub> (2×) before sonication in Et<sub>2</sub>O. Solids were removed by filtration and dried to provide <b>32</b> (210 mg, 24%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.43 (d, <i>J</i> = 2.5 Hz, 1H), 7.48 (dd, <i>J</i> = 10.1, 2.5 Hz, 1H), 7.23 (s, 2H).<sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>) δ −119.96. LC/MS (<i>m</i>/<i>z</i>) 181.0 [M + 1].</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> High Throughput Cyropreserved PBMC Assay</h3><div class="NLM_p">Cryopreserved human PBMCs isolated from healthy donors were purchased from StemCell Technologies (Vancouver, Canada). Cell culture medium used was RPMI with <span class="smallcaps smallerCapital">l</span>-glutamine (Mediatech, Manassas, VA) supplemented with 10% fetal bovine serum (Hyclone, GE Healthcare, Logan, UT) and penicillin–streptomycin (Mediatech). Human TNFα, IL-12p40, and IFNα-2a 384-well capture plates, standards, buffers, and processing reagents were obtained from MesoScale Discovery Technologies (MSD; Rockville, MD). Cryopreserved human PBMCs (1 × 10<sup>8</sup> cells/mL) were thawed at 37 °C and resuspended in 25 mL of warm cell culture medium. The cells were pelleted at 200×g (Beckman Avanti J-E) for 5 min and resuspended in 20 mL of fresh culture media. Cells were counted using a Cellometer (Nexcelcom Bioscience), adjusted to 2 × 10<sup>6</sup> cells, and incubated for 2 h in an incubator set at 37 °C, 5% CO<sub>2</sub> to recover from cryopreservation. Compounds were serially diluted in DMSO at half-log steps to generate a 10-point dose range. Using a Bravo pipet equipped with a 384-well head (Agilent), 0.4 μL of compound was transferred to each well of a 384-well black, clear-bottom plate (Greiner Bio-One, Germany) containing 30 μL of cell culture medium. Recovered PBMCs were then dispensed into the assay plate at 50 μL per well (100 000 cells/well) using the MicroFlow multichannel dispenser (Biotek). Final DMSO concentration was 0.5%. Positive controls used were 10 μM GS-651557 for the TNFα and IL-12p40 assays and 10 μM GS-9620 for the IFNα-2a assay. DMSO was used as the negative control. The plates were incubated for 24 h at 37 °C. PBMCs in the assay plate were pelleted by centrifugation (Beckman Avanti J-E) at 200<i>g</i> for 5 min. Using a Biomek FX 384-well pipetting station (Beckman), conditioned culture medium (CCM) from the assay plate was transferred to MSD capture plates customized for each cytokine. For IFNα and IL-12p40 detection, 25 and 20 μL of CCM were added directly to each capture plate, respectively. For TNFα detection, CCM was diluted 1:10 in fresh culture medium and 20 μL of diluted CCM was used. Serially diluted calibration standards for each cytokine were used to generate standard curves and establish assay linearity. The plates were sealed and incubated overnight at 4 °C in a plate shaker (Titer Plate) set at 200 rpm. On the following day, antibodies specific for each cytokine were diluted 1:50 in MSD Diluent 100 antibody dilution buffer. Diluted antibodies were added to corresponding capture plates at 10 μL/well and incubated at rt for 1–2 h in the shaker. The plates were washed with PBST buffer (3×, 60 μL/well) using a Biotek Multiflow plate washer. MSD Read Buffer diluted to 2× in deionized water and 35 μL/well was added via Biomek FX instrument. The plates were read immediately in a MSD6000 reader. Data were normalized to positive and negative controls in each assay plate. EC<sub>50</sub> values represent compound concentrations at half-maximal effect based on normalized percent activation and calculated using four-parameter logistic curve fit with Pipeline Pilot software (Accelrys, San Diego, CA).</div><div class="NLM_p last">HBV infected primary human hepatocyte assay has been previously described.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(29)</a></div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> HEK Innate Immune Receptor Reporter Assays, MT-4 Cell Viability Assay, Pharmacokinetic Methods, Structural Modeling, and Crystallography Methods</h3><div class="NLM_p last">See <a href="/doi/suppl/10.1021/acs.jmedchem.0c00100/suppl_file/jm0c00100_si_002.pdf" class="ext-link">Supporting Information</a>. All in vivo studies were performed in accordance with local IACUC guidelines.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i49"><a href="/doi/suppl/10.1021/acs.jmedchem.0c00100" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_23481" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_23481" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c00100?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00100</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Pharmacokinetic methods, cell-based assays, preparation of amines, molecular modeling/single crystal x-ray diffraction methods, appendix of final compound HPLC and NMR spectra (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00100/suppl_file/jm0c00100_si_002.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00100/suppl_file/jm0c00100_si_001.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">TLR8 <b>6a</b> model (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00100/suppl_file/jm0c00100_si_003.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">TLR8 (<i>R</i>)-<b>6d</b> model (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00100/suppl_file/jm0c00100_si_004.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">TLR8 (<i>R</i>)-<b>6d</b> no H<sub>2</sub>O model (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00100/suppl_file/jm0c00100_si_005.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">TLR8 (<i>S</i>)-<b>6d</b> model (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00100/suppl_file/jm0c00100_si_006.pdb" class="ext-link">PDB</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00100/suppl_file/jm0c00100_si_001.csv">jm0c00100_si_001.csv (3.41 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00100/suppl_file/jm0c00100_si_002.pdf">jm0c00100_si_002.pdf (1.9 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00100/suppl_file/jm0c00100_si_003.pdb">jm0c00100_si_003.pdb (1.98 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00100/suppl_file/jm0c00100_si_004.pdb">jm0c00100_si_004.pdb (1.99 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00100/suppl_file/jm0c00100_si_005.pdb">jm0c00100_si_005.pdb (1.98 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00100/suppl_file/jm0c00100_si_006.pdb">jm0c00100_si_006.pdb (1.99 MB)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">The PDB code for the TLR8 X-ray structure of (<i>R</i>)-<b>7</b> is <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6WML">6WML</a>. Authors will release the atomic coordinates upon article publication. Homology models: PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3W3M">3W3M</a> structure was used for the models of <b>6a</b>, (<i>R</i>)-<b>6d</b>, and (<i>S</i>)-<b>6d</b>.</p><div class="testing" data-doi="10.1021/acs.jmedchem.0c00100" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_58274" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_58274" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Richard L. Mackman</span> - <span class="hlFld-Affiliation affiliation">Gilead
Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-8861-7205" title="Orcid link">http://orcid.org/0000-0001-8861-7205</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#97e5fef4fff6e5f3b9faf6f4fcfaf6f9d7f0fefbf2f6f3b9f4f8fa"><span class="__cf_email__" data-cfemail="a6d4cfc5cec7d4c288cbc7c5cdcbc7c8e6c1cfcac3c7c288c5c9cb">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael Mish</span> - <span class="hlFld-Affiliation affiliation">Gilead
Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gregory Chin</span> - <span class="hlFld-Affiliation affiliation">Gilead
Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jason K. Perry</span> - <span class="hlFld-Affiliation affiliation">Gilead
Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-5492-0652" title="Orcid link">http://orcid.org/0000-0001-5492-0652</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Todd Appleby</span> - <span class="hlFld-Affiliation affiliation">Gilead
Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Vangelis Aktoudianakis</span> - <span class="hlFld-Affiliation affiliation">Gilead
Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sammy Metobo</span> - <span class="hlFld-Affiliation affiliation">Gilead
Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Peter Pyun</span> - <span class="hlFld-Affiliation affiliation">Gilead
Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Congrong Niu</span> - <span class="hlFld-Affiliation affiliation">Gilead
Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stephane Daffis</span> - <span class="hlFld-Affiliation affiliation">Gilead
Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Helen Yu</span> - <span class="hlFld-Affiliation affiliation">Gilead
Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jim Zheng</span> - <span class="hlFld-Affiliation affiliation">Gilead
Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Armando G. Villasenor</span> - <span class="hlFld-Affiliation affiliation">Gilead
Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jeff Zablocki</span> - <span class="hlFld-Affiliation affiliation">Gilead
Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404, United States</span>; 
    <span>Present Address:
                        For J. Z.: Pharmacyclics, an Abbvie Company, 999 East Arques Avenue, Sunnyvale, California 94085, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jason Chamberlain</span> - <span class="hlFld-Affiliation affiliation">Gilead
Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404, United States</span>; 
    <span>Present Address:
                        For J.C.: Horizon Therapeutics, Two Tower Place, 12th floor, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Haolun Jin</span> - <span class="hlFld-Affiliation affiliation">Gilead
Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gary Lee</span> - <span class="hlFld-Affiliation affiliation">Gilead
Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kimberley Suekawa-Pirrone</span> - <span class="hlFld-Affiliation affiliation">Gilead
Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rex Santos</span> - <span class="hlFld-Affiliation affiliation">Gilead
Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">William E. Delaney</span> - <span class="hlFld-Affiliation affiliation">Gilead
Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Simon P. Fletcher</span> - <span class="hlFld-Affiliation affiliation">Gilead
Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare the following competing financial interest(s): Some authors are current or former employees of Gilead Sciences and may own company stock.<br /></br></div></li></ul></div><div class="ack" id="ACK-d7e5628-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i53">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_20017" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_20017" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We acknowledge the TLR8 protein used to determine the (<i>R</i>)-<b>7</b> X-ray structure complex was made available for purchase from Professor T. Shimizu, Graduate School of Pharmaceutical Sciences, University of Tokyo.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">BOP</td><td class="NLM_def"><p class="first last">(benzotriazol-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate</p></td></tr><tr><td class="NLM_term">cccDNA</td><td class="NLM_def"><p class="first last">covalent closed circular DNA</p></td></tr><tr><td class="NLM_term">CHB</td><td class="NLM_def"><p class="first last">chronic hepatitis B</p></td></tr><tr><td class="NLM_term">CCM</td><td class="NLM_def"><p class="first last">cell culture media</p></td></tr><tr><td class="NLM_term">CC<sub>50</sub></td><td class="NLM_def"><p class="first last">concentration for 50% cell viability loss</p></td></tr><tr><td class="NLM_term">Dmb</td><td class="NLM_def"><p class="first last">2,4-dimethoxybenzyl</p></td></tr><tr><td class="NLM_term">HATU</td><td class="NLM_def"><p class="first last">(1-[bis(dimethylamino)methylene]-1<i>H</i>-1,2,3-triazolo[4,5-<i>b</i>]pyridinium 3-oxide hexafluorophosphate</p></td></tr><tr><td class="NLM_term">HBV</td><td class="NLM_def"><p class="first last">hepatitis B virus</p></td></tr><tr><td class="NLM_term">HEK</td><td class="NLM_def"><p class="first last">human embryonic kidney cells</p></td></tr><tr><td class="NLM_term">IACUC</td><td class="NLM_def"><p class="first last">International Animal Care and Use Committee</p></td></tr><tr><td class="NLM_term">IFN</td><td class="NLM_def"><p class="first last">interferon</p></td></tr><tr><td class="NLM_term">MEC</td><td class="NLM_def"><p class="first last">minimum effective concentration equivalent to a 3-fold increase in measurement over baseline</p></td></tr><tr><td class="NLM_term">MSD</td><td class="NLM_def"><p class="first last">MesoScale discovery</p></td></tr><tr><td class="NLM_term">PBMC</td><td class="NLM_def"><p class="first last">peripheral blood mononuclear cell</p></td></tr><tr><td class="NLM_term">PBST</td><td class="NLM_def"><p class="first last">phosphate buffered saline with tween 20</p></td></tr><tr><td class="NLM_term">PHH</td><td class="NLM_def"><p class="first last">primary human hepatocytes</p></td></tr><tr><td class="NLM_term">TLR</td><td class="NLM_def"><p class="first last">Toll-like receptor</p></td></tr><tr><td class="NLM_term">WHV</td><td class="NLM_def"><p class="first last">woodchuck hepatitis B virus</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i55">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_06664" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_06664" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 29 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Neill, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golenbock, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowie, A. G.</span></span> <span> </span><span class="NLM_article-title">The History of Toll-like Receptors - Redefining Innate Immunity</span>. <i>Nat. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">453</span>– <span class="NLM_lpage">460</span>, <span class="refDoi"> DOI: 10.1038/nri3446</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=10.1038%2Fnri3446" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=23681101" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnslaisLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=453-460&issue=6&author=L.+A.+O%E2%80%99Neillauthor=D.+Golenbockauthor=A.+G.+Bowie&title=The+History+of+Toll-like+Receptors+-+Redefining+Innate+Immunity&doi=10.1038%2Fnri3446"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The history of Toll-like receptors - redefining innate immunity</span></div><div class="casAuthors">O'Neill, Luke A. J.; Golenbock, Douglas; Bowie, Andrew G.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">453-460</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The discovery of Toll-like receptors (TLRs) was an important event for immunol. research and was recognized as such with the awarding of the 2011 Nobel Prize in Physiol. or Medicine to Jules Hoffmann and Bruce Beutler, who, together with Ralph Steinman, the third winner of the 2011 Nobel Prize and the person who discovered the dendritic cell, were pioneers in the field of innate immunity.  TLRs have a central role in immunity - in this Timeline article, we describe the landmark findings that gave rise to this important field of research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNQuHgmx29MrVg90H21EOLACvtfcHk0ljOZcFSUNCHTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnslaisLc%253D&md5=4d5ca89abf3932000ae422d79ecbe93f</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnri3446&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri3446%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DL.%2BA.%26aulast%3DGolenbock%26aufirst%3DD.%26aulast%3DBowie%26aufirst%3DA.%2BG.%26atitle%3DThe%2520History%2520of%2520Toll-like%2520Receptors%2520-%2520Redefining%2520Innate%2520Immunity%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2013%26volume%3D13%26issue%3D6%26spage%3D453%26epage%3D460%26doi%3D10.1038%2Fnri3446" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gorden, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorski, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibson, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kedl, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kieper, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomai, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alkan, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasilakos, J. P.</span></span> <span> </span><span class="NLM_article-title">Synthetic TLR Agonists Reveal Functional Differences Between Human TLR7 and TLR8</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>174</i></span>,  <span class="NLM_fpage">1259</span>– <span class="NLM_lpage">1268</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.174.3.1259</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=10.4049%2Fjimmunol.174.3.1259" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=15661881" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlsFyhsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=174&publication_year=2005&pages=1259-1268&author=K.+B.+Gordenauthor=K.+S.+Gorskiauthor=S.+J.+Gibsonauthor=R.+M.+Kedlauthor=W.+C.+Kieperauthor=X.+Qiuauthor=M.+A.+Tomaiauthor=S.+S.+Alkanauthor=J.+P.+Vasilakos&title=Synthetic+TLR+Agonists+Reveal+Functional+Differences+Between+Human+TLR7+and+TLR8&doi=10.4049%2Fjimmunol.174.3.1259"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic TLR Agonists Reveal Functional Differences between Human TLR7 and TLR8</span></div><div class="casAuthors">Gorden, Keith B.; Gorski, Kevin S.; Gibson, Sheila J.; Kedl, Ross M.; Kieper, William C.; Qiu, Xiaohong; Tomai, Mark A.; Alkan, Sefik S.; Vasilakos, John P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">174</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1259-1268</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">Although TLR7 and TLR8 are phylogenetically and structurally related, their relative functions are largely unknown.  The role of TLR7 has been established using TLR7-deficient mice and small mol. TLR7 agonists.  The absence of TLR8-selective agonists has hampered the authors' understanding of the role of TLR8.  In this study TLR agonists selective for TLR7 or TLR8 were used to det. the repertoire of human innate immune cells that are activated through these TLRs.  The authors found that TLR7 agonists directly activated purified plasmacytoid dendritic cells and, to a lesser extent, monocytes.  Conversely, TLR8 agonists directly activated purified myeloid dendritic cells, monocytes, and monocyte-derived dendritic cells (GM-CSF/IL-4/TGF-β).  Accordingly, TLR7-selective agonists were more effective than TLR8-selective agonists at inducing IFN-α- and IFN-regulated chemokines such as IFN-inducible protein and IFN-inducible T cell α chemoattractant from human PBMC.  In contrast, TLR8 agonists were more effective than TLR7 agonists at inducing proinflammatory cytokines and chemokines, such as TNF-α, IL-12, and MIP-1α.  Thus, this study demonstrated that TLR7 and TLR8 agonists differ in their target cell selectivity and cytokine induction profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxUMK2LBltvrVg90H21EOLACvtfcHk0liTFrpaRWRQLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlsFyhsQ%253D%253D&md5=1893fde2508086be1f79df76d09e919a</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.174.3.1259&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.174.3.1259%26sid%3Dliteratum%253Aachs%26aulast%3DGorden%26aufirst%3DK.%2BB.%26aulast%3DGorski%26aufirst%3DK.%2BS.%26aulast%3DGibson%26aufirst%3DS.%2BJ.%26aulast%3DKedl%26aufirst%3DR.%2BM.%26aulast%3DKieper%26aufirst%3DW.%2BC.%26aulast%3DQiu%26aufirst%3DX.%26aulast%3DTomai%26aufirst%3DM.%2BA.%26aulast%3DAlkan%26aufirst%3DS.%2BS.%26aulast%3DVasilakos%26aufirst%3DJ.%2BP.%26atitle%3DSynthetic%2520TLR%2520Agonists%2520Reveal%2520Functional%2520Differences%2520Between%2520Human%2520TLR7%2520and%2520TLR8%26jtitle%3DJ.%2520Immunol.%26date%3D2005%26volume%3D174%26spage%3D1259%26epage%3D1268%26doi%3D10.4049%2Fjimmunol.174.3.1259" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span> <i>Hepatitis
B</i>; <span class="NLM_series">Fact Sheet no. 204</span>; <span class="NLM_publisher-name">World
Health Organization
(WHO)</span>, <span class="NLM_year">2019</span>; <a href="http://www.who.int/mediacentre/factsheets/fs204/en/" class="extLink">http://www.who.int/mediacentre/factsheets/fs204/en/</a> (accessed 2019-11-02).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Hepatitis%0AB%3B+Fact+Sheet+no.+204%3B+World%0AHealth+Organization%0A%28WHO%29%2C+2019%3B+http%3A%2F%2Fwww.who.int%2Fmediacentre%2Ffactsheets%2Ffs204%2Fen%2F+%28accessed+2019-11-02%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26jtitle%3DHepatitis%250AB%26pub%3DWorld%250AHealth%2520Organization%250A%2528WHO%2529%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ott, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groeger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiersma, S. T.</span></span> <span> </span><span class="NLM_article-title">Global Epidemiology of Hepatitis B Virus Infection: New Estimates of Age-Specific HBsAg Seroprevalence and Endemicity</span>. <i>Vaccine</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>30</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">2212</span>– <span class="NLM_lpage">2219</span>, <span class="refDoi"> DOI: 10.1016/j.vaccine.2011.12.116</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=10.1016%2Fj.vaccine.2011.12.116" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=22273662" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=1%3ACAS%3A280%3ADC%252BC383mt12hsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=2212-2219&issue=12&author=J.+J.+Ottauthor=G.+A.+Stevensauthor=J.+Groegerauthor=S.+T.+Wiersma&title=Global+Epidemiology+of+Hepatitis+B+Virus+Infection%3A+New+Estimates+of+Age-Specific+HBsAg+Seroprevalence+and+Endemicity&doi=10.1016%2Fj.vaccine.2011.12.116"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity</span></div><div class="casAuthors">Ott J J; Stevens G A; Groeger J; Wiersma S T</div><div class="citationInfo"><span class="NLM_cas:title">Vaccine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2212-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVE:  Chronic hepatitis B virus infection is one of the most serious infections and a major risk factor for deaths from cirrhosis and liver cancer.  We estimate age-, sex- and region-specific prevalence of chronic HBV infection and calculate the absolute number of persons being chronically infected.  METHODS:  A systematic review of the literature for studies reporting HBV infection was conducted and worldwide HBsAg seroprevalence data was collected over a 27-year period (1980-2007).  Based on observed data, age-specific prevalence and endemicity were estimated on a global level and for all world regions for 1990 and 2005 using an empirical Bayesian hierarchical model.  FINDINGS:  From 1990 to 2005, the prevalence of chronic HBV infection decreased in most regions.  This was particularly evident in Central sub-Saharan Africa, Tropical and Central Latin America, South East Asia and Central Europe.  Despite this decrease in prevalence, the absolute number of HBsAg positive persons increased from 223 million in 1990 to 240 million in 2005.  Age-specific prevalence varied by geographical region with highest endemicity levels in sub-Saharan Africa and prevalence below 2% in regions such as Tropical and Central Latin America, North America and Western Europe.  Asian regions showed distinct prevalence patterns with lower intermediate prevalence in South Asia, but up to 8.6% HBsAg prevalence in East Asia.  Strong declines were seen in South East Asian children.  CONCLUSION:  Declines in HBV infection prevalence may be related to expanded immunization.  The increasing overall number of individuals being chronically infected with HBV, and the widespread global differences in HBV prevalence call for targeted approaches to tackle HBV-related mortality and morbidity.  HBV infection prevalence data are needed at country and sub-national level to estimate disease burden and guide health and vaccine policy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTBkb3C3wv7Da-9TkgmBqTqfW6udTcc2eYZKwlyBwxaA7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC383mt12hsA%253D%253D&md5=f17cf650a072050baf83cb73b1036779</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.vaccine.2011.12.116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.vaccine.2011.12.116%26sid%3Dliteratum%253Aachs%26aulast%3DOtt%26aufirst%3DJ.%2BJ.%26aulast%3DStevens%26aufirst%3DG.%2BA.%26aulast%3DGroeger%26aufirst%3DJ.%26aulast%3DWiersma%26aufirst%3DS.%2BT.%26atitle%3DGlobal%2520Epidemiology%2520of%2520Hepatitis%2520B%2520Virus%2520Infection%253A%2520New%2520Estimates%2520of%2520Age-Specific%2520HBsAg%2520Seroprevalence%2520and%2520Endemicity%26jtitle%3DVaccine%26date%3D2012%26volume%3D30%26issue%3D12%26spage%3D2212%26epage%3D2219%26doi%3D10.1016%2Fj.vaccine.2011.12.116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bertoletti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrari, C.</span></span> <span> </span><span class="NLM_article-title">Adaptive Immunity in HBV Infection</span>. <i>J. Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>64</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">S71</span>– <span class="NLM_lpage">S83</span>, <span class="refDoi"> DOI: 10.1016/j.jhep.2016.01.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=10.1016%2Fj.jhep.2016.01.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=27084039" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=1%3ACAS%3A528%3ADC%252BC28XmtVart7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2016&pages=S71-S83&issue=1&author=A.+Bertolettiauthor=C.+Ferrari&title=Adaptive+Immunity+in+HBV+Infection&doi=10.1016%2Fj.jhep.2016.01.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Adaptive immunity in HBV infection</span></div><div class="casAuthors">Bertoletti, Antonio; Ferrari, Carlo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hepatology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">1_Suppl.</span>),
    <span class="NLM_cas:pages">S71-S83</span>CODEN:
                <span class="NLM_cas:coden">JOHEEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-8278</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">During hepatitis B virus (HBV) infection, the presence of HBV-specific antibody producing B cells and functional HBV-specific T cells (with helper or cytotoxic effects) ultimately dets. HBV infection outcome.  In this review, in addn. to summarizing the present state of knowledge of HBV-adaptive immunity, we will highlight controversies and uncertainties concerning the HBV-specific B and T lymphocyte response, and propose future directions for research aimed at the generation of more efficient immunotherapeutic strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0DCzFYSMYqLVg90H21EOLACvtfcHk0liTFrpaRWRQLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmtVart7w%253D&md5=a212ced9423f2e1db502572b049290ad</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2016.01.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2016.01.026%26sid%3Dliteratum%253Aachs%26aulast%3DBertoletti%26aufirst%3DA.%26aulast%3DFerrari%26aufirst%3DC.%26atitle%3DAdaptive%2520Immunity%2520in%2520HBV%2520Infection%26jtitle%3DJ.%2520Hepatol.%26date%3D2016%26volume%3D64%26issue%3D1%26spage%3DS71%26epage%3DS83%26doi%3D10.1016%2Fj.jhep.2016.01.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Du, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Randolph, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, C.</span></span> <span> </span><span class="NLM_article-title">TLR8 Agonists Stimulate Newly Recruited Monocyte-Derived Cells Into Potent APCs That Enhance HBsAg Immunogenicity</span>. <i>Vaccine</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">38</span>),  <span class="NLM_fpage">6273</span>– <span class="NLM_lpage">6281</span>, <span class="refDoi"> DOI: 10.1016/j.vaccine.2010.06.117</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=10.1016%2Fj.vaccine.2010.06.117" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=20637759" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVaqu7%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2010&pages=6273-6281&issue=38&author=J.+Duauthor=Z.+Wuauthor=S.+Renauthor=Y.+Weiauthor=M.+Gaoauthor=G.+J.+Randolphauthor=C.+Qu&title=TLR8+Agonists+Stimulate+Newly+Recruited+Monocyte-Derived+Cells+Into+Potent+APCs+That+Enhance+HBsAg+Immunogenicity&doi=10.1016%2Fj.vaccine.2010.06.117"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">TLR8 agonists stimulate newly recruited monocyte-derived cells into potent APCs that enhance HBsAg immunogenicity</span></div><div class="casAuthors">Du, Jun; Wu, Zhiyuan; Ren, Shurong; Wei, Yong; Gao, Meihua; Randolph, Gwendalyn J.; Qu, Chunfeng</div><div class="citationInfo"><span class="NLM_cas:title">Vaccine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">38</span>),
    <span class="NLM_cas:pages">6273-6281</span>CODEN:
                <span class="NLM_cas:coden">VACCDE</span>;
        ISSN:<span class="NLM_cas:issn">0264-410X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">We previously reported that synthetic or natural Toll-like receptor (TLR) 7/8 agonists present within dead cells enhanced cell-assocd. antigen presentation both in vitro and in vivo.  Here, we investigated the immunopotency of different chem. synthesized TLR7/8 agonists, Resiquimod, Gardiquimod, CL075, and CL097, on HBsAg immunogenicity.  These agonists stimulated inflammatory monocyte-derived cells to become potent antigen-presenting dendritic cells (DCs), which augmented HBsAg specific T cell proliferation after they were conditioned with HBsAg.  The TLR8 agonist CL075 and the TLR7/8 dual agonist CL097 showed more potent effects than the TLR7 agonist.  Compared with alum adjuvant, when HBsAg mixed with CL075 was injected i.m. into mice, more monocyte-derived DCs carried antigens into draining lymph nodes and spleens.  Specific Abs, particularly IgG2a, were significantly increased, and more IL-5 and IFN-γ were produced by splenocytes and intrahepatic immunocytes in mice that received HBsAg mixed with CL075 and CL097.  These results suggest that TLR8 agonists are good candidates to enhance recombinant HBsAg immunogenicity to induce specific humoral and cellular immune responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1vp0F5zWgfbVg90H21EOLACvtfcHk0lguLx5qPniLlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVaqu7%252FP&md5=142e5048b9a73de56593b79c173e5376</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.vaccine.2010.06.117&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.vaccine.2010.06.117%26sid%3Dliteratum%253Aachs%26aulast%3DDu%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DZ.%26aulast%3DRen%26aufirst%3DS.%26aulast%3DWei%26aufirst%3DY.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DRandolph%26aufirst%3DG.%2BJ.%26aulast%3DQu%26aufirst%3DC.%26atitle%3DTLR8%2520Agonists%2520Stimulate%2520Newly%2520Recruited%2520Monocyte-Derived%2520Cells%2520Into%2520Potent%2520APCs%2520That%2520Enhance%2520HBsAg%2520Immunogenicity%26jtitle%3DVaccine%26date%3D2010%26volume%3D28%26issue%3D38%26spage%3D6273%26epage%3D6281%26doi%3D10.1016%2Fj.vaccine.2010.06.117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schurich, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pallett, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lubowiecki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, H. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gill, U. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nastouli, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanwar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenberg, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maini, M. K.</span></span> <span> </span><span class="NLM_article-title">The Third Signal Cytokine IL-12 Rescues the Anti-Viral Function of Exhausted HBV-Specific CD8 T cells</span>. <i>PLoS Pathog.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">e1003208</span>, <span class="refDoi"> DOI: 10.1371/journal.ppat.1003208</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=10.1371%2Fjournal.ppat.1003208" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=23516358" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmtVeltbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2013&pages=e1003208&issue=3&author=A.+Schurichauthor=L.+J.+Pallettauthor=M.+Lubowieckiauthor=H.+D.+Singhauthor=U.+S.+Gillauthor=P.+T.+Kennedyauthor=E.+Nastouliauthor=S.+Tanwarauthor=W.+Rosenbergauthor=M.+K.+Maini&title=The+Third+Signal+Cytokine+IL-12+Rescues+the+Anti-Viral+Function+of+Exhausted+HBV-Specific+CD8+T+cells&doi=10.1371%2Fjournal.ppat.1003208"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">The third signal cytokine IL-12 rescues the anti-viral function of exhausted HBV-specific CD8 T cells</span></div><div class="casAuthors">Schurich, Anna; Pallett, Laura J.; Lubowiecki, Marcin; Singh, Harsimran D.; Gill, Upkar S.; Kennedy, Patrick T.; Nastouli, Eleni; Tanwar, Sudeep; Rosenberg, William; Maini, Mala K.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Pathogens</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">e1003208</span>CODEN:
                <span class="NLM_cas:coden">PPLACN</span>;
        ISSN:<span class="NLM_cas:issn">1553-7374</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Optimal immune activation of naive CD8 T cells requires signal 1 mediated by the T cell receptor, signal 2 mediated by co-stimulation and signal 3 provided by pro-inflammatory cytokines.  However, the potential for signal 3 cytokines to rescue anti-viral responses in functionally exhausted T cells has not been defined.  We investigated the effect of using third signal cytokines IL-12 or IFN-α to rescue the exhausted CD8 T cell response characteristic of patients persistently infected with hepatitis B virus (HBV).  We found that IL-12, but not IFN-α, potently augmented the capacity of HBV-specific CD8 T cells to produce effector cytokines upon stimulation by cognate antigen.  Functional recovery mediated by IL-12 was accompanied by down-modulation of the hallmark inhibitory receptor PD-1 and an increase in the transcription factor T-bet.  PD-1 down-regulation was obsd. in HBV but not CMV-specific T cells, in line with our finding that the highly functional CMV response was not further enhanced by IL-12.  IL-12 enhanced a no. of characteristics of HBV-specific T cells important for viral control: cytotoxicity, polyfunctionality and multispecificity.  Furthermore, IL-12 significantly decreased the pro-apoptotic mol. Bim, which is capable of mediating premature attrition of HBV-specific CD8 T cells.  Combining IL-12 with blockade of the PD-1 pathway further increased CD8 functionality in the majority of patients.  These data provide new insights into the distinct signalling requirements of exhausted T cells and the potential to recover responses optimized to control persistent viral infections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlNEnlXP0crrVg90H21EOLACvtfcHk0lguLx5qPniLlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmtVeltbw%253D&md5=bd2d813bb89d009a34709828a536489d</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1371%2Fjournal.ppat.1003208&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.ppat.1003208%26sid%3Dliteratum%253Aachs%26aulast%3DSchurich%26aufirst%3DA.%26aulast%3DPallett%26aufirst%3DL.%2BJ.%26aulast%3DLubowiecki%26aufirst%3DM.%26aulast%3DSingh%26aufirst%3DH.%2BD.%26aulast%3DGill%26aufirst%3DU.%2BS.%26aulast%3DKennedy%26aufirst%3DP.%2BT.%26aulast%3DNastouli%26aufirst%3DE.%26aulast%3DTanwar%26aufirst%3DS.%26aulast%3DRosenberg%26aufirst%3DW.%26aulast%3DMaini%26aufirst%3DM.%2BK.%26atitle%3DThe%2520Third%2520Signal%2520Cytokine%2520IL-12%2520Rescues%2520the%2520Anti-Viral%2520Function%2520of%2520Exhausted%2520HBV-Specific%2520CD8%2520T%2520cells%26jtitle%3DPLoS%2520Pathog.%26date%3D2013%26volume%3D9%26issue%3D3%26spage%3De1003208%26doi%3D10.1371%2Fjournal.ppat.1003208" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ussher, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandalova, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, X.-Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan-Garcia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">To, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gill, U. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Libero, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gehring, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willberg, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klenerman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertoletti, A.</span></span> <span> </span><span class="NLM_article-title">Toll-Like Receptor 8 Agonist and Bacteria Trigger Potent Activation of Innate Immune Cells in Human Liver</span>. <i>PLoS Pathog.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">e1004210</span>, <span class="refDoi"> DOI: 10.1371/journal.ppat.1004210</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=10.1371%2Fjournal.ppat.1004210" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=24967632" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFelsrjM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=e1004210&issue=6&author=J.+Joauthor=A.+T.+Tanauthor=J.+E.+Ussherauthor=E.+Sandalovaauthor=X.-Z.+Tangauthor=A.+Tan-Garciaauthor=N.+Toauthor=M.+Hongauthor=A.+Chiaauthor=U.+S.+Gillauthor=P.+T.+Kennedyauthor=K.+C.+Tanauthor=K.+H.+Leeauthor=G.+De+Liberoauthor=A.+J.+Gehringauthor=C.+B.+Willbergauthor=P.+Klenermanauthor=A.+Bertoletti&title=Toll-Like+Receptor+8+Agonist+and+Bacteria+Trigger+Potent+Activation+of+Innate+Immune+Cells+in+Human+Liver&doi=10.1371%2Fjournal.ppat.1004210"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Toll-like receptor 8 agonist and bacteria trigger potent activation of innate immune cells in human liver</span></div><div class="casAuthors">Jo, Juandy; Tan, Anthony T.; Ussher, James E.; Sandalova, Elena; Tang, Xin-Zi; Tan-Garcia, Alfonso; To, Natalie; Hong, Michelle; Chia, Adeline; Gill, Upkar S.; Kennedy, Patrick T.; Tan, Kai Chah; Lee, Kang Hoe; De Libero, Gennaro; Gehring, Adam J.; Willberg, Christian B.; Klenerman, Paul; Bertoletti, Antonio</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Pathogens</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">e1004210/1-e1004210/13, 13 pp.</span>CODEN:
                <span class="NLM_cas:coden">PPLACN</span>;
        ISSN:<span class="NLM_cas:issn">1553-7374</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">The ability of innate immune cells to sense and respond to impending danger varies by anatomical location.  The liver is considered tolerogenic but is still capable of mounting a successful immune response to clear various infections.  To understand whether hepatic immune cells tune their response to different infectious challenges, we probed mononuclear cells purified from human healthy and diseased livers with distinct pathogen-assocd. mols.  We discovered that only the TLR8 agonist ssRNA40 selectively activated liver-resident innate immune cells to produce substantial quantities of IFN-γ.  We identified CD161Bright mucosal-assocd. invariant T (MAIT) and CD56Bright NK cells as the responding liver-resident innate immune cells.  Their activation was not directly induced by the TLR8 agonist but was dependent on IL-12 and IL-18 prodn. by ssRNA40-activated intrahepatic monocytes.  Importantly, the ssRNA40-induced cytokine-dependent activation of MAIT cells mirrored responses induced by bacteria, i.e., generating a selective prodn. of high levels of IFN-γ, without the concomitant prodn. of TNF-α or IL-17A.  The intrahepatic IFN-γ prodn. could be detected not only in healthy livers, but also in HBV- or HCV-infected livers.  In conclusion, the human liver harbors a network of immune cells able to modulate their immunol. responses to different pathogen-assocd. mols.  Their ability to generate a strong prodn. of IFN-γ upon stimulation with TLR8 agonist opens new therapeutic opportunities for the treatment of diverse liver pathologies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQTrIPcC7CZLVg90H21EOLACvtfcHk0lguLx5qPniLlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFelsrjM&md5=db069ff7f302df907b4a7a68e07a3c9a</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1371%2Fjournal.ppat.1004210&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.ppat.1004210%26sid%3Dliteratum%253Aachs%26aulast%3DJo%26aufirst%3DJ.%26aulast%3DTan%26aufirst%3DA.%2BT.%26aulast%3DUssher%26aufirst%3DJ.%2BE.%26aulast%3DSandalova%26aufirst%3DE.%26aulast%3DTang%26aufirst%3DX.-Z.%26aulast%3DTan-Garcia%26aufirst%3DA.%26aulast%3DTo%26aufirst%3DN.%26aulast%3DHong%26aufirst%3DM.%26aulast%3DChia%26aufirst%3DA.%26aulast%3DGill%26aufirst%3DU.%2BS.%26aulast%3DKennedy%26aufirst%3DP.%2BT.%26aulast%3DTan%26aufirst%3DK.%2BC.%26aulast%3DLee%26aufirst%3DK.%2BH.%26aulast%3DDe%2BLibero%26aufirst%3DG.%26aulast%3DGehring%26aufirst%3DA.%2BJ.%26aulast%3DWillberg%26aufirst%3DC.%2BB.%26aulast%3DKlenerman%26aufirst%3DP.%26aulast%3DBertoletti%26aufirst%3DA.%26atitle%3DToll-Like%2520Receptor%25208%2520Agonist%2520and%2520Bacteria%2520Trigger%2520Potent%2520Activation%2520of%2520Innate%2520Immune%2520Cells%2520in%2520Human%2520Liver%26jtitle%3DPLoS%2520Pathog.%26date%3D2014%26volume%3D10%26issue%3D6%26spage%3De1004210%26doi%3D10.1371%2Fjournal.ppat.1004210" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, L.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wohlleber, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reisinger, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenne, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, R.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdullah, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schildberg, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Odenthal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dienes, H.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Rooijen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garbi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Croft, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurts, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubes, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Protzer, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heikenwalder, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knolle, P. A.</span></span> <span> </span><span class="NLM_article-title">Intrahepatic Myeloid-Cell Aggregates Enable Local Proliferation of CD8<sup>+</sup> T Cells and Successful Immunotherapy Against Chronic Viral Liver Infection</span>. <i>Nat. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">574</span>– <span class="NLM_lpage">583</span>, <span class="refDoi"> DOI: 10.1038/ni.2573</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=10.1038%2Fni.2573" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=23584070" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlslyqsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2013&pages=574-583&issue=6&author=L.-R.+Huangauthor=D.+Wohlleberauthor=F.+Reisingerauthor=C.+N.+Jenneauthor=R.-L.+Chengauthor=Z.+Abdullahauthor=F.+A.+Schildbergauthor=M.+Odenthalauthor=H.-P.+Dienesauthor=N.+van+Rooijenauthor=E.+Schmittauthor=N.+Garbiauthor=M.+Croftauthor=C.+Kurtsauthor=P.+Kubesauthor=U.+Protzerauthor=M.+Heikenwalderauthor=P.+A.+Knolle&title=Intrahepatic+Myeloid-Cell+Aggregates+Enable+Local+Proliferation+of+CD8%2B+T+Cells+and+Successful+Immunotherapy+Against+Chronic+Viral+Liver+Infection&doi=10.1038%2Fni.2573"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Intrahepatic myeloid-cell aggregates enable local proliferation of CD8+ T cells and successful immunotherapy against chronic viral liver infection</span></div><div class="casAuthors">Huang, Li-Rung; Wohlleber, Dirk; Reisinger, Florian; Jenne, Craig N.; Cheng, Ru-Lin; Abdullah, Zeinab; Schildberg, Frank A.; Odenthal, Margarete; Dienes, Hans-Peter; van Rooijen, Nico; Schmitt, Edgar; Garbi, Natalio; Croft, Michael; Kurts, Christian; Kubes, Paul; Protzer, Ulrike; Heikenwaelder, Mathias; Knolle, Percy A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Immunology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">574-583</span>CODEN:
                <span class="NLM_cas:coden">NIAMCZ</span>;
        ISSN:<span class="NLM_cas:issn">1529-2908</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Chronic infection is difficult to overcome because of exhaustion or depletion of cytotoxic effector CD8+ T cells (cytotoxic T lymphocytes (CTLs)).  Here we report that signaling via Toll-like receptors (TLRs) induced intrahepatic aggregates of myeloid cells that enabled the population expansion of CTLs (iMATEs: 'intrahepatic myeloid-cell aggregates for T cell population expansion') without causing immunopathol.  In the liver, CTL proliferation was restricted to iMATEs that were composed of inflammatory monocyte-derived CD11b+ cells.  Signaling via tumor-necrosis factor (TNF) caused iMATE formation that facilitated costimulation dependent on the receptor OX40 for expansion of the CTL population.  The iMATEs arose during acute viral infection but were absent during chronic viral infection, yet they were still induced by TLR signaling.  Such hepatic expansion of the CTL population controlled chronic viral infection of the liver after vaccination with DNA.  Thus, iMATEs are dynamic structures that overcome regulatory cues that limit the population expansion of CTLs during chronic infection and can be used in new therapeutic vaccination strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxbbT4E45LeLVg90H21EOLACvtfcHk0lgPCSGt1xh1ZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlslyqsL0%253D&md5=3105ab62af74f0cdb4d9bca9df075f46</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fni.2573&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fni.2573%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DL.-R.%26aulast%3DWohlleber%26aufirst%3DD.%26aulast%3DReisinger%26aufirst%3DF.%26aulast%3DJenne%26aufirst%3DC.%2BN.%26aulast%3DCheng%26aufirst%3DR.-L.%26aulast%3DAbdullah%26aufirst%3DZ.%26aulast%3DSchildberg%26aufirst%3DF.%2BA.%26aulast%3DOdenthal%26aufirst%3DM.%26aulast%3DDienes%26aufirst%3DH.-P.%26aulast%3Dvan%2BRooijen%26aufirst%3DN.%26aulast%3DSchmitt%26aufirst%3DE.%26aulast%3DGarbi%26aufirst%3DN.%26aulast%3DCroft%26aufirst%3DM.%26aulast%3DKurts%26aufirst%3DC.%26aulast%3DKubes%26aufirst%3DP.%26aulast%3DProtzer%26aufirst%3DU.%26aulast%3DHeikenwalder%26aufirst%3DM.%26aulast%3DKnolle%26aufirst%3DP.%2BA.%26atitle%3DIntrahepatic%2520Myeloid-Cell%2520Aggregates%2520Enable%2520Local%2520Proliferation%2520of%2520CD8%252B%2520T%2520Cells%2520and%2520Successful%2520Immunotherapy%2520Against%2520Chronic%2520Viral%2520Liver%2520Infection%26jtitle%3DNat.%2520Immunol.%26date%3D2013%26volume%3D14%26issue%3D6%26spage%3D574%26epage%3D583%26doi%3D10.1038%2Fni.2573" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Biermer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puro, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, R. J.</span></span> <span> </span><span class="NLM_article-title">Tumor Necrosis Factor Alpha Inhibition of Hepatitis B Virus Replication Involves Disruption of Capsid Integrity Through Activation of NF-κB</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>77</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">4033</span>– <span class="NLM_lpage">4042</span>, <span class="refDoi"> DOI: 10.1128/JVI.77.7.4033-4042.2003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=10.1128%2FJVI.77.7.4033-4042.2003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=12634363" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=1%3ACAS%3A528%3ADC%252BD3sXisVKku7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2003&pages=4033-4042&issue=7&author=M.+Biermerauthor=R.+Puroauthor=R.+J.+Schneider&title=Tumor+Necrosis+Factor+Alpha+Inhibition+of+Hepatitis+B+Virus+Replication+Involves+Disruption+of+Capsid+Integrity+Through+Activation+of+NF-%CE%BAB&doi=10.1128%2FJVI.77.7.4033-4042.2003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Tumor necrosis factor alpha inhibition of hepatitis B virus replication involves disruption of capsid integrity through activation of NF-κB</span></div><div class="casAuthors">Biermer, Michael; Puro, Robyn; Schneider, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">4033-4042</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Chronic infection by hepatitis B virus results from an inability to clear the virus, which is assocd. with liver disease and liver cancer.  Tumor necrosis factor alpha (TNF-α) is assocd. with noncytopathic clearance of hepatitis B virus in animal models.  Here we demonstrate that the nuclear factor κB (NF-κB) signaling pathway is a central mediator of inhibition of hepatitis B virus by TNF-α and we describe the mol. mechanism.  TNF-α is shown to suppress hepatitis B virus DNA replication without cell killing by disrupting the formation or stability of cytoplasmic viral capsids through a pathway requiring the NF-κB-activating inhibitor of κB kinase complex IKK-α/β and active transcription factor NF-κB.  Hepatitis B virus replication could also be inhibited and viral capsid formation could be disrupted in the absence of TNF-α solely by overexpression of IKK-α/β or strong activation of NF-κB.  In contrast, inhibition of NF-κB signaling stimulated viral replication, demonstrating that HBV replication is both pos. and neg. regulated by the level of activity of the NF-κB pathway.  Studies are presented that exclude the possibility that HBV inhibition by NF-κB is carried out by secondary prodn. of gamma interferon or alpha/beta interferon.  These results identify a novel mechanism for noncytopathic suppression of hepatitis B virus replication that is mediated by the NF-κB signaling pathway and activated by TNF-α.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0hS6lF97_KbVg90H21EOLACvtfcHk0lgPCSGt1xh1ZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXisVKku7g%253D&md5=f8cb4fde4611b75867673118a2cfdf95</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1128%2FJVI.77.7.4033-4042.2003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.77.7.4033-4042.2003%26sid%3Dliteratum%253Aachs%26aulast%3DBiermer%26aufirst%3DM.%26aulast%3DPuro%26aufirst%3DR.%26aulast%3DSchneider%26aufirst%3DR.%2BJ.%26atitle%3DTumor%2520Necrosis%2520Factor%2520Alpha%2520Inhibition%2520of%2520Hepatitis%2520B%2520Virus%2520Replication%2520Involves%2520Disruption%2520of%2520Capsid%2520Integrity%2520Through%2520Activation%2520of%2520NF-%25CE%25BAB%26jtitle%3DJ.%2520Virol.%26date%3D2003%26volume%3D77%26issue%3D7%26spage%3D4033%26epage%3D4042%26doi%3D10.1128%2FJVI.77.7.4033-4042.2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Watashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwamoto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marusawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uchida, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daito, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitamura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muramatsu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohashi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiyohara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murata, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aizaki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wakita, T.</span></span> <span> </span><span class="NLM_article-title">Interleukin-1 and Tumor Necrosis Factor-α Trigger Restriction of Hepatitis B Virus Infection Via a Cytidine Deaminase Activation-Induced Cytidine Deaminase (AID)</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>288</i></span> (<span class="NLM_issue">44</span>),  <span class="NLM_fpage">31715</span>– <span class="NLM_lpage">31727</span>, <span class="refDoi"> DOI: 10.1074/jbc.M113.501122</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=10.1074%2Fjbc.M113.501122" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=24025329" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslaitbbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=288&publication_year=2013&pages=31715-31727&issue=44&author=K.+Watashiauthor=G.+Liangauthor=M.+Iwamotoauthor=H.+Marusawaauthor=N.+Uchidaauthor=T.+Daitoauthor=K.+Kitamuraauthor=M.+Muramatsuauthor=H.+Ohashiauthor=T.+Kiyoharaauthor=R.+Suzukiauthor=J.+Liauthor=S.+Tongauthor=Y.+Tanakaauthor=K.+Murataauthor=H.+Aizakiauthor=T.+Wakita&title=Interleukin-1+and+Tumor+Necrosis+Factor-%CE%B1+Trigger+Restriction+of+Hepatitis+B+Virus+Infection+Via+a+Cytidine+Deaminase+Activation-Induced+Cytidine+Deaminase+%28AID%29&doi=10.1074%2Fjbc.M113.501122"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Interleukin-1 and Tumor Necrosis Factor-α Trigger Restriction of Hepatitis B Virus Infection via a Cytidine Deaminase Activation-induced Cytidine Deaminase (AID)</span></div><div class="casAuthors">Watashi, Koichi; Liang, Guoxin; Iwamoto, Masashi; Marusawa, Hiroyuki; Uchida, Nanako; Daito, Takuji; Kitamura, Kouichi; Muramatsu, Masamichi; Ohashi, Hirofumi; Kiyohara, Tomoko; Suzuki, Ryosuke; Li, Jisu; Tong, Shuping; Tanaka, Yasuhito; Murata, Kazumoto; Aizaki, Hideki; Wakita, Takaji</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">288</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">31715-31727</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Virus infection is restricted by intracellular immune responses in host cells, and this is typically modulated by stimulation of cytokines.  The cytokines and host factors that det. the host cell restriction against hepatitis B virus (HBV) infection are not well understood.  We screened 36 cytokines and chemokines to det. which were able to reduce the susceptibility of HepaRG cells to HBV infection.  Here, we found that pretreatment with IL-1β and TNFα remarkably reduced the host cell susceptibility to HBV infection.  This effect was mediated by activation of the NF-κB signaling pathway.  A cytidine deaminase, activation-induced cytidine deaminase (AID), was up-regulated by both IL-1β and TNFα in a variety of hepatocyte cell lines and primary human hepatocytes.  Another deaminase APOBEC3G was not induced by these proinflammatory cytokines.  Knockdown of AID expression impaired the anti-HBV effect of IL-1β, and overexpression of AID antagonized HBV infection, suggesting that AID was one of the responsible factors for the anti-HBV activity of IL-1/TNFα.  Although AID induced hypermutation of HBV DNA, this activity was dispensable for the anti-HBV activity.  The antiviral effect of IL-1/TNFα was also obsd. on different HBV genotypes but not on hepatitis C virus.  These results demonstrate that proinflammatory cytokines IL-1/TNFα trigger a novel antiviral mechanism involving AID to regulate host cell permissiveness to HBV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqA-GbKRcw1ZLVg90H21EOLACvtfcHk0lgPCSGt1xh1ZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslaitbbK&md5=36b60d1c3fbae71bd6f81e9c10b1d33c</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M113.501122&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M113.501122%26sid%3Dliteratum%253Aachs%26aulast%3DWatashi%26aufirst%3DK.%26aulast%3DLiang%26aufirst%3DG.%26aulast%3DIwamoto%26aufirst%3DM.%26aulast%3DMarusawa%26aufirst%3DH.%26aulast%3DUchida%26aufirst%3DN.%26aulast%3DDaito%26aufirst%3DT.%26aulast%3DKitamura%26aufirst%3DK.%26aulast%3DMuramatsu%26aufirst%3DM.%26aulast%3DOhashi%26aufirst%3DH.%26aulast%3DKiyohara%26aufirst%3DT.%26aulast%3DSuzuki%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DTong%26aufirst%3DS.%26aulast%3DTanaka%26aufirst%3DY.%26aulast%3DMurata%26aufirst%3DK.%26aulast%3DAizaki%26aufirst%3DH.%26aulast%3DWakita%26aufirst%3DT.%26atitle%3DInterleukin-1%2520and%2520Tumor%2520Necrosis%2520Factor-%25CE%25B1%2520Trigger%2520Restriction%2520of%2520Hepatitis%2520B%2520Virus%2520Infection%2520Via%2520a%2520Cytidine%2520Deaminase%2520Activation-Induced%2520Cytidine%2520Deaminase%2520%2528AID%2529%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2013%26volume%3D288%26issue%3D44%26spage%3D31715%26epage%3D31727%26doi%3D10.1074%2Fjbc.M113.501122" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Isorce, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Testoni, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Locatelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fresquet, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivoire, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luangsay, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoulim, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durantel, D.</span></span> <span> </span><span class="NLM_article-title">Antiviral Activity of Various Interferons and Pro-Inflammatory Cytokines in Non-Transformed Cultured Hepatocytes Infected with Hepatitis B Virus</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>130</i></span>,  <span class="NLM_fpage">36</span>– <span class="NLM_lpage">45</span>, <span class="refDoi"> DOI: 10.1016/j.antiviral.2016.03.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=10.1016%2Fj.antiviral.2016.03.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=26971407" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=1%3ACAS%3A528%3ADC%252BC28XltFGlsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2016&pages=36-45&author=N.+Isorceauthor=B.+Testoniauthor=M.+Locatelliauthor=J.+Fresquetauthor=M.+Rivoireauthor=S.+Luangsayauthor=F.+Zoulimauthor=D.+Durantel&title=Antiviral+Activity+of+Various+Interferons+and+Pro-Inflammatory+Cytokines+in+Non-Transformed+Cultured+Hepatocytes+Infected+with+Hepatitis+B+Virus&doi=10.1016%2Fj.antiviral.2016.03.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Antiviral activity of various interferons and pro-inflammatory cytokines in non-transformed cultured hepatocytes infected with hepatitis B virus</span></div><div class="casAuthors">Isorce, Nathalie; Testoni, Barbara; Locatelli, Maelle; Fresquet, Judith; Rivoire, Michel; Luangsay, Souphalone; Zoulim, Fabien; Durantel, David</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">130</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">36-45</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">In HBV-infected patients, therapies with nucleoside analogs or IFNα remain ineffective in eradicating the infection.  Our aim was to re-analyze the anti-HBV activity of a large panel of IFNs and cytokines in vitro using non-transformed cultured hepatocytes infected with HBV, to identify new immune-therapeutic options.  HepaRG cells and primary human hepatocytes were infected with HBV and, when infection was established, treated with various concns. of different IFNs or inflammatory cytokines.  Viral parameters were evaluated by quantifying HBV nucleic acids by qPCR and Southern Blot, and secreted HBV antigens were evaluated using ELISA.  The cytokines tested were type-I IFNs, IFNγ, type-III IFNs, TNFα, IL-6, IL-1β, IL-18 as well as nucleos(t)ide analogs tenofovir and ribavirin.  Cytokines and drugs, with the exception of IL-18 and ribavirin, exhibited a suppressive effect on HBV replication at least as strong as, but often stronger than, IFNα.  The cytokine presenting the highest effect on HBV DNA was IL-1β, which exerted its inhibition within picomolar range.  Importantly, we noticed differential effects on other parameters (HBV RNA, HBeAg, HBsAg) between both IFNs and inflammatory cytokines, thus suggesting different mechanisms of action.  The combination of IL-1β and already used therapies, i.e.  IFNα or tenofovir, demonstrated a stronger or similar anti-HBV activity.  IL-1β was found to have a very potent antiviral effect against HBV in vitro.  HBV was previously shown to promptly inhibit IL-1β prodn. in Kupffer cells.  Strategies aiming at unlocking this inhibition and restoring local prodn. of IL-1β may help to further inhibit HBV replication in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo44bbOm9PIxbVg90H21EOLACvtfcHk0lhZUa6QEYoozw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XltFGlsbY%253D&md5=0d741647ca93100b340613059c7d1f3e</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2016.03.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2016.03.008%26sid%3Dliteratum%253Aachs%26aulast%3DIsorce%26aufirst%3DN.%26aulast%3DTestoni%26aufirst%3DB.%26aulast%3DLocatelli%26aufirst%3DM.%26aulast%3DFresquet%26aufirst%3DJ.%26aulast%3DRivoire%26aufirst%3DM.%26aulast%3DLuangsay%26aufirst%3DS.%26aulast%3DZoulim%26aufirst%3DF.%26aulast%3DDurantel%26aufirst%3DD.%26atitle%3DAntiviral%2520Activity%2520of%2520Various%2520Interferons%2520and%2520Pro-Inflammatory%2520Cytokines%2520in%2520Non-Transformed%2520Cultured%2520Hepatocytes%2520Infected%2520with%2520Hepatitis%2520B%2520Virus%26jtitle%3DAntiviral%2520Res.%26date%3D2016%26volume%3D130%26spage%3D36%26epage%3D45%26doi%3D10.1016%2Fj.antiviral.2016.03.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roethle, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McFadden, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hrvatin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hui, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graupe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallagher, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hesselgesser, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duatschek, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tumas, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halcomb, R. L.</span></span> <span> </span><span class="NLM_article-title">Identification and Optimization of Pteridinone Toll-like Receptor 7 (TLR7) Agonists for the Oral Treatment of Viral Hepatitis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">7324</span>– <span class="NLM_lpage">7333</span>, <span class="refDoi"> DOI: 10.1021/jm400815m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400815m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlSjtbfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=7324-7333&issue=18&author=P.+A.+Roethleauthor=R.+M.+McFaddenauthor=H.+Yangauthor=P.+Hrvatinauthor=H.+Huiauthor=M.+Graupeauthor=B.+Gallagherauthor=J.+Chaoauthor=J.+Hesselgesserauthor=P.+Duatschekauthor=J.+Zhengauthor=B.+Luauthor=D.+B.+Tumasauthor=J.+Perryauthor=R.+L.+Halcomb&title=Identification+and+Optimization+of+Pteridinone+Toll-like+Receptor+7+%28TLR7%29+Agonists+for+the+Oral+Treatment+of+Viral+Hepatitis&doi=10.1021%2Fjm400815m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and Optimization of Pteridinone Toll-like Receptor 7 (TLR7) Agonists for the Oral Treatment of Viral Hepatitis</span></div><div class="casAuthors">Roethle, Paul A.; McFadden, Ryan M.; Yang, Hong; Hrvatin, Paul; Hui, Hon; Graupe, Michael; Gallagher, Brian; Chao, Jessica; Hesselgesser, Joseph; Duatschek, Paul; Zheng, Jim; Lu, Bing; Tumas, Daniel B.; Perry, Jason; Halcomb, Randall L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">7324-7333</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Pteridinone-based Toll-like receptor 7 (TLR7) agonists were identified as potent and selective alternatives to the previously reported adenine-based agonists, leading to the discovery of GS-9620 (I).  Analogs were optimized for the immunomodulatory activity and selectivity vs. other TLRs, based on differential induction of key cytokines including interferon α (IFN-α) and tumor necrosis factor α (TNF-α).  In addn., physicochem. properties were adjusted to achieve desirable in vivo pharmacokinetic and pharmacodynamic properties.  GS-9620 is currently in clin. evaluation for the treatment of chronic hepatitis B (HBV) infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGog2wrWq68pK7Vg90H21EOLACvtfcHk0lhZUa6QEYoozw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlSjtbfL&md5=753aa20b0d0f9b16eb3a1d205fbe0a30</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Fjm400815m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400815m%26sid%3Dliteratum%253Aachs%26aulast%3DRoethle%26aufirst%3DP.%2BA.%26aulast%3DMcFadden%26aufirst%3DR.%2BM.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DHrvatin%26aufirst%3DP.%26aulast%3DHui%26aufirst%3DH.%26aulast%3DGraupe%26aufirst%3DM.%26aulast%3DGallagher%26aufirst%3DB.%26aulast%3DChao%26aufirst%3DJ.%26aulast%3DHesselgesser%26aufirst%3DJ.%26aulast%3DDuatschek%26aufirst%3DP.%26aulast%3DZheng%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DB.%26aulast%3DTumas%26aufirst%3DD.%2BB.%26aulast%3DPerry%26aufirst%3DJ.%26aulast%3DHalcomb%26aufirst%3DR.%2BL.%26atitle%3DIdentification%2520and%2520Optimization%2520of%2520Pteridinone%2520Toll-like%2520Receptor%25207%2520%2528TLR7%2529%2520Agonists%2520for%2520the%2520Oral%2520Treatment%2520of%2520Viral%2520Hepatitis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26issue%3D18%26spage%3D7324%26epage%3D7333%26doi%3D10.1021%2Fjm400815m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tanji, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohto, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shibata, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyake, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimizu, T.</span></span> <span> </span><span class="NLM_article-title">Structural Reorganization of the Toll-Like Receptor 8 Dimer Induced by Agonistic Ligands</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>339</i></span> (<span class="NLM_issue">6126</span>),  <span class="NLM_fpage">1426</span>– <span class="NLM_lpage">1429</span>, <span class="refDoi"> DOI: 10.1126/science.1229159</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=10.1126%2Fscience.1229159" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=23520111" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=1%3ACAS%3A528%3ADC%252BC3sXktF2qsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=339&publication_year=2013&pages=1426-1429&issue=6126&author=H.+Tanjiauthor=U.+Ohtoauthor=T.+Shibataauthor=K.+Miyakeauthor=T.+Shimizu&title=Structural+Reorganization+of+the+Toll-Like+Receptor+8+Dimer+Induced+by+Agonistic+Ligands&doi=10.1126%2Fscience.1229159"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Reorganization of the Toll-Like Receptor 8 Dimer Induced by Agonistic Ligands</span></div><div class="casAuthors">Tanji, Hiromi; Ohto, Umeharu; Shibata, Takuma; Miyake, Kensuke; Shimizu, Toshiyuki</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">339</span>
        (<span class="NLM_cas:issue">6126</span>),
    <span class="NLM_cas:pages">1426-1429</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Toll-like receptor 7 (TLR7) and TLR8 recognize single-stranded RNA and initiate innate immune responses.  Several synthetic agonists of TLR7-TLR8 display novel therapeutic potential; however, the mol. basis for ligand recognition and activation of signaling by TLR7 or TLR8 is largely unknown.  In this study, the crystal structures of unliganded and ligand-induced activated human TLR8 dimers were elucidated.  Ligand recognition was mediated by a dimerization interface formed by two protomers.  Upon ligand stimulation, the TLR8 dimer was reorganized such that the two C termini were brought into proximity.  The loop between leucine-rich repeat 14 (LRR14) and LRR15 was cleaved; however, the N- and C-terminal halves remained assocd. and contributed to ligand recognition and dimerization.  Thus, ligand binding induces reorganization of the TLR8 dimer, which enables downstream signaling processes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzF-H0sxwN0rVg90H21EOLACvtfcHk0lgfISOHkPKpsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXktF2qsr4%253D&md5=13b8f32cd70dc59890820d03e88d62ab</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1126%2Fscience.1229159&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1229159%26sid%3Dliteratum%253Aachs%26aulast%3DTanji%26aufirst%3DH.%26aulast%3DOhto%26aufirst%3DU.%26aulast%3DShibata%26aufirst%3DT.%26aulast%3DMiyake%26aufirst%3DK.%26aulast%3DShimizu%26aufirst%3DT.%26atitle%3DStructural%2520Reorganization%2520of%2520the%2520Toll-Like%2520Receptor%25208%2520Dimer%2520Induced%2520by%2520Agonistic%2520Ligands%26jtitle%3DScience%26date%3D2013%26volume%3D339%26issue%3D6126%26spage%3D1426%26epage%3D1429%26doi%3D10.1126%2Fscience.1229159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kokatla, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salunke, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sil, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balakrishna, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malladi, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">David, S. A.</span></span> <span> </span><span class="NLM_article-title">Toll-like Receptor-8 Agonistic Activities in C2, C4, and C8 Modified Thiazolo[4,5-c]quinolines</span>. <i>Org. Biomol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1179</span>– <span class="NLM_lpage">1198</span>, <span class="refDoi"> DOI: 10.1039/c2ob26705e</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=10.1039%2Fc2ob26705e" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=23314908" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVCnt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2013&pages=1179-1198&author=H.+P.+Kokatlaauthor=E.+Yooauthor=D.+B.+Salunkeauthor=D.+Silauthor=C.+F.+Ngauthor=R.+Balakrishnaauthor=S.+S.+Malladiauthor=L.+M.+Foxauthor=S.+A.+David&title=Toll-like+Receptor-8+Agonistic+Activities+in+C2%2C+C4%2C+and+C8+Modified+Thiazolo%5B4%2C5-c%5Dquinolines&doi=10.1039%2Fc2ob26705e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Toll-like receptor-8 agonistic activities in C2, C4, and C8 modified thiazolo[4,5-c]quinolines</span></div><div class="casAuthors">Kokatla, Hari Prasad; Yoo, Euna; Salunke, Deepak B.; Sil, Diptesh; Ng, Cameron F.; Balakrishna, Rajalakshmi; Malladi, Subbalakshmi S.; Fox, Lauren M.; David, Sunil A.</div><div class="citationInfo"><span class="NLM_cas:title">Organic & Biomolecular Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1179-1198</span>CODEN:
                <span class="NLM_cas:coden">OBCRAK</span>;
        ISSN:<span class="NLM_cas:issn">1477-0520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Toll-like receptor (TLR)-8 agonists typified by the 2-alkylthiazolo[4,5-c]quinolin-4-amine (CL075) chemotype are uniquely potent in activating adaptive immune responses by inducing robust prodn. of T helper 1-polarizing cytokines, suggesting that TLR8-active compds. could be promising candidate vaccine adjuvants, esp. for neonatal vaccines.  Alkylthiazoloquinolines with Me, Et, Pr and Bu groups at C2 displayed comparable TLR8-agonistic potencies; activity diminished precipitously in the C2-pentyl compd., and higher homologues were inactive.  The C2-Bu compd. was unique in possessing substantial TLR7-agonistic activity.  Analogs with branched alkyl groups at C2 displayed poor tolerance of terminal steric bulk.  Virtually all modifications at C8 led to abrogation of agonistic activity.  Alkylation on the C4-amine was not tolerated, whereas N-acyl analogs with short acyl groups (other than acetyl) retained TLR8 agonistic activity, but were substantially less water-sol.  Immunization in rabbits with a model subunit antigen adjuvanted with the lead C2-Bu thiazoloquinoline showed enhancements of antigen-specific antibody titers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYAWu83GzZRLVg90H21EOLACvtfcHk0lgfISOHkPKpsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVCnt7o%253D&md5=50ab5984b3920a890201960880e9003e</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1039%2Fc2ob26705e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc2ob26705e%26sid%3Dliteratum%253Aachs%26aulast%3DKokatla%26aufirst%3DH.%2BP.%26aulast%3DYoo%26aufirst%3DE.%26aulast%3DSalunke%26aufirst%3DD.%2BB.%26aulast%3DSil%26aufirst%3DD.%26aulast%3DNg%26aufirst%3DC.%2BF.%26aulast%3DBalakrishna%26aufirst%3DR.%26aulast%3DMalladi%26aufirst%3DS.%2BS.%26aulast%3DFox%26aufirst%3DL.%2BM.%26aulast%3DDavid%26aufirst%3DS.%2BA.%26atitle%3DToll-like%2520Receptor-8%2520Agonistic%2520Activities%2520in%2520C2%252C%2520C4%252C%2520and%2520C8%2520Modified%2520Thiazolo%255B4%252C5-c%255Dquinolines%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2013%26volume%3D11%26spage%3D1179%26epage%3D1198%26doi%3D10.1039%2Fc2ob26705e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miller, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerster, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owens, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slade, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomai, M. A.</span></span> <span> </span><span class="NLM_article-title">Imiquimod Applied Topically: A Novel Immune Response Modifier and New Class of Drug</span>. <i>Int. J. Immunopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">14</span>, <span class="refDoi"> DOI: 10.1016/S0192-0561(98)00068-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=10.1016%2FS0192-0561%2898%2900068-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=10411278" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=1%3ACAS%3A528%3ADyaK1MXitFyqtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=1999&pages=1-14&issue=1&author=R.+L.+Millerauthor=J.+F.+Gersterauthor=M.+L.+Owensauthor=H.+B.+Sladeauthor=M.+A.+Tomai&title=Imiquimod+Applied+Topically%3A+A+Novel+Immune+Response+Modifier+and+New+Class+of+Drug&doi=10.1016%2FS0192-0561%2898%2900068-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Imiquimod applied topically: a novel immune response modifier and new class of drug</span></div><div class="casAuthors">Miller, R. L.; Gerster, J. F.; Owens, M. L.; Slade, H. B.; Tomai, M. A.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Immunopharmacology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-14</span>CODEN:
                <span class="NLM_cas:coden">IJIMDS</span>;
        ISSN:<span class="NLM_cas:issn">0192-0561</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review with 70 refs.  Imiquimod (S-26308, R-837) (1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4 amine), an immune response modifier, demonstrates potent antiviral and antitumor activity in animal models (see structure in Fig. 1).  The drug exhibits no direct antiviral or antiproliferative activity when tested in a no. of cell culture systems.  Imiquimod's activity was discovered while screening for anti-herpes virus activity.  One of the first analogs in the series, S-25059 was tested in the early 1980's and due to slight toxicity, caused slightly reduced herpes cytopathol. in Vero cell cultures.  Follow-up testing in herpes infected guinea pigs showed complete protection toward lesion development.  Activity of these drugs results primarily from interferon alpha (IFN-α) induction and other cytokine induction.  At least part of the cytokine induction is mediated through NF-κB activation.  These cytokines stimulate several other aspects of the innate immune response.  In addn., imiquimod stimulates acquired immunity, in particular the cellular arm which is important for control of viral infections and various tumors.  This effect is mediated by drug induced IFN-α and Interleukin-12 (IL-12) and IFN-γ induced by these cytokines.  Imiquimod is expected to be effective where exogenous IFN-α has shown utility and where enhancement of cell-mediated immunity is needed.  The following is a brief review of the preclin. pharmacol. of imiquimod and the clin. results of genital wart trials.  The mechanism of action of topically applied imiquimod will likely lead to benefits in several other chronic virus infections and tumors of the skin.  Two other reviews on imiquimod that focus mainly on the clin. results have been published (Beutner & Geisse, 1997; Slade, Owens, Tomai & Miller, 1998).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSom1Nk4ulLrVg90H21EOLACvtfcHk0lgfISOHkPKpsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXitFyqtLk%253D&md5=b4b47faaa21fb4eb2e530ca2bcd6d442</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2FS0192-0561%2898%2900068-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0192-0561%252898%252900068-X%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DR.%2BL.%26aulast%3DGerster%26aufirst%3DJ.%2BF.%26aulast%3DOwens%26aufirst%3DM.%2BL.%26aulast%3DSlade%26aufirst%3DH.%2BB.%26aulast%3DTomai%26aufirst%3DM.%2BA.%26atitle%3DImiquimod%2520Applied%2520Topically%253A%2520A%2520Novel%2520Immune%2520Response%2520Modifier%2520and%2520New%2520Class%2520of%2520Drug%26jtitle%3DInt.%2520J.%2520Immunopharmacol.%26date%3D1999%26volume%3D21%26issue%3D1%26spage%3D1%26epage%3D14%26doi%3D10.1016%2FS0192-0561%2898%2900068-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dietsch, G. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthews, M.-A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghanekar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inokuma, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maino, V. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henderson, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howbert, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Disis, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hershberg, R. M.</span></span> <span> </span><span class="NLM_article-title">VTX-2337 Is a Novel TLR8 Agonist That Activates NK Cells and Augments ADCC</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">499</span>– <span class="NLM_lpage">509</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-11-1625</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=10.1158%2F1078-0432.CCR-11-1625" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=22128302" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVGqsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=499-509&issue=2&author=H.+Luauthor=G.+N.+Dietschauthor=M.-A.+H.+Matthewsauthor=Y.+Yangauthor=S.+Ghanekarauthor=M.+Inokumaauthor=M.+Suniauthor=V.+C.+Mainoauthor=K.+E.+Hendersonauthor=J.+J.+Howbertauthor=M.+L.+Disisauthor=R.+M.+Hershberg&title=VTX-2337+Is+a+Novel+TLR8+Agonist+That+Activates+NK+Cells+and+Augments+ADCC&doi=10.1158%2F1078-0432.CCR-11-1625"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">VTX-2337 Is a Novel TLR8 Agonist That Activates NK Cells and Augments ADCC</span></div><div class="casAuthors">Lu, Hailing; Dietsch, Gregory N.; Matthews, Maura-Ann H.; Yang, Yi; Ghanekar, Smita; Inokuma, Margaret; Suni, Maria; Maino, Vernon C.; Henderson, Katherine E.; Howbert, James Jeffry; Disis, Mary L.; Hershberg, Robert M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">499-509</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The study's aim was to characterize VTX-2337, a novel Toll-like receptor (TLR) 8 agonist in clin. development, and investigate its potential to improve monoclonal antibody-based immunotherapy that includes the activation of natural killer (NK) cells.  HEK-TLR transfectants were used to compare the selectivity and potency of VTX-2337, imiquimod, CpG ODN2006, and CL075.  The ability of VTX-2337 to induce cytokine and chemokine prodn. from human peripheral blood mononuclear cells (PBMC) and activation of specific immune cell subsets was examd.  The potential for VTX-2337 to activate NK cell activity through direct and indirect mechanisms was also investigated.  Finally, we tested the potential for VTX-2337 to augment antibody-dependent cell-mediated cytotoxicity (ADCC), esp. in individuals with low-affinity FcγR3A single-nucleotide polymorphism (SNP).  VTX-2337 selectively activates TLR8 with an EC50 of about 100 nmol/L and stimulates prodn. of TNFα and interleukin (IL)-12 from monocytes and myeloid dendritic cells (mDC).  VTX-2337 stimulates IFNγ prodn. from NK cells and increases the cytotoxicity of NK cells against K562 and ADCC by rituximab and trastuzumab.  Effects of VTX-2337 on NK cells were, in part, from direct activation as increased IFNγ prodn. and cytotoxic activity were seen with purified NK cells.  Finally, VTX-2337 augments ADCC by rituximab in PBMCs with different FcγR3A genotypes (V/V, V/F, and F/F at position 158).  VTX-2337 is a novel small-mol. TLR8 agonist that activates monocytes, DCs, and NK cells.  Through the activation of NK cells, it has the potential to augment the effectiveness of monoclonal antibody treatments where a polymorphism in FcγR3A limits clin. efficacy.  Clin Cancer Res; 18(2); 499-509.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQFakqLqEzJLVg90H21EOLACvtfcHk0ljPLaMXVK9mUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVGqsrY%253D&md5=73e1fd4bfd0b935cc4f917979e78a1f0</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-1625&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-1625%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DH.%26aulast%3DDietsch%26aufirst%3DG.%2BN.%26aulast%3DMatthews%26aufirst%3DM.-A.%2BH.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DGhanekar%26aufirst%3DS.%26aulast%3DInokuma%26aufirst%3DM.%26aulast%3DSuni%26aufirst%3DM.%26aulast%3DMaino%26aufirst%3DV.%2BC.%26aulast%3DHenderson%26aufirst%3DK.%2BE.%26aulast%3DHowbert%26aufirst%3DJ.%2BJ.%26aulast%3DDisis%26aufirst%3DM.%2BL.%26aulast%3DHershberg%26aufirst%3DR.%2BM.%26atitle%3DVTX-2337%2520Is%2520a%2520Novel%2520TLR8%2520Agonist%2520That%2520Activates%2520NK%2520Cells%2520and%2520Augments%2520ADCC%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26issue%3D2%26spage%3D499%26epage%3D509%26doi%3D10.1158%2F1078-0432.CCR-11-1625" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beesu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caruso, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salyer, A. C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khetani, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sil, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weerasinghe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanji, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohto, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimizu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">David, S. A.</span></span> <span> </span><span class="NLM_article-title">Structure-Based Design of Human TLR8-Specific Agonists with Augmented Potency and Adjuvanticity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">7833</span>– <span class="NLM_lpage">7849</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01087</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01087" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVyhu7fN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=7833-7849&author=M.+Beesuauthor=G.+Carusoauthor=A.+C.+D.+Salyerauthor=K.+K.+Khetaniauthor=D.+Silauthor=M.+Weerasingheauthor=H.+Tanjiauthor=U.+Ohtoauthor=T.+Shimizuauthor=S.+A.+David&title=Structure-Based+Design+of+Human+TLR8-Specific+Agonists+with+Augmented+Potency+and+Adjuvanticity&doi=10.1021%2Facs.jmedchem.5b01087"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Design of Human TLR8-Specific Agonists with Augmented Potency and Adjuvanticity</span></div><div class="casAuthors">Beesu, Mallesh; Caruso, Giuseppe; Salyer, Alex C. D.; Khetani, Karishma K.; Sil, Diptesh; Weerasinghe, Mihiri; Tanji, Hiromi; Ohto, Umeharu; Shimizu, Toshiyuki; David, Sunil A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7833-7849</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Human Toll-like receptor 8 (hTLR8) is expressed in myeloid dendritic cells, monocytes, and monocyte-derived dendritic cells.  Engagement by TLR8 agonists evokes a distinct cytokine profile which favors the development of type 1 helper T cells.  Crystal structures of the ectodomain of hTLR8 cocrystd. with two regioisomers of a dual TLR7/8-agonistic N1-substituted imidazoquinolines showed subtle differences in their interactions in the binding site of hTLR8.  The authors hypothesized that the potency of a previously reported best-in-class pure TLR8 agonist, 3-pentylquinoline-2-amine, could be further enhanced by "designing in" functional groups that would mimic key intermol. interactions that the authors had obsd. in the crystal structures.  The authors performed a focused exploration of decorating the quinoline core with alkylamino groups at all possible positions.  These studies have led to the identification of a novel TLR8 agonist that was ∼20-fold more potent than the parent compd. and displays prominent adjuvantic activity in a rabbit model of immunization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_vD5opmBVbrVg90H21EOLACvtfcHk0ljPLaMXVK9mUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVyhu7fN&md5=799d7d25cd9819e46b9a1086025587e1</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01087&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01087%26sid%3Dliteratum%253Aachs%26aulast%3DBeesu%26aufirst%3DM.%26aulast%3DCaruso%26aufirst%3DG.%26aulast%3DSalyer%26aufirst%3DA.%2BC.%2BD.%26aulast%3DKhetani%26aufirst%3DK.%2BK.%26aulast%3DSil%26aufirst%3DD.%26aulast%3DWeerasinghe%26aufirst%3DM.%26aulast%3DTanji%26aufirst%3DH.%26aulast%3DOhto%26aufirst%3DU.%26aulast%3DShimizu%26aufirst%3DT.%26aulast%3DDavid%26aufirst%3DS.%2BA.%26atitle%3DStructure-Based%2520Design%2520of%2520Human%2520TLR8-Specific%2520Agonists%2520with%2520Augmented%2520Potency%2520and%2520Adjuvanticity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D7833%26epage%3D7849%26doi%3D10.1021%2Facs.jmedchem.5b01087" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beesu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salyer, A. C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trautman, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">David, S. A.</span></span> <span> </span><span class="NLM_article-title">Human Toll-like Receptor (TLR) 8-Specific Agonistic Activity in Substituted Pyrimidine-2,4-diamines</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">8082</span>– <span class="NLM_lpage">8093</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00872</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00872" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhtlamt7vI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=8082-8093&author=M.+Beesuauthor=A.+C.+D.+Salyerauthor=K.+L.+Trautmanauthor=J.+K.+Hillauthor=S.+A.+David&title=Human+Toll-like+Receptor+%28TLR%29+8-Specific+Agonistic+Activity+in+Substituted+Pyrimidine-2%2C4-diamines&doi=10.1021%2Facs.jmedchem.6b00872"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Human Toll-like Receptor (TLR) 8-Specific Agonistic Activity in Substituted Pyrimidine-2,4-diamines</span></div><div class="casAuthors">Beesu, Mallesh; Salyer, Alex C. D.; Trautman, Kathryn L.; Hill, Justin K.; David, Sunil A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">8082-8093</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Activation of human toll-like receptor-8 (TLR8) evokes a distinct cytokine profile favoring the generation of Type 1 helper T cells.  A multiplexed high-throughput screen had led to the identification of N4-butyl-5-iodo-6-methylpyrimidine-2,4-diamine as a pure TLR8 agonist, and a detailed SAR study of this chemotype was undertaken.  A Bu substituent at N4 was optimal, and replacement of the 5-iodo group with chloro, bromo, or fluoro groups led to losses in potency, as did the introduction of arom. bulk.  Drawing from the previous structure-based design, several 5-alkylamino derivs. were evaluated.  Significant enhancement of potency was achieved in 5-(4-aminobutyl)-N4-butyl-6-methylpyrimidine-2,4-diamine.  This compd. potently induced Th1-biasing IFN-γ and IL-12 in human blood, but lower levels of the proinflammatory cytokines IL-1β, IL-6 and IL-8.  These results suggest that the inflammatory and reactogenic propensities of this compd. could be considerably more favorable than other TLR8 agonists under evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDCMECaTCj-bVg90H21EOLACvtfcHk0ljPLaMXVK9mUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhtlamt7vI&md5=3632c71b22857ff6f3561dc372b5e52f</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00872&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00872%26sid%3Dliteratum%253Aachs%26aulast%3DBeesu%26aufirst%3DM.%26aulast%3DSalyer%26aufirst%3DA.%2BC.%2BD.%26aulast%3DTrautman%26aufirst%3DK.%2BL.%26aulast%3DHill%26aufirst%3DJ.%2BK.%26aulast%3DDavid%26aufirst%3DS.%2BA.%26atitle%3DHuman%2520Toll-like%2520Receptor%2520%2528TLR%2529%25208-Specific%2520Agonistic%2520Activity%2520in%2520Substituted%2520Pyrimidine-2%252C4-diamines%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D8082%26epage%3D8093%26doi%3D10.1021%2Facs.jmedchem.6b00872" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McGowan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herschke, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pauwels, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoops, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Last, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pieters, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scholliers, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thoné, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Schoubroeck, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Pooter, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mostmans, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khamlichi, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Embrechts, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhuyvetter, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smyej, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnoult, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borghys, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fanning, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vlach, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raboisson, P.</span></span> <span> </span><span class="NLM_article-title">Novel Pyrimidine Toll-Like Receptor 7 and 8 Dual Agonists to Treat Hepatitis B Virus</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">7936</span>– <span class="NLM_lpage">7949</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00747</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00747" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhtlamt7vF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=7936-7949&author=D.+McGowanauthor=F.+Herschkeauthor=F.+Pauwelsauthor=B.+Stoopsauthor=S.+Lastauthor=S.+Pietersauthor=A.+Scholliersauthor=T.+Thon%C3%A9author=B.+Van+Schoubroeckauthor=D.+D.+De+Pooterauthor=W.+Mostmansauthor=M.+D.+Khamlichiauthor=W.+Embrechtsauthor=D.+Dhuyvetterauthor=I.+Smyejauthor=E.+Arnoultauthor=S.+Deminauthor=H.+Borghysauthor=G.+Fanningauthor=J.+Vlachauthor=P.+Raboisson&title=Novel+Pyrimidine+Toll-Like+Receptor+7+and+8+Dual+Agonists+to+Treat+Hepatitis+B+Virus&doi=10.1021%2Facs.jmedchem.6b00747"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Pyrimidine Toll-like Receptor 7 and 8 Dual Agonists to Treat Hepatitis B Virus</span></div><div class="casAuthors">McGowan, David; Herschke, Florence; Pauwels, Frederik; Stoops, Bart; Last, Stefaan; Pieters, Serge; Scholliers, Annick; Thone, Tine; Van Schoubroeck, Bertrand; De Pooter, Dorien; Mostmans, Wendy; Khamlichi, Mourad Daoubi; Embrechts, Werner; Dhuyvetter, Deborah; Smyej, Ilham; Arnoult, Eric; Demin, Samuel; Borghys, Herman; Fanning, Gregory; Vlach, Jaromir; Raboisson, Pierre</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7936-7949</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Toll-like receptor (TLR) 7 and 8 agonists can potentially be used in the treatment of viral infections and are particularly promising for chronic hepatitis B virus (HBV) infection.  An internal screening effort identified a pyrimidine Toll-like receptor 7 and 8 dual agonist.  This provided a novel alternative over the previously reported adenine and pteridone type of agonists.  Structure-activity relationship, lead optimization, in silico docking, pharmacokinetics, and demonstration of ex vivo and in vivo cytokine prodn. of the lead compd. are presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-fRW7IJ3nZ7Vg90H21EOLACvtfcHk0liqZcroXHt3cw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhtlamt7vF&md5=f98f5bf04418de548b34463b3ebf2c2e</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00747&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00747%26sid%3Dliteratum%253Aachs%26aulast%3DMcGowan%26aufirst%3DD.%26aulast%3DHerschke%26aufirst%3DF.%26aulast%3DPauwels%26aufirst%3DF.%26aulast%3DStoops%26aufirst%3DB.%26aulast%3DLast%26aufirst%3DS.%26aulast%3DPieters%26aufirst%3DS.%26aulast%3DScholliers%26aufirst%3DA.%26aulast%3DThon%25C3%25A9%26aufirst%3DT.%26aulast%3DVan%2BSchoubroeck%26aufirst%3DB.%26aulast%3DDe%2BPooter%26aufirst%3DD.%2BD.%26aulast%3DMostmans%26aufirst%3DW.%26aulast%3DKhamlichi%26aufirst%3DM.%2BD.%26aulast%3DEmbrechts%26aufirst%3DW.%26aulast%3DDhuyvetter%26aufirst%3DD.%26aulast%3DSmyej%26aufirst%3DI.%26aulast%3DArnoult%26aufirst%3DE.%26aulast%3DDemin%26aufirst%3DS.%26aulast%3DBorghys%26aufirst%3DH.%26aulast%3DFanning%26aufirst%3DG.%26aulast%3DVlach%26aufirst%3DJ.%26aulast%3DRaboisson%26aufirst%3DP.%26atitle%3DNovel%2520Pyrimidine%2520Toll-Like%2520Receptor%25207%2520and%25208%2520Dual%2520Agonists%2520to%2520Treat%2520Hepatitis%2520B%2520Virus%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D7936%26epage%3D7949%26doi%3D10.1021%2Facs.jmedchem.6b00747" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bondy, S.</span>; <span class="NLM_string-name">Chou, C.-H.</span>; <span class="NLM_string-name">Watkins, W. J.</span>; <span class="NLM_string-name">Chong, L. S.</span>; <span class="NLM_string-name">Zhang, J. R.</span>; <span class="NLM_string-name">Mishra, R.</span></span> <span> </span><span class="NLM_article-title">Pyrido(3,2-<i>d</i>)pyrimidines Useful For Treating Viral Infections</span>. WO <span class="NLM_patent">WO2008/077651 A1</span>, <span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=S.+Bondy&author=C.-H.+Chou&author=W.+J.+Watkins&author=L.+S.+Chong&author=J.+R.+Zhang&author=R.+Mishra&title=Pyrido%283%2C2-d%29pyrimidines+Useful+For+Treating+Viral+Infections"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBondy%26aufirst%3DS.%26atitle%3DPyrido%25283%252C2-d%2529pyrimidines%2520Useful%2520For%2520Treating%2520Viral%2520Infections%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Daffis, S.</span>; <span class="NLM_string-name">Balsitis, S.</span>; <span class="NLM_string-name">Chamberlain, J.</span>; <span class="NLM_string-name">Zheng, J.</span>; <span class="NLM_string-name">Santos, R.</span>; <span class="NLM_string-name">Rowe, W.</span>; <span class="NLM_string-name">Ramakrishnan, D.</span>; <span class="NLM_string-name">Pattabiraman, D.</span>; <span class="NLM_string-name">Spurlock, S.</span>; <span class="NLM_string-name">Chu, R.</span>; <span class="NLM_string-name">Kang, D.</span>; <span class="NLM_string-name">Mish, M.</span>; <span class="NLM_string-name">Ramirez, R.</span>; <span class="NLM_string-name">Li, L.</span>; <span class="NLM_string-name">Li, B.</span>; <span class="NLM_string-name">Ma, S.</span>; <span class="NLM_string-name">Hung, M.</span>; <span class="NLM_string-name">Voitenleitner, C.</span>; <span class="NLM_string-name">Yon, C.</span>; <span class="NLM_string-name">Suresh, M.</span>; <span class="NLM_string-name">Menne, S.</span>; <span class="NLM_string-name">Cote, P.</span>; <span class="NLM_string-name">Delaney, W. E.,  IV</span>; <span class="NLM_string-name">Mackman, R.</span>; <span class="NLM_string-name">Fletcher, S. P.</span></span> <span> </span><span class="NLM_article-title">Toll-Like Receptor 8 Agonist GS-9688 Induces Sustained Efficacy in the Woodchuck Model of Chronic Hepatitis B</span>.  <i>Hepatology</i> <span class="NLM_year" style="font-weight: bold;">2020</span> <span class="refDoi"> DOI: 10.1002/hep.31255</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=10.1002%2Fhep.31255" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=32246499" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=S.+Daffis&author=S.+Balsitis&author=J.+Chamberlain&author=J.+Zheng&author=R.+Santos&author=W.+Rowe&author=D.+Ramakrishnan&author=D.+Pattabiraman&author=S.+Spurlock&author=R.+Chu&author=D.+Kang&author=M.+Mish&author=R.+Ramirez&author=L.+Li&author=B.+Li&author=S.+Ma&author=M.+Hung&author=C.+Voitenleitner&author=C.+Yon&author=M.+Suresh&author=S.+Menne&author=P.+Cote&author=W.+E.+Delaney&author=R.+Mackman&author=S.+P.+Fletcher&title=Toll-Like+Receptor+8+Agonist+GS-9688+Induces+Sustained+Efficacy+in+the+Woodchuck+Model+of+Chronic+Hepatitis+B&doi=10.1002%2Fhep.31255"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1002%2Fhep.31255&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.31255%26sid%3Dliteratum%253Aachs%26aulast%3DDaffis%26aufirst%3DS.%26atitle%3DToll-Like%2520Receptor%25208%2520Agonist%2520GS-9688%2520Induces%2520Sustained%2520Efficacy%2520in%2520the%2520Woodchuck%2520Model%2520of%2520Chronic%2520Hepatitis%2520B%26jtitle%3DHepatology%26date%3D2020%26doi%3D10.1002%2Fhep.31255" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohto, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shibata, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taoka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamauchi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shukla, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">David, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isobe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyake, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimizu, T.</span></span> <span> </span><span class="NLM_article-title">Structural Analyses of Toll-like Receptor 7 Reveal Detailed RNA Sequence Specificity and Recognition Mechanism of Agonistic Ligands</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">3371</span>– <span class="NLM_lpage">3381</span>, <span class="refDoi"> DOI: 10.1016/j.celrep.2018.11.081</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=10.1016%2Fj.celrep.2018.11.081" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=30566863" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFKhsbvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2018&pages=3371-3381&author=Z.+Zhangauthor=U.+Ohtoauthor=T.+Shibataauthor=M.+Taokaauthor=Y.+Yamauchiauthor=R.+Satoauthor=N.+M.+Shuklaauthor=S.+A.+Davidauthor=T.+Isobeauthor=K.+Miyakeauthor=T.+Shimizu&title=Structural+Analyses+of+Toll-like+Receptor+7+Reveal+Detailed+RNA+Sequence+Specificity+and+Recognition+Mechanism+of+Agonistic+Ligands&doi=10.1016%2Fj.celrep.2018.11.081"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Analyses of Toll-like Receptor 7 Reveal Detailed RNA Sequence Specificity and Recognition Mechanism of Agonistic Ligands</span></div><div class="casAuthors">Zhang, Zhikuan; Ohto, Umeharu; Shibata, Takuma; Taoka, Masato; Yamauchi, Yoshio; Sato, Ryota; Shukla, Nikunj M.; David, Sunil A.; Isobe, Toshiaki; Miyake, Kensuke; Shimizu, Toshiyuki</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3371-3381.e5</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Toll-like receptor 7 (TLR7) is an innate immune receptor for single-stranded RNA (ssRNA) and has important roles in infectious diseases.  We previously reported that TLR7 shows synergistic activation in response to two ligands, guanosine and ssRNA.  However, the specific ssRNA sequence preference, detailed recognition mode of TLR7 and its ligand, and mol. determinants of TLR7 and TLR8 selectivity remain unknown.  Here, we report on TLR7 from a large-scale crystallog. study combined with a multifaceted approach.  We reveal that successive uridine-contg. ssRNAs fully or moderately bind TLR7, whereas single uridine-contg. ssRNAs have reduced affinities.  We also reveal the detailed relationships between the chem. structures of ligands and their binding to TLR7.  We demonstrate that an engineered TLR8 mutant alters its responsiveness to TLR7-specific ligands.  Finally, we identify guanosine 2',3'-cyclic phosphate (2',3'-cGMP) as a possible endogenous ligand for TLR7 with greater affinity than guanosine.  The abundant structural information will facilitate future development of treatments targeting TLR7.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSfIvVPXG7NbVg90H21EOLACvtfcHk0liqZcroXHt3cw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFKhsbvK&md5=2b8c37cd45a96e9298540bd87fb77faa</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2018.11.081&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2018.11.081%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DOhto%26aufirst%3DU.%26aulast%3DShibata%26aufirst%3DT.%26aulast%3DTaoka%26aufirst%3DM.%26aulast%3DYamauchi%26aufirst%3DY.%26aulast%3DSato%26aufirst%3DR.%26aulast%3DShukla%26aufirst%3DN.%2BM.%26aulast%3DDavid%26aufirst%3DS.%2BA.%26aulast%3DIsobe%26aufirst%3DT.%26aulast%3DMiyake%26aufirst%3DK.%26aulast%3DShimizu%26aufirst%3DT.%26atitle%3DStructural%2520Analyses%2520of%2520Toll-like%2520Receptor%25207%2520Reveal%2520Detailed%2520RNA%2520Sequence%2520Specificity%2520and%2520Recognition%2520Mechanism%2520of%2520Agonistic%2520Ligands%26jtitle%3DCell%2520Rep.%26date%3D2018%26volume%3D25%26spage%3D3371%26epage%3D3381%26doi%3D10.1016%2Fj.celrep.2018.11.081" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Embrechts, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herschke, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pauwels, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoops, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Last, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pieters, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pande, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pille, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amssoms, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smyej, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhuyvetter, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scholliers, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mostmans, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Dijck, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Schoubroeck, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thone, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Pooter, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fanning, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jonckers, T. H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horton, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raboisson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGowan, D.</span></span> <span> </span><span class="NLM_article-title">2,4-Diaminoquinazolines as Dual Toll-like Receptor (TLR) 7/8 Modulators for the Treatment of Hepatitis B Virus</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">6236</span>– <span class="NLM_lpage">6246</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00643</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00643" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1CqurvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=6236-6246&author=W.+Embrechtsauthor=F.+Herschkeauthor=F.+Pauwelsauthor=B.+Stoopsauthor=S.+Lastauthor=S.+Pietersauthor=V.+Pandeauthor=G.+Pilleauthor=K.+Amssomsauthor=I.+Smyejauthor=D.+Dhuyvetterauthor=A.+Scholliersauthor=W.+Mostmansauthor=K.+Van+Dijckauthor=B.+Van+Schoubroeckauthor=T.+Thoneauthor=D.+De+Pooterauthor=G.+Fanningauthor=T.+H.+M.+Jonckersauthor=H.+Hortonauthor=P.+Raboissonauthor=D.+McGowan&title=2%2C4-Diaminoquinazolines+as+Dual+Toll-like+Receptor+%28TLR%29+7%2F8+Modulators+for+the+Treatment+of+Hepatitis+B+Virus&doi=10.1021%2Facs.jmedchem.8b00643"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">2,4-Diaminoquinazolines as Dual Toll-like Receptor (TLR) 7/8 Modulators for the Treatment of Hepatitis B Virus</span></div><div class="casAuthors">Embrechts, Werner; Herschke, Florence; Pauwels, Frederik; Stoops, Bart; Last, Stefaan; Pieters, Serge; Pande, Vineet; Pille, Geert; Amssoms, Katie; Smyej, Ilham; Dhuyvetter, Deborah; Scholliers, Annick; Mostmans, Wendy; Van Dijck, Kris; Van Schoubroeck, Bertrand; Thone, Tine; De Pooter, Dorien; Fanning, Gregory; Jonckers, Tim H. M.; Horton, Helen; Raboisson, Pierre; McGowan, David</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6236-6246</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel series of 2,4-diaminoquinazolines was identified as potent dual Toll-like receptor (TLR) 7 and 8 agonists with reduced off-target activity.  The stereochem. of the amino alc. was found to influence the TLR7/8 selectivity with the (R) isomer resulting in selective TLR8 agonism.  Lead optimization toward a dual agonist afforded (S)-3-((2-amino-8-fluoroquinazolin-4-yl)amino)hexanol 31 as a potent analog, being structurally different from previously described dual agonists (McGowan J. Med. Chem. 2016, 59, 7936).  Pharmacokinetic and pharmacodynamic (PK/PD) studies revealed the desired high first pass profile aimed at limiting systemic cytokine activation.  In vivo pharmacodynamic studies with lead compd. 31 demonstrated prodn. of cytokines consistent with TLR7/8 activation in mice and cynomolgus monkeys and ex vivo inhibition of hepatitis B virus (HBV).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIZ2UOyVhderVg90H21EOLACvtfcHk0ljpYkAb1FZCLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1CqurvM&md5=7cc741c6b341d318798e26150ce7856c</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00643&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00643%26sid%3Dliteratum%253Aachs%26aulast%3DEmbrechts%26aufirst%3DW.%26aulast%3DHerschke%26aufirst%3DF.%26aulast%3DPauwels%26aufirst%3DF.%26aulast%3DStoops%26aufirst%3DB.%26aulast%3DLast%26aufirst%3DS.%26aulast%3DPieters%26aufirst%3DS.%26aulast%3DPande%26aufirst%3DV.%26aulast%3DPille%26aufirst%3DG.%26aulast%3DAmssoms%26aufirst%3DK.%26aulast%3DSmyej%26aufirst%3DI.%26aulast%3DDhuyvetter%26aufirst%3DD.%26aulast%3DScholliers%26aufirst%3DA.%26aulast%3DMostmans%26aufirst%3DW.%26aulast%3DVan%2BDijck%26aufirst%3DK.%26aulast%3DVan%2BSchoubroeck%26aufirst%3DB.%26aulast%3DThone%26aufirst%3DT.%26aulast%3DDe%2BPooter%26aufirst%3DD.%26aulast%3DFanning%26aufirst%3DG.%26aulast%3DJonckers%26aufirst%3DT.%2BH.%2BM.%26aulast%3DHorton%26aufirst%3DH.%26aulast%3DRaboisson%26aufirst%3DP.%26aulast%3DMcGowan%26aufirst%3DD.%26atitle%3D2%252C4-Diaminoquinazolines%2520as%2520Dual%2520Toll-like%2520Receptor%2520%2528TLR%2529%25207%252F8%2520Modulators%2520for%2520the%2520Treatment%2520of%2520Hepatitis%2520B%2520Virus%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D6236%26epage%3D6246%26doi%3D10.1021%2Facs.jmedchem.8b00643" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span> <i>pKa Calculator</i>; <span class="NLM_publisher-name">ACD Labs</span>, <span class="NLM_year">2020</span>; <a href="https://www.acdlabs.com/products/percepta/predictors/pka/index.php" class="extLink">https://www.acdlabs.com/products/percepta/predictors/pka/index.php</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+pKa+Calculator%3B+ACD+Labs%2C+2020%3B+https%3A%2F%2Fwww.acdlabs.com%2Fproducts%2Fpercepta%2Fpredictors%2Fpka%2Findex.php."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DpKa%2520Calculator%26pub%3DACD%2520Labs%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harwood, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vines, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drew, M. G. B.</span></span> <span> </span><span class="NLM_article-title">Synthesis of Homochiral α-Substituted Alanine Derivatives by Daistereocontrolled Alkylation of (5R)-5-Phenyl-3-methyl-3,4-dehydromorpholinones</span>. <i>Synlett</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>1996</i></span>,  <span class="NLM_fpage">1051</span>– <span class="NLM_lpage">1053</span>, <span class="refDoi"> DOI: 10.1055/s-1996-5682</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=10.1055%2Fs-1996-5682" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1996&publication_year=1996&pages=1051-1053&author=L.+M.+Harwoodauthor=K.+J.+Vinesauthor=M.+G.+B.+Drew&title=Synthesis+of+Homochiral+%CE%B1-Substituted+Alanine+Derivatives+by+Daistereocontrolled+Alkylation+of+%285R%29-5-Phenyl-3-methyl-3%2C4-dehydromorpholinones&doi=10.1055%2Fs-1996-5682"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1055%2Fs-1996-5682&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-1996-5682%26sid%3Dliteratum%253Aachs%26aulast%3DHarwood%26aufirst%3DL.%2BM.%26aulast%3DVines%26aufirst%3DK.%2BJ.%26aulast%3DDrew%26aufirst%3DM.%2BG.%2BB.%26atitle%3DSynthesis%2520of%2520Homochiral%2520%25CE%25B1-Substituted%2520Alanine%2520Derivatives%2520by%2520Daistereocontrolled%2520Alkylation%2520of%2520%25285R%2529-5-Phenyl-3-methyl-3%252C4-dehydromorpholinones%26jtitle%3DSynlett%26date%3D1996%26volume%3D1996%26spage%3D1051%26epage%3D1053%26doi%3D10.1055%2Fs-1996-5682" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Menne, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tumas, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thampi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">AlDeghaither, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baldwin, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellezza, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cote, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halcomb, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fosdick, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daffis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yue, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolfgang, G. H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tennant, B. C.</span></span> <span> </span><span class="NLM_article-title">Sustained Efficacy and Serconversion with the Toll-like Receptor 7 Agonist GS-9620 in the Woodchuck Model of Chronic Hepatitis B</span>. <i>J. Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1237</span>– <span class="NLM_lpage">1245</span>, <span class="refDoi"> DOI: 10.1016/j.jhep.2014.12.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=10.1016%2Fj.jhep.2014.12.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=25559326" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmtFSju74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2015&pages=1237-1245&issue=6&author=S.+Menneauthor=D.+B.+Tumasauthor=K.+H.+Liuauthor=L.+Thampiauthor=D.+AlDeghaitherauthor=B.+H.+Baldwinauthor=C.+A.+Bellezzaauthor=P.+J.+Coteauthor=J.+Zhengauthor=R.+Halcombauthor=A.+Fosdickauthor=S.+P.+Fletcherauthor=S.+Daffisauthor=L.+Liauthor=P.+Yueauthor=G.+H.+I.+Wolfgangauthor=B.+C.+Tennant&title=Sustained+Efficacy+and+Serconversion+with+the+Toll-like+Receptor+7+Agonist+GS-9620+in+the+Woodchuck+Model+of+Chronic+Hepatitis+B&doi=10.1016%2Fj.jhep.2014.12.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Sustained efficacy and seroconversion with the Toll-like receptor 7 agonist GS-9620 in the Woodchuck model of chronic hepatitis B</span></div><div class="casAuthors">Menne, Stephan; Tumas, Daniel B.; Liu, Katherine H.; Thampi, Linta; AlDeghaither, Dalal; Baldwin, Betty H.; Bellezza, Christine A.; Cote, Paul J.; Zheng, Jim; Halcomb, Randall; Fosdick, Abigail; Fletcher, Simon P.; Daffis, Stephane; Li, Li; Yue, Peng; Wolfgang, Grushenka H. I.; Tennant, Bud C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hepatology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1237-1245</span>CODEN:
                <span class="NLM_cas:coden">JOHEEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-8278</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">New therapies for chronic hepatitis B (CHB) are urgently needed since current treatments rarely lead to cure.  We evaluated whether the oral small mol. toll-like receptor (TLR7) agonist GS-9620 could induce durable antiviral efficacy in woodchucks chronically infected with woodchuck hepatitis virus (WHV), a hepadnavirus closely related to human hepatitis B virus (HBV).  After evaluating the pharmacokinetics, pharmacodynamics and tolerability of oral GS-9620 in uninfected woodchucks, adult woodchucks chronically infected with WHV (n = 7 per group) were dosed with GS-9620 or placebo for 4 or 8 wk with different treatment schedules.  GS-9620 treatment induced rapid, marked and sustained redn. in serum viral DNA (mean maximal 6.2 log10 redn.), and hepatic WHV DNA replicative intermediates, WHV cccDNA and WHV RNA, as well as loss of detectable serum WHV surface antigen (WHsAg).  GS-9620 treatment also induced a sustained antibody response against WHsAg in a subset of animals.  Strikingly, treatment reduced the incidence of hepatocellular carcinoma (HCC) from 71% in the placebo group to 8% in GS-9620-treated woodchucks with sustained viral load redn.  GS-9620 treatment was assocd. with reversible increases in serum liver enzymes and thrombocytopenia, and induced intrahepatic CD8+ T cell, NK cell, B cell and interferon response transcriptional signatures.  The data demonstrate that short duration, finite treatment with the oral TLR7 agonist GS-9620 can induce a sustained antiviral response in the woodchuck model of CHB, and support investigation of this compd. as a therapeutic approach to attain a functional cure in CHB patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpH0B6F10zhw7Vg90H21EOLACvtfcHk0lgHp_4KGNn48w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmtFSju74%253D&md5=65d5f40b523dfedca5146e0bfbc54baf</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2014.12.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2014.12.026%26sid%3Dliteratum%253Aachs%26aulast%3DMenne%26aufirst%3DS.%26aulast%3DTumas%26aufirst%3DD.%2BB.%26aulast%3DLiu%26aufirst%3DK.%2BH.%26aulast%3DThampi%26aufirst%3DL.%26aulast%3DAlDeghaither%26aufirst%3DD.%26aulast%3DBaldwin%26aufirst%3DB.%2BH.%26aulast%3DBellezza%26aufirst%3DC.%2BA.%26aulast%3DCote%26aufirst%3DP.%2BJ.%26aulast%3DZheng%26aufirst%3DJ.%26aulast%3DHalcomb%26aufirst%3DR.%26aulast%3DFosdick%26aufirst%3DA.%26aulast%3DFletcher%26aufirst%3DS.%2BP.%26aulast%3DDaffis%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DYue%26aufirst%3DP.%26aulast%3DWolfgang%26aufirst%3DG.%2BH.%2BI.%26aulast%3DTennant%26aufirst%3DB.%2BC.%26atitle%3DSustained%2520Efficacy%2520and%2520Serconversion%2520with%2520the%2520Toll-like%2520Receptor%25207%2520Agonist%2520GS-9620%2520in%2520the%2520Woodchuck%2520Model%2520of%2520Chronic%2520Hepatitis%2520B%26jtitle%3DJ.%2520Hepatol.%26date%3D2015%26volume%3D62%26issue%3D6%26spage%3D1237%26epage%3D1245%26doi%3D10.1016%2Fj.jhep.2014.12.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tikad, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akssira, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massip, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Léger, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarry, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guillaumet, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Routier, S.</span></span> <span> </span><span class="NLM_article-title">Regiocontroled S<sub>N</sub>Ar and Palladium Cross-Coupling Reactions of 2,4,7-Trichloropyrido[3,2-<i>d</i>]pyrimidine</span>. <i>Eur. J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>2012</i></span>,  <span class="NLM_fpage">4523</span>– <span class="NLM_lpage">4532</span>, <span class="refDoi"> DOI: 10.1002/ejoc.201200521</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=10.1002%2Fejoc.201200521" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=1%3ACAS%3A528%3ADC%252BC38Xps1Ors70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2012&publication_year=2012&pages=4523-4532&author=A.+Tikadauthor=M.+Akssiraauthor=S.+Massipauthor=J.-M.+L%C3%A9gerauthor=C.+Jarryauthor=G.+Guillaumetauthor=S.+Routier&title=Regiocontroled+SNAr+and+Palladium+Cross-Coupling+Reactions+of+2%2C4%2C7-Trichloropyrido%5B3%2C2-d%5Dpyrimidine&doi=10.1002%2Fejoc.201200521"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Regiocontroled SNAr and Palladium Cross-Coupling Reactions of 2,4,7-Trichloropyrido[3,2-d]pyrimidine</span></div><div class="casAuthors">Tikad, Abdellatif; Akssira, Mohamed; Massip, Stephane; Leger, Jean-Michel; Jarry, Christian; Guillaumet, Gerald; Routier, Sylvain</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">2012</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">4523-4532, S4523/1-S4523/53</span>CODEN:
                <span class="NLM_cas:coden">EJOCFK</span>;
        ISSN:<span class="NLM_cas:issn">1099-0690</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">An efficient and original synthesis of various 2,4,7-trisubstituted pyrido[3,2-d]pyrimidines is reported.  The first access to and the chem. interest of 2,4,7-trichloropyrido[3,2-d]pyrimidine is described.  Double arylations and SNAr reactions occurred selectively at the C4 and C2 positions of 2,4,7-trichloropyrido[3,2-d]pyrimidine.  The reactions at the C7 position were achieved under microwave irradn. in a few minutes.  A one-step synthesis of a 2,4,7-tris(aminated) deriv. was achieved as a highly efficient alternative.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIDfMAffPqqbVg90H21EOLACvtfcHk0lgHp_4KGNn48w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xps1Ors70%253D&md5=1fb02978d762657dc5284d74a8483bd9</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1002%2Fejoc.201200521&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fejoc.201200521%26sid%3Dliteratum%253Aachs%26aulast%3DTikad%26aufirst%3DA.%26aulast%3DAkssira%26aufirst%3DM.%26aulast%3DMassip%26aufirst%3DS.%26aulast%3DL%25C3%25A9ger%26aufirst%3DJ.-M.%26aulast%3DJarry%26aufirst%3DC.%26aulast%3DGuillaumet%26aufirst%3DG.%26aulast%3DRoutier%26aufirst%3DS.%26atitle%3DRegiocontroled%2520SNAr%2520and%2520Palladium%2520Cross-Coupling%2520Reactions%2520of%25202%252C4%252C7-Trichloropyrido%255B3%252C2-d%255Dpyrimidine%26jtitle%3DEur.%2520J.%2520Org.%2520Chem.%26date%3D2012%26volume%3D2012%26spage%3D4523%26epage%3D4532%26doi%3D10.1002%2Fejoc.201200521" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Niu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daffis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucifora, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maadadi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salas, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramos, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Livingston, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beran, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garg, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balsitis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durantel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoulim, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delaney, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, S. P.</span></span> <span> </span><span class="NLM_article-title">Toll-like Receptor 7 Agonist GS-9620 Induces Prolonged Inhibition of HBV Via a Type I Interferon-Dependent Mechanism</span>. <i>J. Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">922</span>– <span class="NLM_lpage">931</span>, <span class="refDoi"> DOI: 10.1016/j.jhep.2017.12.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=10.1016%2Fj.jhep.2017.12.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=29247725" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVent7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2018&pages=922-931&author=C.+Niuauthor=L.+Liauthor=S.+Daffisauthor=J.+Luciforaauthor=M.+Bonninauthor=S.+Maadadiauthor=E.+Salasauthor=R.+Chuauthor=H.+Ramosauthor=C.+M.+Livingstonauthor=R.+K.+Beranauthor=A.+V.+Gargauthor=S.+Balsitisauthor=D.+Durantelauthor=F.+Zoulimauthor=W.+E.+Delaneyauthor=S.+P.+Fletcher&title=Toll-like+Receptor+7+Agonist+GS-9620+Induces+Prolonged+Inhibition+of+HBV+Via+a+Type+I+Interferon-Dependent+Mechanism&doi=10.1016%2Fj.jhep.2017.12.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Toll-like receptor 7 agonist GS-9620 induces prolonged inhibition of HBV via a type I interferon-dependent mechanism</span></div><div class="casAuthors">Niu, Congrong; Li, Li; Daffis, Stephane; Lucifora, Julie; Bonnin, Marc; Maadadi, Sarah; Salas, Eduardo; Chu, Ruth; Ramos, Hilario; Livingston, Christine M.; Beran, Rudolf K.; Garg, Abhishek V.; Balsitis, Scott; Durantel, David; Zoulim, Fabien; Delaney, William E., IV; Fletcher, Simon P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hepatology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">922-931</span>CODEN:
                <span class="NLM_cas:coden">JOHEEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-8278</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">GS-9620, an oral agonist of toll-like receptor 7 (TLR7), is in clin. development for the treatment of chronic hepatitis B (CHB).  GS-9620 was previously shown to induce prolonged suppression of serum viral DNA and antigens in the woodchuck and chimpanzee models of CHB.  Herein, we investigated the mol. mechanisms that contribute to the antiviral response to GS-9620 using in vitro models of hepatitis B virus (HBV) infection.  Cryopreserved primary human hepatocytes (PHH) and differentiated HepaRG (dHepaRG) cells were infected with HBV and treated with GS-9620, conditioned media from human peripheral blood mononuclear cells treated with GS-9620 (GS-9620 conditioned media [GS-9620-CM]), or other innate immune stimuli.  The antiviral and transcriptional response to these agents was detd.  GS-9620 had no antiviral activity in HBV-infected PHH, consistent with low level TLR7 mRNA expression in human hepatocytes.  In contrast, GS-9620-CM induced prolonged redn. of HBV DNA, RNA, and antigen levels in PHH and dHepaRG cells via a type I interferon (IFN)-dependent mechanism.  GS-9620-CM did not reduce covalently closed circular DNA (cccDNA) levels in either cell type.  Transcriptional profiling demonstrated that GS-9620-CM strongly induced various HBV restriction factors - although not APOBEC3A or the Smc5/6 complex - and indicated that established HBV infection does not modulate innate immune sensing or signaling in cryopreserved PHH.  GS-9620-CM also induced expression of immunoproteasome subunits and enhanced presentation of an immunodominant viral peptide in HBV-infected PHH.  Type I IFN induced by GS-9620 durably suppressed HBV in human hepatocytes without reducing cccDNA levels.  Moreover, HBV antigen presentation was enhanced, suggesting addnl. components of the TLR7-induced immune response played a role in the antiviral response to GS-9620 in animal models of CHB.GS-9620 is a drug currently being tested in clin. trials for the treatment of chronic hepatitis B virus (HBV) infection.  GS-9620 has previously been shown to suppress HBV in various animal models, but the underlying antiviral mechanisms were not completely understood.  In this study, we detd. that GS-9620 does not directly activate antiviral pathways in human liver cells, but can induce prolonged suppression of HBV via induction of an antiviral cytokine called interferon.  However, interferon did not destroy the HBV genome, suggesting that other parts of the immune response (e.g. activation of immune cells that kill infected cells) also play an important role in the antiviral response to GS-9620.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVwmNAOC2M67Vg90H21EOLACvtfcHk0lgHp_4KGNn48w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVent7g%253D&md5=e1a6a4ca710eb312e36f9d84e7f0f29d</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2017.12.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2017.12.007%26sid%3Dliteratum%253Aachs%26aulast%3DNiu%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DDaffis%26aufirst%3DS.%26aulast%3DLucifora%26aufirst%3DJ.%26aulast%3DBonnin%26aufirst%3DM.%26aulast%3DMaadadi%26aufirst%3DS.%26aulast%3DSalas%26aufirst%3DE.%26aulast%3DChu%26aufirst%3DR.%26aulast%3DRamos%26aufirst%3DH.%26aulast%3DLivingston%26aufirst%3DC.%2BM.%26aulast%3DBeran%26aufirst%3DR.%2BK.%26aulast%3DGarg%26aufirst%3DA.%2BV.%26aulast%3DBalsitis%26aufirst%3DS.%26aulast%3DDurantel%26aufirst%3DD.%26aulast%3DZoulim%26aufirst%3DF.%26aulast%3DDelaney%26aufirst%3DW.%2BE.%26aulast%3DFletcher%26aufirst%3DS.%2BP.%26atitle%3DToll-like%2520Receptor%25207%2520Agonist%2520GS-9620%2520Induces%2520Prolonged%2520Inhibition%2520of%2520HBV%2520Via%2520a%2520Type%2520I%2520Interferon-Dependent%2520Mechanism%26jtitle%3DJ.%2520Hepatol.%26date%3D2018%26volume%3D68%26spage%3D922%26epage%3D931%26doi%3D10.1016%2Fj.jhep.2017.12.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref28':['cit28'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref29':['cit29'],'ref30':['cit30']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 16 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Arindam Talukdar, Dipyaman Ganguly, Swarnali Roy, Nirmal Das, <span class="NLM_string-name hlFld-ContribAuthor">Dipika Sarkar</span>. </span><span class="cited-content_cbyCitation_article-title">Structural Evolution and Translational Potential for Agonists and Antagonists of Endosomal Toll-like Receptors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (12)
                                     , 8010-8041. <a href="https://doi.org/10.1021/acs.jmedchem.1c00300" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00300</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00300&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00300%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructural%252BEvolution%252Band%252BTranslational%252BPotential%252Bfor%252BAgonists%252Band%252BAntagonists%252Bof%252BEndosomal%252BToll-like%252BReceptors%26aulast%3DTalukdar%26aufirst%3DArindam%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D16022021%26date%3D10062021%26volume%3D64%26issue%3D12%26spage%3D8010%26epage%3D8041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="NLM_string-name hlFld-ContribAuthor">Tanaji T. Talele</span>. </span><span class="cited-content_cbyCitation_article-title">Opportunities for Tapping into Three-Dimensional Chemical Space through a Quaternary Carbon. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (22)
                                     , 13291-13315. <a href="https://doi.org/10.1021/acs.jmedchem.0c00829" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00829</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00829&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00829%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DOpportunities%252Bfor%252BTapping%252Binto%252BThree-Dimensional%252BChemical%252BSpace%252Bthrough%252Ba%252BQuaternary%252BCarbon%26aulast%3DTalele%26aufirst%3DTanaji%2BT.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D15052020%26date%3D31082020%26date%3D17082020%26volume%3D63%26issue%3D22%26spage%3D13291%26epage%3D13315" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xuan  Huang</span>, <span class="hlFld-ContribAuthor ">Xiaoyong  Zhang</span>, <span class="hlFld-ContribAuthor ">Mengji  Lu</span>. </span><span class="cited-content_cbyCitation_article-title">Recent trends in the development of Toll-like receptor 7/8-targeting therapeutics. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Drug Discovery</span><span> <strong>2021,</strong> <em>16 </em>
                                    (8)
                                     , 869-880. <a href="https://doi.org/10.1080/17460441.2021.1898369" title="DOI URL">https://doi.org/10.1080/17460441.2021.1898369</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/17460441.2021.1898369&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F17460441.2021.1898369%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Drug%2520Discovery%26atitle%3DRecent%252Btrends%252Bin%252Bthe%252Bdevelopment%252Bof%252BToll-like%252Breceptor%252B7%25252F8-targeting%252Btherapeutics%26aulast%3DHuang%26aufirst%3DXuan%26date%3D2021%26date%3D2021%26volume%3D16%26issue%3D8%26spage%3D869%26epage%3D880" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Philipp E.  Hofmann</span>, <span class="hlFld-ContribAuthor ">Jannick  Meinecke</span>, <span class="hlFld-ContribAuthor ">Klaus  Harms</span>, <span class="hlFld-ContribAuthor ">Ulrich  Koert</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and Functionalization of C6/C7 Substituted Pyrido[3,2‐
              d
              ]pyrimidines. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Organic Chemistry</span><span> <strong>2021,</strong> <em> </em><a href="https://doi.org/10.1002/ejoc.202100593" title="DOI URL">https://doi.org/10.1002/ejoc.202100593</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ejoc.202100593&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fejoc.202100593%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DSynthesis%252Band%252BFunctionalization%252Bof%252BC6%25252FC7%252BSubstituted%252BPyrido%25255B3%25252C2%2525E2%252580%252590%252Bd%252B%25255Dpyrimidines%26aulast%3DHofmann%26aufirst%3DPhilipp%2BE.%26date%3D2021%26date%3D2021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sachin  Bhagchandani</span>, <span class="hlFld-ContribAuthor ">Jeremiah A.  Johnson</span>, <span class="hlFld-ContribAuthor ">Darrell J.  Irvine</span>. </span><span class="cited-content_cbyCitation_article-title">Evolution of Toll-like receptor 7/8 agonist therapeutics and their delivery approaches: From antiviral formulations to vaccine adjuvants. </span><span class="cited-content_cbyCitation_journal-name">Advanced Drug Delivery Reviews</span><span> <strong>2021,</strong> <em>175 </em>, 113803. <a href="https://doi.org/10.1016/j.addr.2021.05.013" title="DOI URL">https://doi.org/10.1016/j.addr.2021.05.013</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.addr.2021.05.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.addr.2021.05.013%26sid%3Dliteratum%253Aachs%26jtitle%3DAdvanced%2520Drug%2520Delivery%2520Reviews%26atitle%3DEvolution%252Bof%252BToll-like%252Breceptor%252B7%25252F8%252Bagonist%252Btherapeutics%252Band%252Btheir%252Bdelivery%252Bapproaches%25253A%252BFrom%252Bantiviral%252Bformulations%252Bto%252Bvaccine%252Badjuvants%26aulast%3DBhagchandani%26aufirst%3DSachin%26date%3D2021%26volume%3D175%26spage%3D113803" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Deepender  Kaushik</span>, <span class="hlFld-ContribAuthor ">Arshpreet  Kaur</span>, <span class="hlFld-ContribAuthor ">Nikolai  Petrovsky</span>, <span class="hlFld-ContribAuthor ">Deepak B.  Salunke</span>. </span><span class="cited-content_cbyCitation_article-title">Structural evolution of toll-like receptor 7/8 agonists from imidazoquinolines to imidazoles. </span><span class="cited-content_cbyCitation_journal-name">RSC Medicinal Chemistry</span><span> <strong>2021,</strong> <em>12 </em>
                                    (7)
                                     , 1065-1120. <a href="https://doi.org/10.1039/D1MD00031D" title="DOI URL">https://doi.org/10.1039/D1MD00031D</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D1MD00031D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD1MD00031D%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Medicinal%2520Chemistry%26atitle%3DStructural%252Bevolution%252Bof%252Btoll-like%252Breceptor%252B7%25252F8%252Bagonists%252Bfrom%252Bimidazoquinolines%252Bto%252Bimidazoles%26aulast%3DKaushik%26aufirst%3DDeepender%26date%3D2021%26date%3D2021%26volume%3D12%26issue%3D7%26spage%3D1065%26epage%3D1120" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bingqian  Qu</span>, <span class="hlFld-ContribAuthor ">Richard J. P.  Brown</span>. </span><span class="cited-content_cbyCitation_article-title">Strategies to Inhibit Hepatitis B Virus at the Transcript Level. </span><span class="cited-content_cbyCitation_journal-name">Viruses</span><span> <strong>2021,</strong> <em>13 </em>
                                    (7)
                                     , 1327. <a href="https://doi.org/10.3390/v13071327" title="DOI URL">https://doi.org/10.3390/v13071327</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/v13071327&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fv13071327%26sid%3Dliteratum%253Aachs%26jtitle%3DViruses%26atitle%3DStrategies%252Bto%252BInhibit%252BHepatitis%252BB%252BVirus%252Bat%252Bthe%252BTranscript%252BLevel%26aulast%3DQu%26aufirst%3DBingqian%26date%3D2021%26date%3D2021%26volume%3D13%26issue%3D7%26spage%3D1327" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Oliver E.  Amin</span>, <span class="hlFld-ContribAuthor ">Emily J.  Colbeck</span>, <span class="hlFld-ContribAuthor ">Stephane  Daffis</span>, <span class="hlFld-ContribAuthor ">Shahzada  Khan</span>, <span class="hlFld-ContribAuthor ">Dhivya  Ramakrishnan</span>, <span class="hlFld-ContribAuthor ">Divya  Pattabiraman</span>, <span class="hlFld-ContribAuthor ">Ruth  Chu</span>, <span class="hlFld-ContribAuthor ">Holly  Micolochick Steuer</span>, <span class="hlFld-ContribAuthor ">Sophie  Lehar</span>, <span class="hlFld-ContribAuthor ">Leanne  Peiser</span>, <span class="hlFld-ContribAuthor ">Adam  Palazzo</span>, <span class="hlFld-ContribAuthor ">Christian  Frey</span>, <span class="hlFld-ContribAuthor ">Jessica  Davies</span>, <span class="hlFld-ContribAuthor ">Hassan  Javanbakht</span>, <span class="hlFld-ContribAuthor ">William M.C.  Rosenberg</span>, <span class="hlFld-ContribAuthor ">Simon P.  Fletcher</span>, <span class="hlFld-ContribAuthor ">Mala K.  Maini</span>, <span class="hlFld-ContribAuthor ">Laura J.  Pallett</span>. </span><span class="cited-content_cbyCitation_article-title">Therapeutic Potential of
              TLR8
              Agonist
              GS‐9688
              (Selgantolimod) in Chronic Hepatitis
              B
              : Remodeling of Antiviral and Regulatory Mediators. </span><span class="cited-content_cbyCitation_journal-name">Hepatology</span><span> <strong>2021,</strong> <em>74 </em>
                                    (1)
                                     , 55-71. <a href="https://doi.org/10.1002/hep.31695" title="DOI URL">https://doi.org/10.1002/hep.31695</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/hep.31695&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fhep.31695%26sid%3Dliteratum%253Aachs%26jtitle%3DHepatology%26atitle%3DTherapeutic%252BPotential%252Bof%252BTLR8%252BAgonist%252BGS%2525E2%252580%2525909688%252B%252528Selgantolimod%252529%252Bin%252BChronic%252BHepatitis%252BB%252B%25253A%252BRemodeling%252Bof%252BAntiviral%252Band%252BRegulatory%252BMediators%26aulast%3DAmin%26aufirst%3DOliver%2BE.%26date%3D2021%26date%3D2021%26volume%3D74%26issue%3D1%26spage%3D55%26epage%3D71" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Efthymios P  Tsounis</span>, <span class="hlFld-ContribAuthor ">Evanthia  Tourkochristou</span>, <span class="hlFld-ContribAuthor ">Athanasia  Mouzaki</span>, <span class="hlFld-ContribAuthor ">Christos  Triantos</span>. </span><span class="cited-content_cbyCitation_article-title">Toward a new era of hepatitis B virus therapeutics: The pursuit of a functional cure. </span><span class="cited-content_cbyCitation_journal-name">World Journal of Gastroenterology</span><span> <strong>2021,</strong> <em>27 </em>
                                    (21)
                                     , 2727-2757. <a href="https://doi.org/10.3748/wjg.v27.i21.2727" title="DOI URL">https://doi.org/10.3748/wjg.v27.i21.2727</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3748/wjg.v27.i21.2727&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3748%2Fwjg.v27.i21.2727%26sid%3Dliteratum%253Aachs%26jtitle%3DWorld%2520Journal%2520of%2520Gastroenterology%26atitle%3DToward%252Ba%252Bnew%252Bera%252Bof%252Bhepatitis%252BB%252Bvirus%252Btherapeutics%25253A%252BThe%252Bpursuit%252Bof%252Ba%252Bfunctional%252Bcure%26aulast%3DTsounis%26aufirst%3DEfthymios%2BP%26date%3D2021%26volume%3D27%26issue%3D21%26spage%3D2727%26epage%3D2757" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Georgia-Myrto  Prifti</span>, <span class="hlFld-ContribAuthor ">Dimitrios  Moianos</span>, <span class="hlFld-ContribAuthor ">Erofili  Giannakopoulou</span>, <span class="hlFld-ContribAuthor ">Vasiliki  Pardali</span>, <span class="hlFld-ContribAuthor ">John  Tavis</span>, <span class="hlFld-ContribAuthor ">Grigoris  Zoidis</span>. </span><span class="cited-content_cbyCitation_article-title">Recent Advances in Hepatitis B Treatment. </span><span class="cited-content_cbyCitation_journal-name">Pharmaceuticals</span><span> <strong>2021,</strong> <em>14 </em>
                                    (5)
                                     , 417. <a href="https://doi.org/10.3390/ph14050417" title="DOI URL">https://doi.org/10.3390/ph14050417</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ph14050417&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fph14050417%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmaceuticals%26atitle%3DRecent%252BAdvances%252Bin%252BHepatitis%252BB%252BTreatment%26aulast%3DPrifti%26aufirst%3DGeorgia-Myrto%26date%3D2021%26date%3D2021%26volume%3D14%26issue%3D5%26spage%3D417" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ana  Marina Andrei</span>, <span class="hlFld-ContribAuthor ">Elena  Cristina Andrei</span>, <span class="hlFld-ContribAuthor ">Elena  Camelia Stănciulescu</span>, <span class="hlFld-ContribAuthor ">Mihaela  Cezarina Mehedinți</span>, <span class="hlFld-ContribAuthor ">Mihaela  Jana Țuculină</span>, <span class="hlFld-ContribAuthor ">Ileana  Monica Baniță</span>, <span class="hlFld-ContribAuthor ">Sandra  Alice Buteică</span>, <span class="hlFld-ContribAuthor ">Cătălina  Gabriela Pisoschi</span>. </span><span class="cited-content_cbyCitation_article-title">Innate Immune Response as a New Challenge in Periodontal Inflammation. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,<a href="https://doi.org/10.5772/intechopen.96801" title="DOI URL">https://doi.org/10.5772/intechopen.96801</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.5772/intechopen.96801&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.5772%2Fintechopen.96801%26sid%3Dliteratum%253Aachs%26atitle%3DInnate%252BImmune%252BResponse%252Bas%252Ba%252BNew%252BChallenge%252Bin%252BPeriodontal%252BInflammation%26aulast%3DMarina%2BAndrei%26aufirst%3DAna%26date%3D2021%26date%3D2021%26pub%3DIntechOpen%26atitle%3DPeriodontology%252B-%252BFundamentals%252Band%252BClinical%252BFeatures%252B%25255BWorking%252BTitle%25255D%26date%3D2021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Susanna  Naggie</span>, <span class="hlFld-ContribAuthor ">Anna S.  Lok</span>. </span><span class="cited-content_cbyCitation_article-title">New Therapeutics for Hepatitis B: The Road to Cure. </span><span class="cited-content_cbyCitation_journal-name">Annual Review of Medicine</span><span> <strong>2021,</strong> <em>72 </em>
                                    (1)
                                     , 93-105. <a href="https://doi.org/10.1146/annurev-med-080119-103356" title="DOI URL">https://doi.org/10.1146/annurev-med-080119-103356</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1146/annurev-med-080119-103356&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1146%2Fannurev-med-080119-103356%26sid%3Dliteratum%253Aachs%26jtitle%3DAnnual%2520Review%2520of%2520Medicine%26atitle%3DNew%252BTherapeutics%252Bfor%252BHepatitis%252BB%25253A%252BThe%252BRoad%252Bto%252BCure%26aulast%3DNaggie%26aufirst%3DSusanna%26date%3D2021%26volume%3D72%26issue%3D1%26spage%3D93%26epage%3D105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Valeria  Barili</span>, <span class="hlFld-ContribAuthor ">Carolina  Boni</span>, <span class="hlFld-ContribAuthor ">Marzia  Rossi</span>, <span class="hlFld-ContribAuthor ">Andrea  Vecchi</span>, <span class="hlFld-ContribAuthor ">Alessandra  Zecca</span>, <span class="hlFld-ContribAuthor ">Amalia  Penna</span>, <span class="hlFld-ContribAuthor ">Gabriele  Missale</span>, <span class="hlFld-ContribAuthor ">Carlo  Ferrari</span>, <span class="hlFld-ContribAuthor ">Paola  Fisicaro</span>. </span><span class="cited-content_cbyCitation_article-title">Metabolic regulation of the HBV-specific T cell function. </span><span class="cited-content_cbyCitation_journal-name">Antiviral Research</span><span> <strong>2021,</strong> <em>185 </em>, 104989. <a href="https://doi.org/10.1016/j.antiviral.2020.104989" title="DOI URL">https://doi.org/10.1016/j.antiviral.2020.104989</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.antiviral.2020.104989&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.antiviral.2020.104989%26sid%3Dliteratum%253Aachs%26jtitle%3DAntiviral%2520Research%26atitle%3DMetabolic%252Bregulation%252Bof%252Bthe%252BHBV-specific%252BT%252Bcell%252Bfunction%26aulast%3DBarili%26aufirst%3DValeria%26date%3D2021%26volume%3D185%26spage%3D104989" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Leda  Bassit</span>, <span class="hlFld-ContribAuthor ">Suzane Kioko  Ono</span>, <span class="hlFld-ContribAuthor ">Raymond F.  Schinazi</span>. </span><span class="cited-content_cbyCitation_article-title">Moving Fast Toward Hepatitis B Virus Elimination. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 115-138. <a href="https://doi.org/10.1007/978-981-16-0267-2_5" title="DOI URL">https://doi.org/10.1007/978-981-16-0267-2_5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-981-16-0267-2_5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-981-16-0267-2_5%26sid%3Dliteratum%253Aachs%26atitle%3DMoving%252BFast%252BToward%252BHepatitis%252BB%252BVirus%252BElimination%26aulast%3DBassit%26aufirst%3DLeda%26date%3D2021%26date%3D2021%26spage%3D115%26epage%3D138%26pub%3DSpringer%2520Singapore%26atitle%3DAntiviral%252BDrug%252BDiscovery%252Band%252BDevelopment%26aulast%3DLiu%26aufirst%3DXinyong%26date%3D2021%26volume%3D1322" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jim  Zheng</span>, <span class="hlFld-ContribAuthor ">Scott  Balsitis</span>, <span class="hlFld-ContribAuthor ">Rex  Santos</span>, <span class="hlFld-ContribAuthor ">Bill J.  Smith</span>, <span class="hlFld-ContribAuthor ">Raju  Subramanian</span>. </span><span class="cited-content_cbyCitation_article-title">Characterization of Seasonal Pharmacokinetic Variability in Woodchucks. </span><span class="cited-content_cbyCitation_journal-name">Drug Metabolism and Disposition</span><span> <strong>2020,</strong> <em>48 </em>
                                    (11)
                                     , 1199-1209. <a href="https://doi.org/10.1124/dmd.120.000140" title="DOI URL">https://doi.org/10.1124/dmd.120.000140</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1124/dmd.120.000140&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1124%2Fdmd.120.000140%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Metabolism%2520and%2520Disposition%26atitle%3DCharacterization%252Bof%252BSeasonal%252BPharmacokinetic%252BVariability%252Bin%252BWoodchucks%26aulast%3DZheng%26aufirst%3DJim%26date%3D2020%26date%3D2020%26volume%3D48%26issue%3D11%26spage%3D1199%26epage%3D1209" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Madeleine E.  Kieffer</span>, <span class="hlFld-ContribAuthor ">Akash M.  Patel</span>, <span class="hlFld-ContribAuthor ">Scott A.  Hollingsworth</span>, <span class="hlFld-ContribAuthor ">W. Michael  Seganish</span>. </span><span class="cited-content_cbyCitation_article-title">Small molecule agonists of toll-like receptors 7 and 8: a patent review 2014 – 2020. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2020,</strong> <em>30 </em>
                                    (11)
                                     , 825-845. <a href="https://doi.org/10.1080/13543776.2020.1825687" title="DOI URL">https://doi.org/10.1080/13543776.2020.1825687</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543776.2020.1825687&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543776.2020.1825687%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DSmall%252Bmolecule%252Bagonists%252Bof%252Btoll-like%252Breceptors%252B7%252Band%252B8%25253A%252Ba%252Bpatent%252Breview%252B2014%252B%2525E2%252580%252593%252B2020%26aulast%3DKieffer%26aufirst%3DMadeleine%2BE.%26date%3D2020%26date%3D2020%26volume%3D30%26issue%3D11%26spage%3D825%26epage%3D845" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00100/20200918/images/medium/jm0c00100_0015.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00100/20200918/images/large/jm0c00100_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00100&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00100/20200918/images/medium/jm0c00100_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00100/20200918/images/large/jm0c00100_0001.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. TLR8 agonists.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00100/20200918/images/large/jm0c00100_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00100&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00100/20200918/images/medium/jm0c00100_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00100/20200918/images/large/jm0c00100_0002.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A) TLR8-ectodomain:<b>1</b> X-ray complex with protons added to the ligand by modeling. Lighter green shading indicates chain A surface of one TLR8 monomer and darker green is chain B of the second TLR8 monomer. (B) Model of <b>6a</b>. (C) Model of (<i>R</i>)-<b>6d</b> with a bridging water hydrogen bond to Asp545. (D) Model of (<i>R</i>)-<b>6d</b> with a direct hydrogen bond to Asp545. (E) Cross section view of (<i>R</i>)-<b>6d</b> occupying the lipophilic pocket from model shown in panel D. (F) Model of (<i>S</i>)-<b>6d</b> with a bridging water hydrogen bond to Asp545. All modeled compounds in B–F were docked into the TLR8 X-ray structure. PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3W3M">3W3M</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00100/20200918/images/large/jm0c00100_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00100&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00100/20200918/images/medium/jm0c00100_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00100/20200918/images/large/jm0c00100_0006.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of <i>N</i><sup>4</sup>- and <i>O</i><sup>4</sup>-Substituted Pyrido[3,2-<i>d</i>]pyrimidin-2-amines<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00100/20200918/images/large/jm0c00100_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00100&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) butan-1-ol, NaH (60% disp), 71%; (ii) 2,4-dimethoxybenzyl(Dmb)-NH<sub>2</sub>, iPr<sub>2</sub>NEt, 100 °C, 37%; (iii) TFA, 9%; (iv) amine <b>11a</b>–<b>h</b>, iPr<sub>2</sub>NEt; rt, (100 °C for (<i>R</i>)-<b>11e</b>); (v) Dmb-NH<sub>2</sub>, iPr<sub>2</sub>NEt, 100–135 °C, 52% for <b>12g</b>, 68% for <b>12h</b>; (vi) TFA, 11–73% over 3 steps; (vii) LAH; (viii) TFA, 5% over 2 steps; (ix) KOH(aq), MeOH, quant; (x) TFA, quant; (xi) HATU, iPr<sub>2</sub>NEt, NMP, ammonia (14%) or methylamine (18%); (xii) TFA, 22–42%.</p></p></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00100/20200918/images/medium/jm0c00100_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00100/20200918/images/large/jm0c00100_0007.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of <i>N</i><sup>4</sup>-Substituted Quinazoline-2-amines, <b>14</b>, and Quinoline-2-amines, <b>16</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00100/20200918/images/large/jm0c00100_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00100&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) DMF, DBU, BOP, <b>11d</b>, 62–71%; (ii) Pd(dba)<sub>2</sub>, NaO<sup>t</sup>Bu, (<i>R</i>)-BINAP, <b>11d</b>, 135 °C, 7–16%.</p></p></figure><figure data-id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00100/20200918/images/medium/jm0c00100_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00100/20200918/images/large/jm0c00100_0008.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Stereoselective Synthesis of α,α-Substituted Amino Acid Esters and Alcohols<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00100/20200918/images/large/jm0c00100_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00100&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) TMSCHN<sub>2</sub>, MeOH, quant; (ii) piperidine, THF, 85% over 2 steps; (iii) BH<sub>3</sub>·THF; (iv) BF<sub>3</sub>·OEt<sub>2</sub>, −78 °C, RMgCl, 60–76%; (v) LiBH<sub>4</sub>, 0 °C-rt, quant; (vi) Pd(OH)<sub>2</sub>/C, EtOH, HCl, H<sub>2</sub>, 70–75 °C, quant.</p></p></figure><figure data-id="sch4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00100/20200918/images/medium/jm0c00100_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00100/20200918/images/large/jm0c00100_0009.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of <i>N</i><sup>4</sup>-α,α-Substituted Pyrido[3,2-<i>d</i>]pyrimidin-2-amines<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00100/20200918/images/large/jm0c00100_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00100&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) amine <b>18a</b>–<b>g</b>, iPr<sub>2</sub>NEt, 80 °C; (ii) Dmb-NH<sub>2</sub>, iPr<sub>2</sub>NEt (K<sub>2</sub>CO<sub>3</sub> for (<i>R</i>)-<b>23e</b> and (<i>R</i>)-<b>26a</b>), 85–120 °C, 17–66% over 2 steps; (iii) LAH, 29–100%, (over 2 steps, (<i>R</i>)-<b>23a</b> (45%) and (<i>R</i>)-<b>30</b> (82%); over 3 steps (<i>S</i>)-<b>23c</b> (26%) and (<i>R</i>)-<b>23d</b> (7%)); (iv) Pd/C, H<sub>2</sub>; (v) TFA, 7%-quant; (vi) Pd(Ph<sub>3</sub>)<sub>4</sub>, ZnCN<sub>2</sub>, DMF, 115 °C, quant; (vii) K<sub>2</sub>CO<sub>3</sub>, H<sub>2</sub>O<sub>2</sub>, 0 °C, 97% over 2 steps; (viii) (COCl<sub>2</sub>)<sub>3</sub>, 110 °C, 90%; (ix) PCl<sub>5</sub>, POCl<sub>3</sub>, 110 °C, 75%; (x) fermentation; (xi) CH<sub>3</sub>B(OH)<sub>2</sub>, Pd(Ph<sub>3</sub>)<sub>4</sub>, K<sub>3</sub>PO<sub>4</sub>, 150 °C; (xii) ClC(═NH)-NH<sub>2</sub>, (CH<sub>3</sub>)<sub>2</sub>SO<sub>2</sub>, 160 °C, 24%; (xiii) NMP, BOP, DBU, (<i>S</i>)-<b>18c</b>, 20%.</p></p></figure><figure data-id="fig3" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00100/20200918/images/medium/jm0c00100_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00100/20200918/images/large/jm0c00100_0003.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Single cocrystal structure of TLR8-ectodomain:(<i>R</i>)-<b>7</b> complex. PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6WML">6WML</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00100/20200918/images/large/jm0c00100_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00100&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00100/20200918/images/medium/jm0c00100_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00100/20200918/images/large/jm0c00100_0004.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. TLR8 and TLR7 HEK293 reporter assay response to (<i>R</i>)-<b>7</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00100/20200918/images/large/jm0c00100_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00100&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00100/20200918/images/medium/jm0c00100_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00100/20200918/images/large/jm0c00100_0005.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Antiviral activity in HBV-infected PHH treated with (<i>R</i>)-<b>7</b>-CM.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00100/20200918/images/large/jm0c00100_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00100&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i55">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_73378" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_73378" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 29 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Neill, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golenbock, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowie, A. G.</span></span> <span> </span><span class="NLM_article-title">The History of Toll-like Receptors - Redefining Innate Immunity</span>. <i>Nat. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">453</span>– <span class="NLM_lpage">460</span>, <span class="refDoi"> DOI: 10.1038/nri3446</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=10.1038%2Fnri3446" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=23681101" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnslaisLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=453-460&issue=6&author=L.+A.+O%E2%80%99Neillauthor=D.+Golenbockauthor=A.+G.+Bowie&title=The+History+of+Toll-like+Receptors+-+Redefining+Innate+Immunity&doi=10.1038%2Fnri3446"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The history of Toll-like receptors - redefining innate immunity</span></div><div class="casAuthors">O'Neill, Luke A. J.; Golenbock, Douglas; Bowie, Andrew G.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">453-460</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The discovery of Toll-like receptors (TLRs) was an important event for immunol. research and was recognized as such with the awarding of the 2011 Nobel Prize in Physiol. or Medicine to Jules Hoffmann and Bruce Beutler, who, together with Ralph Steinman, the third winner of the 2011 Nobel Prize and the person who discovered the dendritic cell, were pioneers in the field of innate immunity.  TLRs have a central role in immunity - in this Timeline article, we describe the landmark findings that gave rise to this important field of research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNQuHgmx29MrVg90H21EOLACvtfcHk0lg3veDDKoOANA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnslaisLc%253D&md5=4d5ca89abf3932000ae422d79ecbe93f</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnri3446&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri3446%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DL.%2BA.%26aulast%3DGolenbock%26aufirst%3DD.%26aulast%3DBowie%26aufirst%3DA.%2BG.%26atitle%3DThe%2520History%2520of%2520Toll-like%2520Receptors%2520-%2520Redefining%2520Innate%2520Immunity%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2013%26volume%3D13%26issue%3D6%26spage%3D453%26epage%3D460%26doi%3D10.1038%2Fnri3446" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gorden, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorski, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibson, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kedl, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kieper, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomai, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alkan, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasilakos, J. P.</span></span> <span> </span><span class="NLM_article-title">Synthetic TLR Agonists Reveal Functional Differences Between Human TLR7 and TLR8</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>174</i></span>,  <span class="NLM_fpage">1259</span>– <span class="NLM_lpage">1268</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.174.3.1259</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=10.4049%2Fjimmunol.174.3.1259" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=15661881" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlsFyhsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=174&publication_year=2005&pages=1259-1268&author=K.+B.+Gordenauthor=K.+S.+Gorskiauthor=S.+J.+Gibsonauthor=R.+M.+Kedlauthor=W.+C.+Kieperauthor=X.+Qiuauthor=M.+A.+Tomaiauthor=S.+S.+Alkanauthor=J.+P.+Vasilakos&title=Synthetic+TLR+Agonists+Reveal+Functional+Differences+Between+Human+TLR7+and+TLR8&doi=10.4049%2Fjimmunol.174.3.1259"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic TLR Agonists Reveal Functional Differences between Human TLR7 and TLR8</span></div><div class="casAuthors">Gorden, Keith B.; Gorski, Kevin S.; Gibson, Sheila J.; Kedl, Ross M.; Kieper, William C.; Qiu, Xiaohong; Tomai, Mark A.; Alkan, Sefik S.; Vasilakos, John P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">174</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1259-1268</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">Although TLR7 and TLR8 are phylogenetically and structurally related, their relative functions are largely unknown.  The role of TLR7 has been established using TLR7-deficient mice and small mol. TLR7 agonists.  The absence of TLR8-selective agonists has hampered the authors' understanding of the role of TLR8.  In this study TLR agonists selective for TLR7 or TLR8 were used to det. the repertoire of human innate immune cells that are activated through these TLRs.  The authors found that TLR7 agonists directly activated purified plasmacytoid dendritic cells and, to a lesser extent, monocytes.  Conversely, TLR8 agonists directly activated purified myeloid dendritic cells, monocytes, and monocyte-derived dendritic cells (GM-CSF/IL-4/TGF-β).  Accordingly, TLR7-selective agonists were more effective than TLR8-selective agonists at inducing IFN-α- and IFN-regulated chemokines such as IFN-inducible protein and IFN-inducible T cell α chemoattractant from human PBMC.  In contrast, TLR8 agonists were more effective than TLR7 agonists at inducing proinflammatory cytokines and chemokines, such as TNF-α, IL-12, and MIP-1α.  Thus, this study demonstrated that TLR7 and TLR8 agonists differ in their target cell selectivity and cytokine induction profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxUMK2LBltvrVg90H21EOLACvtfcHk0lhnjnnLi0HLnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlsFyhsQ%253D%253D&md5=1893fde2508086be1f79df76d09e919a</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.174.3.1259&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.174.3.1259%26sid%3Dliteratum%253Aachs%26aulast%3DGorden%26aufirst%3DK.%2BB.%26aulast%3DGorski%26aufirst%3DK.%2BS.%26aulast%3DGibson%26aufirst%3DS.%2BJ.%26aulast%3DKedl%26aufirst%3DR.%2BM.%26aulast%3DKieper%26aufirst%3DW.%2BC.%26aulast%3DQiu%26aufirst%3DX.%26aulast%3DTomai%26aufirst%3DM.%2BA.%26aulast%3DAlkan%26aufirst%3DS.%2BS.%26aulast%3DVasilakos%26aufirst%3DJ.%2BP.%26atitle%3DSynthetic%2520TLR%2520Agonists%2520Reveal%2520Functional%2520Differences%2520Between%2520Human%2520TLR7%2520and%2520TLR8%26jtitle%3DJ.%2520Immunol.%26date%3D2005%26volume%3D174%26spage%3D1259%26epage%3D1268%26doi%3D10.4049%2Fjimmunol.174.3.1259" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span> <i>Hepatitis
B</i>; <span class="NLM_series">Fact Sheet no. 204</span>; <span class="NLM_publisher-name">World
Health Organization
(WHO)</span>, <span class="NLM_year">2019</span>; <a href="http://www.who.int/mediacentre/factsheets/fs204/en/" class="extLink">http://www.who.int/mediacentre/factsheets/fs204/en/</a> (accessed 2019-11-02).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Hepatitis%0AB%3B+Fact+Sheet+no.+204%3B+World%0AHealth+Organization%0A%28WHO%29%2C+2019%3B+http%3A%2F%2Fwww.who.int%2Fmediacentre%2Ffactsheets%2Ffs204%2Fen%2F+%28accessed+2019-11-02%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26jtitle%3DHepatitis%250AB%26pub%3DWorld%250AHealth%2520Organization%250A%2528WHO%2529%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ott, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groeger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiersma, S. T.</span></span> <span> </span><span class="NLM_article-title">Global Epidemiology of Hepatitis B Virus Infection: New Estimates of Age-Specific HBsAg Seroprevalence and Endemicity</span>. <i>Vaccine</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>30</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">2212</span>– <span class="NLM_lpage">2219</span>, <span class="refDoi"> DOI: 10.1016/j.vaccine.2011.12.116</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=10.1016%2Fj.vaccine.2011.12.116" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=22273662" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=1%3ACAS%3A280%3ADC%252BC383mt12hsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=2212-2219&issue=12&author=J.+J.+Ottauthor=G.+A.+Stevensauthor=J.+Groegerauthor=S.+T.+Wiersma&title=Global+Epidemiology+of+Hepatitis+B+Virus+Infection%3A+New+Estimates+of+Age-Specific+HBsAg+Seroprevalence+and+Endemicity&doi=10.1016%2Fj.vaccine.2011.12.116"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity</span></div><div class="casAuthors">Ott J J; Stevens G A; Groeger J; Wiersma S T</div><div class="citationInfo"><span class="NLM_cas:title">Vaccine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2212-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVE:  Chronic hepatitis B virus infection is one of the most serious infections and a major risk factor for deaths from cirrhosis and liver cancer.  We estimate age-, sex- and region-specific prevalence of chronic HBV infection and calculate the absolute number of persons being chronically infected.  METHODS:  A systematic review of the literature for studies reporting HBV infection was conducted and worldwide HBsAg seroprevalence data was collected over a 27-year period (1980-2007).  Based on observed data, age-specific prevalence and endemicity were estimated on a global level and for all world regions for 1990 and 2005 using an empirical Bayesian hierarchical model.  FINDINGS:  From 1990 to 2005, the prevalence of chronic HBV infection decreased in most regions.  This was particularly evident in Central sub-Saharan Africa, Tropical and Central Latin America, South East Asia and Central Europe.  Despite this decrease in prevalence, the absolute number of HBsAg positive persons increased from 223 million in 1990 to 240 million in 2005.  Age-specific prevalence varied by geographical region with highest endemicity levels in sub-Saharan Africa and prevalence below 2% in regions such as Tropical and Central Latin America, North America and Western Europe.  Asian regions showed distinct prevalence patterns with lower intermediate prevalence in South Asia, but up to 8.6% HBsAg prevalence in East Asia.  Strong declines were seen in South East Asian children.  CONCLUSION:  Declines in HBV infection prevalence may be related to expanded immunization.  The increasing overall number of individuals being chronically infected with HBV, and the widespread global differences in HBV prevalence call for targeted approaches to tackle HBV-related mortality and morbidity.  HBV infection prevalence data are needed at country and sub-national level to estimate disease burden and guide health and vaccine policy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTBkb3C3wv7Da-9TkgmBqTqfW6udTcc2easOYvHjaJsxbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC383mt12hsA%253D%253D&md5=f17cf650a072050baf83cb73b1036779</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.vaccine.2011.12.116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.vaccine.2011.12.116%26sid%3Dliteratum%253Aachs%26aulast%3DOtt%26aufirst%3DJ.%2BJ.%26aulast%3DStevens%26aufirst%3DG.%2BA.%26aulast%3DGroeger%26aufirst%3DJ.%26aulast%3DWiersma%26aufirst%3DS.%2BT.%26atitle%3DGlobal%2520Epidemiology%2520of%2520Hepatitis%2520B%2520Virus%2520Infection%253A%2520New%2520Estimates%2520of%2520Age-Specific%2520HBsAg%2520Seroprevalence%2520and%2520Endemicity%26jtitle%3DVaccine%26date%3D2012%26volume%3D30%26issue%3D12%26spage%3D2212%26epage%3D2219%26doi%3D10.1016%2Fj.vaccine.2011.12.116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bertoletti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrari, C.</span></span> <span> </span><span class="NLM_article-title">Adaptive Immunity in HBV Infection</span>. <i>J. Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>64</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">S71</span>– <span class="NLM_lpage">S83</span>, <span class="refDoi"> DOI: 10.1016/j.jhep.2016.01.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=10.1016%2Fj.jhep.2016.01.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=27084039" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=1%3ACAS%3A528%3ADC%252BC28XmtVart7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2016&pages=S71-S83&issue=1&author=A.+Bertolettiauthor=C.+Ferrari&title=Adaptive+Immunity+in+HBV+Infection&doi=10.1016%2Fj.jhep.2016.01.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Adaptive immunity in HBV infection</span></div><div class="casAuthors">Bertoletti, Antonio; Ferrari, Carlo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hepatology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">1_Suppl.</span>),
    <span class="NLM_cas:pages">S71-S83</span>CODEN:
                <span class="NLM_cas:coden">JOHEEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-8278</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">During hepatitis B virus (HBV) infection, the presence of HBV-specific antibody producing B cells and functional HBV-specific T cells (with helper or cytotoxic effects) ultimately dets. HBV infection outcome.  In this review, in addn. to summarizing the present state of knowledge of HBV-adaptive immunity, we will highlight controversies and uncertainties concerning the HBV-specific B and T lymphocyte response, and propose future directions for research aimed at the generation of more efficient immunotherapeutic strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0DCzFYSMYqLVg90H21EOLACvtfcHk0lhnjnnLi0HLnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmtVart7w%253D&md5=a212ced9423f2e1db502572b049290ad</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2016.01.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2016.01.026%26sid%3Dliteratum%253Aachs%26aulast%3DBertoletti%26aufirst%3DA.%26aulast%3DFerrari%26aufirst%3DC.%26atitle%3DAdaptive%2520Immunity%2520in%2520HBV%2520Infection%26jtitle%3DJ.%2520Hepatol.%26date%3D2016%26volume%3D64%26issue%3D1%26spage%3DS71%26epage%3DS83%26doi%3D10.1016%2Fj.jhep.2016.01.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Du, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Randolph, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, C.</span></span> <span> </span><span class="NLM_article-title">TLR8 Agonists Stimulate Newly Recruited Monocyte-Derived Cells Into Potent APCs That Enhance HBsAg Immunogenicity</span>. <i>Vaccine</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">38</span>),  <span class="NLM_fpage">6273</span>– <span class="NLM_lpage">6281</span>, <span class="refDoi"> DOI: 10.1016/j.vaccine.2010.06.117</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=10.1016%2Fj.vaccine.2010.06.117" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=20637759" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVaqu7%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2010&pages=6273-6281&issue=38&author=J.+Duauthor=Z.+Wuauthor=S.+Renauthor=Y.+Weiauthor=M.+Gaoauthor=G.+J.+Randolphauthor=C.+Qu&title=TLR8+Agonists+Stimulate+Newly+Recruited+Monocyte-Derived+Cells+Into+Potent+APCs+That+Enhance+HBsAg+Immunogenicity&doi=10.1016%2Fj.vaccine.2010.06.117"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">TLR8 agonists stimulate newly recruited monocyte-derived cells into potent APCs that enhance HBsAg immunogenicity</span></div><div class="casAuthors">Du, Jun; Wu, Zhiyuan; Ren, Shurong; Wei, Yong; Gao, Meihua; Randolph, Gwendalyn J.; Qu, Chunfeng</div><div class="citationInfo"><span class="NLM_cas:title">Vaccine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">38</span>),
    <span class="NLM_cas:pages">6273-6281</span>CODEN:
                <span class="NLM_cas:coden">VACCDE</span>;
        ISSN:<span class="NLM_cas:issn">0264-410X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">We previously reported that synthetic or natural Toll-like receptor (TLR) 7/8 agonists present within dead cells enhanced cell-assocd. antigen presentation both in vitro and in vivo.  Here, we investigated the immunopotency of different chem. synthesized TLR7/8 agonists, Resiquimod, Gardiquimod, CL075, and CL097, on HBsAg immunogenicity.  These agonists stimulated inflammatory monocyte-derived cells to become potent antigen-presenting dendritic cells (DCs), which augmented HBsAg specific T cell proliferation after they were conditioned with HBsAg.  The TLR8 agonist CL075 and the TLR7/8 dual agonist CL097 showed more potent effects than the TLR7 agonist.  Compared with alum adjuvant, when HBsAg mixed with CL075 was injected i.m. into mice, more monocyte-derived DCs carried antigens into draining lymph nodes and spleens.  Specific Abs, particularly IgG2a, were significantly increased, and more IL-5 and IFN-γ were produced by splenocytes and intrahepatic immunocytes in mice that received HBsAg mixed with CL075 and CL097.  These results suggest that TLR8 agonists are good candidates to enhance recombinant HBsAg immunogenicity to induce specific humoral and cellular immune responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1vp0F5zWgfbVg90H21EOLACvtfcHk0lhnjnnLi0HLnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVaqu7%252FP&md5=142e5048b9a73de56593b79c173e5376</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.vaccine.2010.06.117&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.vaccine.2010.06.117%26sid%3Dliteratum%253Aachs%26aulast%3DDu%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DZ.%26aulast%3DRen%26aufirst%3DS.%26aulast%3DWei%26aufirst%3DY.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DRandolph%26aufirst%3DG.%2BJ.%26aulast%3DQu%26aufirst%3DC.%26atitle%3DTLR8%2520Agonists%2520Stimulate%2520Newly%2520Recruited%2520Monocyte-Derived%2520Cells%2520Into%2520Potent%2520APCs%2520That%2520Enhance%2520HBsAg%2520Immunogenicity%26jtitle%3DVaccine%26date%3D2010%26volume%3D28%26issue%3D38%26spage%3D6273%26epage%3D6281%26doi%3D10.1016%2Fj.vaccine.2010.06.117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schurich, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pallett, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lubowiecki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, H. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gill, U. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nastouli, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanwar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenberg, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maini, M. K.</span></span> <span> </span><span class="NLM_article-title">The Third Signal Cytokine IL-12 Rescues the Anti-Viral Function of Exhausted HBV-Specific CD8 T cells</span>. <i>PLoS Pathog.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">e1003208</span>, <span class="refDoi"> DOI: 10.1371/journal.ppat.1003208</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=10.1371%2Fjournal.ppat.1003208" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=23516358" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmtVeltbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2013&pages=e1003208&issue=3&author=A.+Schurichauthor=L.+J.+Pallettauthor=M.+Lubowieckiauthor=H.+D.+Singhauthor=U.+S.+Gillauthor=P.+T.+Kennedyauthor=E.+Nastouliauthor=S.+Tanwarauthor=W.+Rosenbergauthor=M.+K.+Maini&title=The+Third+Signal+Cytokine+IL-12+Rescues+the+Anti-Viral+Function+of+Exhausted+HBV-Specific+CD8+T+cells&doi=10.1371%2Fjournal.ppat.1003208"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">The third signal cytokine IL-12 rescues the anti-viral function of exhausted HBV-specific CD8 T cells</span></div><div class="casAuthors">Schurich, Anna; Pallett, Laura J.; Lubowiecki, Marcin; Singh, Harsimran D.; Gill, Upkar S.; Kennedy, Patrick T.; Nastouli, Eleni; Tanwar, Sudeep; Rosenberg, William; Maini, Mala K.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Pathogens</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">e1003208</span>CODEN:
                <span class="NLM_cas:coden">PPLACN</span>;
        ISSN:<span class="NLM_cas:issn">1553-7374</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Optimal immune activation of naive CD8 T cells requires signal 1 mediated by the T cell receptor, signal 2 mediated by co-stimulation and signal 3 provided by pro-inflammatory cytokines.  However, the potential for signal 3 cytokines to rescue anti-viral responses in functionally exhausted T cells has not been defined.  We investigated the effect of using third signal cytokines IL-12 or IFN-α to rescue the exhausted CD8 T cell response characteristic of patients persistently infected with hepatitis B virus (HBV).  We found that IL-12, but not IFN-α, potently augmented the capacity of HBV-specific CD8 T cells to produce effector cytokines upon stimulation by cognate antigen.  Functional recovery mediated by IL-12 was accompanied by down-modulation of the hallmark inhibitory receptor PD-1 and an increase in the transcription factor T-bet.  PD-1 down-regulation was obsd. in HBV but not CMV-specific T cells, in line with our finding that the highly functional CMV response was not further enhanced by IL-12.  IL-12 enhanced a no. of characteristics of HBV-specific T cells important for viral control: cytotoxicity, polyfunctionality and multispecificity.  Furthermore, IL-12 significantly decreased the pro-apoptotic mol. Bim, which is capable of mediating premature attrition of HBV-specific CD8 T cells.  Combining IL-12 with blockade of the PD-1 pathway further increased CD8 functionality in the majority of patients.  These data provide new insights into the distinct signalling requirements of exhausted T cells and the potential to recover responses optimized to control persistent viral infections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlNEnlXP0crrVg90H21EOLACvtfcHk0lhId1QPok1M1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmtVeltbw%253D&md5=bd2d813bb89d009a34709828a536489d</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1371%2Fjournal.ppat.1003208&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.ppat.1003208%26sid%3Dliteratum%253Aachs%26aulast%3DSchurich%26aufirst%3DA.%26aulast%3DPallett%26aufirst%3DL.%2BJ.%26aulast%3DLubowiecki%26aufirst%3DM.%26aulast%3DSingh%26aufirst%3DH.%2BD.%26aulast%3DGill%26aufirst%3DU.%2BS.%26aulast%3DKennedy%26aufirst%3DP.%2BT.%26aulast%3DNastouli%26aufirst%3DE.%26aulast%3DTanwar%26aufirst%3DS.%26aulast%3DRosenberg%26aufirst%3DW.%26aulast%3DMaini%26aufirst%3DM.%2BK.%26atitle%3DThe%2520Third%2520Signal%2520Cytokine%2520IL-12%2520Rescues%2520the%2520Anti-Viral%2520Function%2520of%2520Exhausted%2520HBV-Specific%2520CD8%2520T%2520cells%26jtitle%3DPLoS%2520Pathog.%26date%3D2013%26volume%3D9%26issue%3D3%26spage%3De1003208%26doi%3D10.1371%2Fjournal.ppat.1003208" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ussher, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandalova, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, X.-Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan-Garcia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">To, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gill, U. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Libero, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gehring, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willberg, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klenerman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertoletti, A.</span></span> <span> </span><span class="NLM_article-title">Toll-Like Receptor 8 Agonist and Bacteria Trigger Potent Activation of Innate Immune Cells in Human Liver</span>. <i>PLoS Pathog.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">e1004210</span>, <span class="refDoi"> DOI: 10.1371/journal.ppat.1004210</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=10.1371%2Fjournal.ppat.1004210" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=24967632" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFelsrjM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=e1004210&issue=6&author=J.+Joauthor=A.+T.+Tanauthor=J.+E.+Ussherauthor=E.+Sandalovaauthor=X.-Z.+Tangauthor=A.+Tan-Garciaauthor=N.+Toauthor=M.+Hongauthor=A.+Chiaauthor=U.+S.+Gillauthor=P.+T.+Kennedyauthor=K.+C.+Tanauthor=K.+H.+Leeauthor=G.+De+Liberoauthor=A.+J.+Gehringauthor=C.+B.+Willbergauthor=P.+Klenermanauthor=A.+Bertoletti&title=Toll-Like+Receptor+8+Agonist+and+Bacteria+Trigger+Potent+Activation+of+Innate+Immune+Cells+in+Human+Liver&doi=10.1371%2Fjournal.ppat.1004210"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Toll-like receptor 8 agonist and bacteria trigger potent activation of innate immune cells in human liver</span></div><div class="casAuthors">Jo, Juandy; Tan, Anthony T.; Ussher, James E.; Sandalova, Elena; Tang, Xin-Zi; Tan-Garcia, Alfonso; To, Natalie; Hong, Michelle; Chia, Adeline; Gill, Upkar S.; Kennedy, Patrick T.; Tan, Kai Chah; Lee, Kang Hoe; De Libero, Gennaro; Gehring, Adam J.; Willberg, Christian B.; Klenerman, Paul; Bertoletti, Antonio</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Pathogens</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">e1004210/1-e1004210/13, 13 pp.</span>CODEN:
                <span class="NLM_cas:coden">PPLACN</span>;
        ISSN:<span class="NLM_cas:issn">1553-7374</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">The ability of innate immune cells to sense and respond to impending danger varies by anatomical location.  The liver is considered tolerogenic but is still capable of mounting a successful immune response to clear various infections.  To understand whether hepatic immune cells tune their response to different infectious challenges, we probed mononuclear cells purified from human healthy and diseased livers with distinct pathogen-assocd. mols.  We discovered that only the TLR8 agonist ssRNA40 selectively activated liver-resident innate immune cells to produce substantial quantities of IFN-γ.  We identified CD161Bright mucosal-assocd. invariant T (MAIT) and CD56Bright NK cells as the responding liver-resident innate immune cells.  Their activation was not directly induced by the TLR8 agonist but was dependent on IL-12 and IL-18 prodn. by ssRNA40-activated intrahepatic monocytes.  Importantly, the ssRNA40-induced cytokine-dependent activation of MAIT cells mirrored responses induced by bacteria, i.e., generating a selective prodn. of high levels of IFN-γ, without the concomitant prodn. of TNF-α or IL-17A.  The intrahepatic IFN-γ prodn. could be detected not only in healthy livers, but also in HBV- or HCV-infected livers.  In conclusion, the human liver harbors a network of immune cells able to modulate their immunol. responses to different pathogen-assocd. mols.  Their ability to generate a strong prodn. of IFN-γ upon stimulation with TLR8 agonist opens new therapeutic opportunities for the treatment of diverse liver pathologies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQTrIPcC7CZLVg90H21EOLACvtfcHk0lhId1QPok1M1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFelsrjM&md5=db069ff7f302df907b4a7a68e07a3c9a</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1371%2Fjournal.ppat.1004210&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.ppat.1004210%26sid%3Dliteratum%253Aachs%26aulast%3DJo%26aufirst%3DJ.%26aulast%3DTan%26aufirst%3DA.%2BT.%26aulast%3DUssher%26aufirst%3DJ.%2BE.%26aulast%3DSandalova%26aufirst%3DE.%26aulast%3DTang%26aufirst%3DX.-Z.%26aulast%3DTan-Garcia%26aufirst%3DA.%26aulast%3DTo%26aufirst%3DN.%26aulast%3DHong%26aufirst%3DM.%26aulast%3DChia%26aufirst%3DA.%26aulast%3DGill%26aufirst%3DU.%2BS.%26aulast%3DKennedy%26aufirst%3DP.%2BT.%26aulast%3DTan%26aufirst%3DK.%2BC.%26aulast%3DLee%26aufirst%3DK.%2BH.%26aulast%3DDe%2BLibero%26aufirst%3DG.%26aulast%3DGehring%26aufirst%3DA.%2BJ.%26aulast%3DWillberg%26aufirst%3DC.%2BB.%26aulast%3DKlenerman%26aufirst%3DP.%26aulast%3DBertoletti%26aufirst%3DA.%26atitle%3DToll-Like%2520Receptor%25208%2520Agonist%2520and%2520Bacteria%2520Trigger%2520Potent%2520Activation%2520of%2520Innate%2520Immune%2520Cells%2520in%2520Human%2520Liver%26jtitle%3DPLoS%2520Pathog.%26date%3D2014%26volume%3D10%26issue%3D6%26spage%3De1004210%26doi%3D10.1371%2Fjournal.ppat.1004210" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, L.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wohlleber, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reisinger, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenne, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, R.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdullah, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schildberg, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Odenthal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dienes, H.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Rooijen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garbi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Croft, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurts, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubes, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Protzer, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heikenwalder, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knolle, P. A.</span></span> <span> </span><span class="NLM_article-title">Intrahepatic Myeloid-Cell Aggregates Enable Local Proliferation of CD8<sup>+</sup> T Cells and Successful Immunotherapy Against Chronic Viral Liver Infection</span>. <i>Nat. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">574</span>– <span class="NLM_lpage">583</span>, <span class="refDoi"> DOI: 10.1038/ni.2573</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=10.1038%2Fni.2573" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=23584070" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlslyqsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2013&pages=574-583&issue=6&author=L.-R.+Huangauthor=D.+Wohlleberauthor=F.+Reisingerauthor=C.+N.+Jenneauthor=R.-L.+Chengauthor=Z.+Abdullahauthor=F.+A.+Schildbergauthor=M.+Odenthalauthor=H.-P.+Dienesauthor=N.+van+Rooijenauthor=E.+Schmittauthor=N.+Garbiauthor=M.+Croftauthor=C.+Kurtsauthor=P.+Kubesauthor=U.+Protzerauthor=M.+Heikenwalderauthor=P.+A.+Knolle&title=Intrahepatic+Myeloid-Cell+Aggregates+Enable+Local+Proliferation+of+CD8%2B+T+Cells+and+Successful+Immunotherapy+Against+Chronic+Viral+Liver+Infection&doi=10.1038%2Fni.2573"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Intrahepatic myeloid-cell aggregates enable local proliferation of CD8+ T cells and successful immunotherapy against chronic viral liver infection</span></div><div class="casAuthors">Huang, Li-Rung; Wohlleber, Dirk; Reisinger, Florian; Jenne, Craig N.; Cheng, Ru-Lin; Abdullah, Zeinab; Schildberg, Frank A.; Odenthal, Margarete; Dienes, Hans-Peter; van Rooijen, Nico; Schmitt, Edgar; Garbi, Natalio; Croft, Michael; Kurts, Christian; Kubes, Paul; Protzer, Ulrike; Heikenwaelder, Mathias; Knolle, Percy A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Immunology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">574-583</span>CODEN:
                <span class="NLM_cas:coden">NIAMCZ</span>;
        ISSN:<span class="NLM_cas:issn">1529-2908</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Chronic infection is difficult to overcome because of exhaustion or depletion of cytotoxic effector CD8+ T cells (cytotoxic T lymphocytes (CTLs)).  Here we report that signaling via Toll-like receptors (TLRs) induced intrahepatic aggregates of myeloid cells that enabled the population expansion of CTLs (iMATEs: 'intrahepatic myeloid-cell aggregates for T cell population expansion') without causing immunopathol.  In the liver, CTL proliferation was restricted to iMATEs that were composed of inflammatory monocyte-derived CD11b+ cells.  Signaling via tumor-necrosis factor (TNF) caused iMATE formation that facilitated costimulation dependent on the receptor OX40 for expansion of the CTL population.  The iMATEs arose during acute viral infection but were absent during chronic viral infection, yet they were still induced by TLR signaling.  Such hepatic expansion of the CTL population controlled chronic viral infection of the liver after vaccination with DNA.  Thus, iMATEs are dynamic structures that overcome regulatory cues that limit the population expansion of CTLs during chronic infection and can be used in new therapeutic vaccination strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxbbT4E45LeLVg90H21EOLACvtfcHk0lhZVGJz5mx91Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlslyqsL0%253D&md5=3105ab62af74f0cdb4d9bca9df075f46</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fni.2573&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fni.2573%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DL.-R.%26aulast%3DWohlleber%26aufirst%3DD.%26aulast%3DReisinger%26aufirst%3DF.%26aulast%3DJenne%26aufirst%3DC.%2BN.%26aulast%3DCheng%26aufirst%3DR.-L.%26aulast%3DAbdullah%26aufirst%3DZ.%26aulast%3DSchildberg%26aufirst%3DF.%2BA.%26aulast%3DOdenthal%26aufirst%3DM.%26aulast%3DDienes%26aufirst%3DH.-P.%26aulast%3Dvan%2BRooijen%26aufirst%3DN.%26aulast%3DSchmitt%26aufirst%3DE.%26aulast%3DGarbi%26aufirst%3DN.%26aulast%3DCroft%26aufirst%3DM.%26aulast%3DKurts%26aufirst%3DC.%26aulast%3DKubes%26aufirst%3DP.%26aulast%3DProtzer%26aufirst%3DU.%26aulast%3DHeikenwalder%26aufirst%3DM.%26aulast%3DKnolle%26aufirst%3DP.%2BA.%26atitle%3DIntrahepatic%2520Myeloid-Cell%2520Aggregates%2520Enable%2520Local%2520Proliferation%2520of%2520CD8%252B%2520T%2520Cells%2520and%2520Successful%2520Immunotherapy%2520Against%2520Chronic%2520Viral%2520Liver%2520Infection%26jtitle%3DNat.%2520Immunol.%26date%3D2013%26volume%3D14%26issue%3D6%26spage%3D574%26epage%3D583%26doi%3D10.1038%2Fni.2573" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Biermer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puro, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, R. J.</span></span> <span> </span><span class="NLM_article-title">Tumor Necrosis Factor Alpha Inhibition of Hepatitis B Virus Replication Involves Disruption of Capsid Integrity Through Activation of NF-κB</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>77</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">4033</span>– <span class="NLM_lpage">4042</span>, <span class="refDoi"> DOI: 10.1128/JVI.77.7.4033-4042.2003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=10.1128%2FJVI.77.7.4033-4042.2003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=12634363" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=1%3ACAS%3A528%3ADC%252BD3sXisVKku7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2003&pages=4033-4042&issue=7&author=M.+Biermerauthor=R.+Puroauthor=R.+J.+Schneider&title=Tumor+Necrosis+Factor+Alpha+Inhibition+of+Hepatitis+B+Virus+Replication+Involves+Disruption+of+Capsid+Integrity+Through+Activation+of+NF-%CE%BAB&doi=10.1128%2FJVI.77.7.4033-4042.2003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Tumor necrosis factor alpha inhibition of hepatitis B virus replication involves disruption of capsid integrity through activation of NF-κB</span></div><div class="casAuthors">Biermer, Michael; Puro, Robyn; Schneider, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">4033-4042</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Chronic infection by hepatitis B virus results from an inability to clear the virus, which is assocd. with liver disease and liver cancer.  Tumor necrosis factor alpha (TNF-α) is assocd. with noncytopathic clearance of hepatitis B virus in animal models.  Here we demonstrate that the nuclear factor κB (NF-κB) signaling pathway is a central mediator of inhibition of hepatitis B virus by TNF-α and we describe the mol. mechanism.  TNF-α is shown to suppress hepatitis B virus DNA replication without cell killing by disrupting the formation or stability of cytoplasmic viral capsids through a pathway requiring the NF-κB-activating inhibitor of κB kinase complex IKK-α/β and active transcription factor NF-κB.  Hepatitis B virus replication could also be inhibited and viral capsid formation could be disrupted in the absence of TNF-α solely by overexpression of IKK-α/β or strong activation of NF-κB.  In contrast, inhibition of NF-κB signaling stimulated viral replication, demonstrating that HBV replication is both pos. and neg. regulated by the level of activity of the NF-κB pathway.  Studies are presented that exclude the possibility that HBV inhibition by NF-κB is carried out by secondary prodn. of gamma interferon or alpha/beta interferon.  These results identify a novel mechanism for noncytopathic suppression of hepatitis B virus replication that is mediated by the NF-κB signaling pathway and activated by TNF-α.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0hS6lF97_KbVg90H21EOLACvtfcHk0lhZVGJz5mx91Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXisVKku7g%253D&md5=f8cb4fde4611b75867673118a2cfdf95</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1128%2FJVI.77.7.4033-4042.2003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.77.7.4033-4042.2003%26sid%3Dliteratum%253Aachs%26aulast%3DBiermer%26aufirst%3DM.%26aulast%3DPuro%26aufirst%3DR.%26aulast%3DSchneider%26aufirst%3DR.%2BJ.%26atitle%3DTumor%2520Necrosis%2520Factor%2520Alpha%2520Inhibition%2520of%2520Hepatitis%2520B%2520Virus%2520Replication%2520Involves%2520Disruption%2520of%2520Capsid%2520Integrity%2520Through%2520Activation%2520of%2520NF-%25CE%25BAB%26jtitle%3DJ.%2520Virol.%26date%3D2003%26volume%3D77%26issue%3D7%26spage%3D4033%26epage%3D4042%26doi%3D10.1128%2FJVI.77.7.4033-4042.2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Watashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwamoto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marusawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uchida, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daito, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitamura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muramatsu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohashi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiyohara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murata, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aizaki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wakita, T.</span></span> <span> </span><span class="NLM_article-title">Interleukin-1 and Tumor Necrosis Factor-α Trigger Restriction of Hepatitis B Virus Infection Via a Cytidine Deaminase Activation-Induced Cytidine Deaminase (AID)</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>288</i></span> (<span class="NLM_issue">44</span>),  <span class="NLM_fpage">31715</span>– <span class="NLM_lpage">31727</span>, <span class="refDoi"> DOI: 10.1074/jbc.M113.501122</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=10.1074%2Fjbc.M113.501122" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=24025329" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslaitbbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=288&publication_year=2013&pages=31715-31727&issue=44&author=K.+Watashiauthor=G.+Liangauthor=M.+Iwamotoauthor=H.+Marusawaauthor=N.+Uchidaauthor=T.+Daitoauthor=K.+Kitamuraauthor=M.+Muramatsuauthor=H.+Ohashiauthor=T.+Kiyoharaauthor=R.+Suzukiauthor=J.+Liauthor=S.+Tongauthor=Y.+Tanakaauthor=K.+Murataauthor=H.+Aizakiauthor=T.+Wakita&title=Interleukin-1+and+Tumor+Necrosis+Factor-%CE%B1+Trigger+Restriction+of+Hepatitis+B+Virus+Infection+Via+a+Cytidine+Deaminase+Activation-Induced+Cytidine+Deaminase+%28AID%29&doi=10.1074%2Fjbc.M113.501122"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Interleukin-1 and Tumor Necrosis Factor-α Trigger Restriction of Hepatitis B Virus Infection via a Cytidine Deaminase Activation-induced Cytidine Deaminase (AID)</span></div><div class="casAuthors">Watashi, Koichi; Liang, Guoxin; Iwamoto, Masashi; Marusawa, Hiroyuki; Uchida, Nanako; Daito, Takuji; Kitamura, Kouichi; Muramatsu, Masamichi; Ohashi, Hirofumi; Kiyohara, Tomoko; Suzuki, Ryosuke; Li, Jisu; Tong, Shuping; Tanaka, Yasuhito; Murata, Kazumoto; Aizaki, Hideki; Wakita, Takaji</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">288</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">31715-31727</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Virus infection is restricted by intracellular immune responses in host cells, and this is typically modulated by stimulation of cytokines.  The cytokines and host factors that det. the host cell restriction against hepatitis B virus (HBV) infection are not well understood.  We screened 36 cytokines and chemokines to det. which were able to reduce the susceptibility of HepaRG cells to HBV infection.  Here, we found that pretreatment with IL-1β and TNFα remarkably reduced the host cell susceptibility to HBV infection.  This effect was mediated by activation of the NF-κB signaling pathway.  A cytidine deaminase, activation-induced cytidine deaminase (AID), was up-regulated by both IL-1β and TNFα in a variety of hepatocyte cell lines and primary human hepatocytes.  Another deaminase APOBEC3G was not induced by these proinflammatory cytokines.  Knockdown of AID expression impaired the anti-HBV effect of IL-1β, and overexpression of AID antagonized HBV infection, suggesting that AID was one of the responsible factors for the anti-HBV activity of IL-1/TNFα.  Although AID induced hypermutation of HBV DNA, this activity was dispensable for the anti-HBV activity.  The antiviral effect of IL-1/TNFα was also obsd. on different HBV genotypes but not on hepatitis C virus.  These results demonstrate that proinflammatory cytokines IL-1/TNFα trigger a novel antiviral mechanism involving AID to regulate host cell permissiveness to HBV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqA-GbKRcw1ZLVg90H21EOLACvtfcHk0lhZVGJz5mx91Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslaitbbK&md5=36b60d1c3fbae71bd6f81e9c10b1d33c</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M113.501122&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M113.501122%26sid%3Dliteratum%253Aachs%26aulast%3DWatashi%26aufirst%3DK.%26aulast%3DLiang%26aufirst%3DG.%26aulast%3DIwamoto%26aufirst%3DM.%26aulast%3DMarusawa%26aufirst%3DH.%26aulast%3DUchida%26aufirst%3DN.%26aulast%3DDaito%26aufirst%3DT.%26aulast%3DKitamura%26aufirst%3DK.%26aulast%3DMuramatsu%26aufirst%3DM.%26aulast%3DOhashi%26aufirst%3DH.%26aulast%3DKiyohara%26aufirst%3DT.%26aulast%3DSuzuki%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DTong%26aufirst%3DS.%26aulast%3DTanaka%26aufirst%3DY.%26aulast%3DMurata%26aufirst%3DK.%26aulast%3DAizaki%26aufirst%3DH.%26aulast%3DWakita%26aufirst%3DT.%26atitle%3DInterleukin-1%2520and%2520Tumor%2520Necrosis%2520Factor-%25CE%25B1%2520Trigger%2520Restriction%2520of%2520Hepatitis%2520B%2520Virus%2520Infection%2520Via%2520a%2520Cytidine%2520Deaminase%2520Activation-Induced%2520Cytidine%2520Deaminase%2520%2528AID%2529%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2013%26volume%3D288%26issue%3D44%26spage%3D31715%26epage%3D31727%26doi%3D10.1074%2Fjbc.M113.501122" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Isorce, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Testoni, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Locatelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fresquet, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivoire, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luangsay, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoulim, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durantel, D.</span></span> <span> </span><span class="NLM_article-title">Antiviral Activity of Various Interferons and Pro-Inflammatory Cytokines in Non-Transformed Cultured Hepatocytes Infected with Hepatitis B Virus</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>130</i></span>,  <span class="NLM_fpage">36</span>– <span class="NLM_lpage">45</span>, <span class="refDoi"> DOI: 10.1016/j.antiviral.2016.03.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=10.1016%2Fj.antiviral.2016.03.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=26971407" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=1%3ACAS%3A528%3ADC%252BC28XltFGlsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2016&pages=36-45&author=N.+Isorceauthor=B.+Testoniauthor=M.+Locatelliauthor=J.+Fresquetauthor=M.+Rivoireauthor=S.+Luangsayauthor=F.+Zoulimauthor=D.+Durantel&title=Antiviral+Activity+of+Various+Interferons+and+Pro-Inflammatory+Cytokines+in+Non-Transformed+Cultured+Hepatocytes+Infected+with+Hepatitis+B+Virus&doi=10.1016%2Fj.antiviral.2016.03.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Antiviral activity of various interferons and pro-inflammatory cytokines in non-transformed cultured hepatocytes infected with hepatitis B virus</span></div><div class="casAuthors">Isorce, Nathalie; Testoni, Barbara; Locatelli, Maelle; Fresquet, Judith; Rivoire, Michel; Luangsay, Souphalone; Zoulim, Fabien; Durantel, David</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">130</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">36-45</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">In HBV-infected patients, therapies with nucleoside analogs or IFNα remain ineffective in eradicating the infection.  Our aim was to re-analyze the anti-HBV activity of a large panel of IFNs and cytokines in vitro using non-transformed cultured hepatocytes infected with HBV, to identify new immune-therapeutic options.  HepaRG cells and primary human hepatocytes were infected with HBV and, when infection was established, treated with various concns. of different IFNs or inflammatory cytokines.  Viral parameters were evaluated by quantifying HBV nucleic acids by qPCR and Southern Blot, and secreted HBV antigens were evaluated using ELISA.  The cytokines tested were type-I IFNs, IFNγ, type-III IFNs, TNFα, IL-6, IL-1β, IL-18 as well as nucleos(t)ide analogs tenofovir and ribavirin.  Cytokines and drugs, with the exception of IL-18 and ribavirin, exhibited a suppressive effect on HBV replication at least as strong as, but often stronger than, IFNα.  The cytokine presenting the highest effect on HBV DNA was IL-1β, which exerted its inhibition within picomolar range.  Importantly, we noticed differential effects on other parameters (HBV RNA, HBeAg, HBsAg) between both IFNs and inflammatory cytokines, thus suggesting different mechanisms of action.  The combination of IL-1β and already used therapies, i.e.  IFNα or tenofovir, demonstrated a stronger or similar anti-HBV activity.  IL-1β was found to have a very potent antiviral effect against HBV in vitro.  HBV was previously shown to promptly inhibit IL-1β prodn. in Kupffer cells.  Strategies aiming at unlocking this inhibition and restoring local prodn. of IL-1β may help to further inhibit HBV replication in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo44bbOm9PIxbVg90H21EOLACvtfcHk0ljVHlApS16_pA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XltFGlsbY%253D&md5=0d741647ca93100b340613059c7d1f3e</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2016.03.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2016.03.008%26sid%3Dliteratum%253Aachs%26aulast%3DIsorce%26aufirst%3DN.%26aulast%3DTestoni%26aufirst%3DB.%26aulast%3DLocatelli%26aufirst%3DM.%26aulast%3DFresquet%26aufirst%3DJ.%26aulast%3DRivoire%26aufirst%3DM.%26aulast%3DLuangsay%26aufirst%3DS.%26aulast%3DZoulim%26aufirst%3DF.%26aulast%3DDurantel%26aufirst%3DD.%26atitle%3DAntiviral%2520Activity%2520of%2520Various%2520Interferons%2520and%2520Pro-Inflammatory%2520Cytokines%2520in%2520Non-Transformed%2520Cultured%2520Hepatocytes%2520Infected%2520with%2520Hepatitis%2520B%2520Virus%26jtitle%3DAntiviral%2520Res.%26date%3D2016%26volume%3D130%26spage%3D36%26epage%3D45%26doi%3D10.1016%2Fj.antiviral.2016.03.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roethle, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McFadden, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hrvatin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hui, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graupe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallagher, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hesselgesser, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duatschek, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tumas, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halcomb, R. L.</span></span> <span> </span><span class="NLM_article-title">Identification and Optimization of Pteridinone Toll-like Receptor 7 (TLR7) Agonists for the Oral Treatment of Viral Hepatitis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">7324</span>– <span class="NLM_lpage">7333</span>, <span class="refDoi"> DOI: 10.1021/jm400815m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400815m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlSjtbfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=7324-7333&issue=18&author=P.+A.+Roethleauthor=R.+M.+McFaddenauthor=H.+Yangauthor=P.+Hrvatinauthor=H.+Huiauthor=M.+Graupeauthor=B.+Gallagherauthor=J.+Chaoauthor=J.+Hesselgesserauthor=P.+Duatschekauthor=J.+Zhengauthor=B.+Luauthor=D.+B.+Tumasauthor=J.+Perryauthor=R.+L.+Halcomb&title=Identification+and+Optimization+of+Pteridinone+Toll-like+Receptor+7+%28TLR7%29+Agonists+for+the+Oral+Treatment+of+Viral+Hepatitis&doi=10.1021%2Fjm400815m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and Optimization of Pteridinone Toll-like Receptor 7 (TLR7) Agonists for the Oral Treatment of Viral Hepatitis</span></div><div class="casAuthors">Roethle, Paul A.; McFadden, Ryan M.; Yang, Hong; Hrvatin, Paul; Hui, Hon; Graupe, Michael; Gallagher, Brian; Chao, Jessica; Hesselgesser, Joseph; Duatschek, Paul; Zheng, Jim; Lu, Bing; Tumas, Daniel B.; Perry, Jason; Halcomb, Randall L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">7324-7333</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Pteridinone-based Toll-like receptor 7 (TLR7) agonists were identified as potent and selective alternatives to the previously reported adenine-based agonists, leading to the discovery of GS-9620 (I).  Analogs were optimized for the immunomodulatory activity and selectivity vs. other TLRs, based on differential induction of key cytokines including interferon α (IFN-α) and tumor necrosis factor α (TNF-α).  In addn., physicochem. properties were adjusted to achieve desirable in vivo pharmacokinetic and pharmacodynamic properties.  GS-9620 is currently in clin. evaluation for the treatment of chronic hepatitis B (HBV) infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGog2wrWq68pK7Vg90H21EOLACvtfcHk0ljVHlApS16_pA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlSjtbfL&md5=753aa20b0d0f9b16eb3a1d205fbe0a30</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Fjm400815m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400815m%26sid%3Dliteratum%253Aachs%26aulast%3DRoethle%26aufirst%3DP.%2BA.%26aulast%3DMcFadden%26aufirst%3DR.%2BM.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DHrvatin%26aufirst%3DP.%26aulast%3DHui%26aufirst%3DH.%26aulast%3DGraupe%26aufirst%3DM.%26aulast%3DGallagher%26aufirst%3DB.%26aulast%3DChao%26aufirst%3DJ.%26aulast%3DHesselgesser%26aufirst%3DJ.%26aulast%3DDuatschek%26aufirst%3DP.%26aulast%3DZheng%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DB.%26aulast%3DTumas%26aufirst%3DD.%2BB.%26aulast%3DPerry%26aufirst%3DJ.%26aulast%3DHalcomb%26aufirst%3DR.%2BL.%26atitle%3DIdentification%2520and%2520Optimization%2520of%2520Pteridinone%2520Toll-like%2520Receptor%25207%2520%2528TLR7%2529%2520Agonists%2520for%2520the%2520Oral%2520Treatment%2520of%2520Viral%2520Hepatitis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26issue%3D18%26spage%3D7324%26epage%3D7333%26doi%3D10.1021%2Fjm400815m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tanji, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohto, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shibata, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyake, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimizu, T.</span></span> <span> </span><span class="NLM_article-title">Structural Reorganization of the Toll-Like Receptor 8 Dimer Induced by Agonistic Ligands</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>339</i></span> (<span class="NLM_issue">6126</span>),  <span class="NLM_fpage">1426</span>– <span class="NLM_lpage">1429</span>, <span class="refDoi"> DOI: 10.1126/science.1229159</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=10.1126%2Fscience.1229159" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=23520111" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=1%3ACAS%3A528%3ADC%252BC3sXktF2qsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=339&publication_year=2013&pages=1426-1429&issue=6126&author=H.+Tanjiauthor=U.+Ohtoauthor=T.+Shibataauthor=K.+Miyakeauthor=T.+Shimizu&title=Structural+Reorganization+of+the+Toll-Like+Receptor+8+Dimer+Induced+by+Agonistic+Ligands&doi=10.1126%2Fscience.1229159"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Reorganization of the Toll-Like Receptor 8 Dimer Induced by Agonistic Ligands</span></div><div class="casAuthors">Tanji, Hiromi; Ohto, Umeharu; Shibata, Takuma; Miyake, Kensuke; Shimizu, Toshiyuki</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">339</span>
        (<span class="NLM_cas:issue">6126</span>),
    <span class="NLM_cas:pages">1426-1429</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Toll-like receptor 7 (TLR7) and TLR8 recognize single-stranded RNA and initiate innate immune responses.  Several synthetic agonists of TLR7-TLR8 display novel therapeutic potential; however, the mol. basis for ligand recognition and activation of signaling by TLR7 or TLR8 is largely unknown.  In this study, the crystal structures of unliganded and ligand-induced activated human TLR8 dimers were elucidated.  Ligand recognition was mediated by a dimerization interface formed by two protomers.  Upon ligand stimulation, the TLR8 dimer was reorganized such that the two C termini were brought into proximity.  The loop between leucine-rich repeat 14 (LRR14) and LRR15 was cleaved; however, the N- and C-terminal halves remained assocd. and contributed to ligand recognition and dimerization.  Thus, ligand binding induces reorganization of the TLR8 dimer, which enables downstream signaling processes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzF-H0sxwN0rVg90H21EOLACvtfcHk0ljVHlApS16_pA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXktF2qsr4%253D&md5=13b8f32cd70dc59890820d03e88d62ab</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1126%2Fscience.1229159&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1229159%26sid%3Dliteratum%253Aachs%26aulast%3DTanji%26aufirst%3DH.%26aulast%3DOhto%26aufirst%3DU.%26aulast%3DShibata%26aufirst%3DT.%26aulast%3DMiyake%26aufirst%3DK.%26aulast%3DShimizu%26aufirst%3DT.%26atitle%3DStructural%2520Reorganization%2520of%2520the%2520Toll-Like%2520Receptor%25208%2520Dimer%2520Induced%2520by%2520Agonistic%2520Ligands%26jtitle%3DScience%26date%3D2013%26volume%3D339%26issue%3D6126%26spage%3D1426%26epage%3D1429%26doi%3D10.1126%2Fscience.1229159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kokatla, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salunke, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sil, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balakrishna, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malladi, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">David, S. A.</span></span> <span> </span><span class="NLM_article-title">Toll-like Receptor-8 Agonistic Activities in C2, C4, and C8 Modified Thiazolo[4,5-c]quinolines</span>. <i>Org. Biomol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1179</span>– <span class="NLM_lpage">1198</span>, <span class="refDoi"> DOI: 10.1039/c2ob26705e</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=10.1039%2Fc2ob26705e" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=23314908" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVCnt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2013&pages=1179-1198&author=H.+P.+Kokatlaauthor=E.+Yooauthor=D.+B.+Salunkeauthor=D.+Silauthor=C.+F.+Ngauthor=R.+Balakrishnaauthor=S.+S.+Malladiauthor=L.+M.+Foxauthor=S.+A.+David&title=Toll-like+Receptor-8+Agonistic+Activities+in+C2%2C+C4%2C+and+C8+Modified+Thiazolo%5B4%2C5-c%5Dquinolines&doi=10.1039%2Fc2ob26705e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Toll-like receptor-8 agonistic activities in C2, C4, and C8 modified thiazolo[4,5-c]quinolines</span></div><div class="casAuthors">Kokatla, Hari Prasad; Yoo, Euna; Salunke, Deepak B.; Sil, Diptesh; Ng, Cameron F.; Balakrishna, Rajalakshmi; Malladi, Subbalakshmi S.; Fox, Lauren M.; David, Sunil A.</div><div class="citationInfo"><span class="NLM_cas:title">Organic & Biomolecular Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1179-1198</span>CODEN:
                <span class="NLM_cas:coden">OBCRAK</span>;
        ISSN:<span class="NLM_cas:issn">1477-0520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Toll-like receptor (TLR)-8 agonists typified by the 2-alkylthiazolo[4,5-c]quinolin-4-amine (CL075) chemotype are uniquely potent in activating adaptive immune responses by inducing robust prodn. of T helper 1-polarizing cytokines, suggesting that TLR8-active compds. could be promising candidate vaccine adjuvants, esp. for neonatal vaccines.  Alkylthiazoloquinolines with Me, Et, Pr and Bu groups at C2 displayed comparable TLR8-agonistic potencies; activity diminished precipitously in the C2-pentyl compd., and higher homologues were inactive.  The C2-Bu compd. was unique in possessing substantial TLR7-agonistic activity.  Analogs with branched alkyl groups at C2 displayed poor tolerance of terminal steric bulk.  Virtually all modifications at C8 led to abrogation of agonistic activity.  Alkylation on the C4-amine was not tolerated, whereas N-acyl analogs with short acyl groups (other than acetyl) retained TLR8 agonistic activity, but were substantially less water-sol.  Immunization in rabbits with a model subunit antigen adjuvanted with the lead C2-Bu thiazoloquinoline showed enhancements of antigen-specific antibody titers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYAWu83GzZRLVg90H21EOLACvtfcHk0lhe1i6FUsVQTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVCnt7o%253D&md5=50ab5984b3920a890201960880e9003e</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1039%2Fc2ob26705e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc2ob26705e%26sid%3Dliteratum%253Aachs%26aulast%3DKokatla%26aufirst%3DH.%2BP.%26aulast%3DYoo%26aufirst%3DE.%26aulast%3DSalunke%26aufirst%3DD.%2BB.%26aulast%3DSil%26aufirst%3DD.%26aulast%3DNg%26aufirst%3DC.%2BF.%26aulast%3DBalakrishna%26aufirst%3DR.%26aulast%3DMalladi%26aufirst%3DS.%2BS.%26aulast%3DFox%26aufirst%3DL.%2BM.%26aulast%3DDavid%26aufirst%3DS.%2BA.%26atitle%3DToll-like%2520Receptor-8%2520Agonistic%2520Activities%2520in%2520C2%252C%2520C4%252C%2520and%2520C8%2520Modified%2520Thiazolo%255B4%252C5-c%255Dquinolines%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2013%26volume%3D11%26spage%3D1179%26epage%3D1198%26doi%3D10.1039%2Fc2ob26705e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miller, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerster, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owens, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slade, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomai, M. A.</span></span> <span> </span><span class="NLM_article-title">Imiquimod Applied Topically: A Novel Immune Response Modifier and New Class of Drug</span>. <i>Int. J. Immunopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">14</span>, <span class="refDoi"> DOI: 10.1016/S0192-0561(98)00068-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=10.1016%2FS0192-0561%2898%2900068-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=10411278" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=1%3ACAS%3A528%3ADyaK1MXitFyqtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=1999&pages=1-14&issue=1&author=R.+L.+Millerauthor=J.+F.+Gersterauthor=M.+L.+Owensauthor=H.+B.+Sladeauthor=M.+A.+Tomai&title=Imiquimod+Applied+Topically%3A+A+Novel+Immune+Response+Modifier+and+New+Class+of+Drug&doi=10.1016%2FS0192-0561%2898%2900068-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Imiquimod applied topically: a novel immune response modifier and new class of drug</span></div><div class="casAuthors">Miller, R. L.; Gerster, J. F.; Owens, M. L.; Slade, H. B.; Tomai, M. A.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Immunopharmacology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-14</span>CODEN:
                <span class="NLM_cas:coden">IJIMDS</span>;
        ISSN:<span class="NLM_cas:issn">0192-0561</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review with 70 refs.  Imiquimod (S-26308, R-837) (1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4 amine), an immune response modifier, demonstrates potent antiviral and antitumor activity in animal models (see structure in Fig. 1).  The drug exhibits no direct antiviral or antiproliferative activity when tested in a no. of cell culture systems.  Imiquimod's activity was discovered while screening for anti-herpes virus activity.  One of the first analogs in the series, S-25059 was tested in the early 1980's and due to slight toxicity, caused slightly reduced herpes cytopathol. in Vero cell cultures.  Follow-up testing in herpes infected guinea pigs showed complete protection toward lesion development.  Activity of these drugs results primarily from interferon alpha (IFN-α) induction and other cytokine induction.  At least part of the cytokine induction is mediated through NF-κB activation.  These cytokines stimulate several other aspects of the innate immune response.  In addn., imiquimod stimulates acquired immunity, in particular the cellular arm which is important for control of viral infections and various tumors.  This effect is mediated by drug induced IFN-α and Interleukin-12 (IL-12) and IFN-γ induced by these cytokines.  Imiquimod is expected to be effective where exogenous IFN-α has shown utility and where enhancement of cell-mediated immunity is needed.  The following is a brief review of the preclin. pharmacol. of imiquimod and the clin. results of genital wart trials.  The mechanism of action of topically applied imiquimod will likely lead to benefits in several other chronic virus infections and tumors of the skin.  Two other reviews on imiquimod that focus mainly on the clin. results have been published (Beutner & Geisse, 1997; Slade, Owens, Tomai & Miller, 1998).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSom1Nk4ulLrVg90H21EOLACvtfcHk0lhe1i6FUsVQTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXitFyqtLk%253D&md5=b4b47faaa21fb4eb2e530ca2bcd6d442</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2FS0192-0561%2898%2900068-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0192-0561%252898%252900068-X%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DR.%2BL.%26aulast%3DGerster%26aufirst%3DJ.%2BF.%26aulast%3DOwens%26aufirst%3DM.%2BL.%26aulast%3DSlade%26aufirst%3DH.%2BB.%26aulast%3DTomai%26aufirst%3DM.%2BA.%26atitle%3DImiquimod%2520Applied%2520Topically%253A%2520A%2520Novel%2520Immune%2520Response%2520Modifier%2520and%2520New%2520Class%2520of%2520Drug%26jtitle%3DInt.%2520J.%2520Immunopharmacol.%26date%3D1999%26volume%3D21%26issue%3D1%26spage%3D1%26epage%3D14%26doi%3D10.1016%2FS0192-0561%2898%2900068-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dietsch, G. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthews, M.-A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghanekar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inokuma, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maino, V. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henderson, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howbert, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Disis, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hershberg, R. M.</span></span> <span> </span><span class="NLM_article-title">VTX-2337 Is a Novel TLR8 Agonist That Activates NK Cells and Augments ADCC</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">499</span>– <span class="NLM_lpage">509</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-11-1625</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=10.1158%2F1078-0432.CCR-11-1625" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=22128302" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVGqsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=499-509&issue=2&author=H.+Luauthor=G.+N.+Dietschauthor=M.-A.+H.+Matthewsauthor=Y.+Yangauthor=S.+Ghanekarauthor=M.+Inokumaauthor=M.+Suniauthor=V.+C.+Mainoauthor=K.+E.+Hendersonauthor=J.+J.+Howbertauthor=M.+L.+Disisauthor=R.+M.+Hershberg&title=VTX-2337+Is+a+Novel+TLR8+Agonist+That+Activates+NK+Cells+and+Augments+ADCC&doi=10.1158%2F1078-0432.CCR-11-1625"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">VTX-2337 Is a Novel TLR8 Agonist That Activates NK Cells and Augments ADCC</span></div><div class="casAuthors">Lu, Hailing; Dietsch, Gregory N.; Matthews, Maura-Ann H.; Yang, Yi; Ghanekar, Smita; Inokuma, Margaret; Suni, Maria; Maino, Vernon C.; Henderson, Katherine E.; Howbert, James Jeffry; Disis, Mary L.; Hershberg, Robert M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">499-509</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The study's aim was to characterize VTX-2337, a novel Toll-like receptor (TLR) 8 agonist in clin. development, and investigate its potential to improve monoclonal antibody-based immunotherapy that includes the activation of natural killer (NK) cells.  HEK-TLR transfectants were used to compare the selectivity and potency of VTX-2337, imiquimod, CpG ODN2006, and CL075.  The ability of VTX-2337 to induce cytokine and chemokine prodn. from human peripheral blood mononuclear cells (PBMC) and activation of specific immune cell subsets was examd.  The potential for VTX-2337 to activate NK cell activity through direct and indirect mechanisms was also investigated.  Finally, we tested the potential for VTX-2337 to augment antibody-dependent cell-mediated cytotoxicity (ADCC), esp. in individuals with low-affinity FcγR3A single-nucleotide polymorphism (SNP).  VTX-2337 selectively activates TLR8 with an EC50 of about 100 nmol/L and stimulates prodn. of TNFα and interleukin (IL)-12 from monocytes and myeloid dendritic cells (mDC).  VTX-2337 stimulates IFNγ prodn. from NK cells and increases the cytotoxicity of NK cells against K562 and ADCC by rituximab and trastuzumab.  Effects of VTX-2337 on NK cells were, in part, from direct activation as increased IFNγ prodn. and cytotoxic activity were seen with purified NK cells.  Finally, VTX-2337 augments ADCC by rituximab in PBMCs with different FcγR3A genotypes (V/V, V/F, and F/F at position 158).  VTX-2337 is a novel small-mol. TLR8 agonist that activates monocytes, DCs, and NK cells.  Through the activation of NK cells, it has the potential to augment the effectiveness of monoclonal antibody treatments where a polymorphism in FcγR3A limits clin. efficacy.  Clin Cancer Res; 18(2); 499-509.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQFakqLqEzJLVg90H21EOLACvtfcHk0lhe1i6FUsVQTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVGqsrY%253D&md5=73e1fd4bfd0b935cc4f917979e78a1f0</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-1625&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-1625%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DH.%26aulast%3DDietsch%26aufirst%3DG.%2BN.%26aulast%3DMatthews%26aufirst%3DM.-A.%2BH.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DGhanekar%26aufirst%3DS.%26aulast%3DInokuma%26aufirst%3DM.%26aulast%3DSuni%26aufirst%3DM.%26aulast%3DMaino%26aufirst%3DV.%2BC.%26aulast%3DHenderson%26aufirst%3DK.%2BE.%26aulast%3DHowbert%26aufirst%3DJ.%2BJ.%26aulast%3DDisis%26aufirst%3DM.%2BL.%26aulast%3DHershberg%26aufirst%3DR.%2BM.%26atitle%3DVTX-2337%2520Is%2520a%2520Novel%2520TLR8%2520Agonist%2520That%2520Activates%2520NK%2520Cells%2520and%2520Augments%2520ADCC%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26issue%3D2%26spage%3D499%26epage%3D509%26doi%3D10.1158%2F1078-0432.CCR-11-1625" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beesu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caruso, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salyer, A. C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khetani, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sil, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weerasinghe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanji, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohto, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimizu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">David, S. A.</span></span> <span> </span><span class="NLM_article-title">Structure-Based Design of Human TLR8-Specific Agonists with Augmented Potency and Adjuvanticity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">7833</span>– <span class="NLM_lpage">7849</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01087</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01087" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVyhu7fN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=7833-7849&author=M.+Beesuauthor=G.+Carusoauthor=A.+C.+D.+Salyerauthor=K.+K.+Khetaniauthor=D.+Silauthor=M.+Weerasingheauthor=H.+Tanjiauthor=U.+Ohtoauthor=T.+Shimizuauthor=S.+A.+David&title=Structure-Based+Design+of+Human+TLR8-Specific+Agonists+with+Augmented+Potency+and+Adjuvanticity&doi=10.1021%2Facs.jmedchem.5b01087"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Design of Human TLR8-Specific Agonists with Augmented Potency and Adjuvanticity</span></div><div class="casAuthors">Beesu, Mallesh; Caruso, Giuseppe; Salyer, Alex C. D.; Khetani, Karishma K.; Sil, Diptesh; Weerasinghe, Mihiri; Tanji, Hiromi; Ohto, Umeharu; Shimizu, Toshiyuki; David, Sunil A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7833-7849</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Human Toll-like receptor 8 (hTLR8) is expressed in myeloid dendritic cells, monocytes, and monocyte-derived dendritic cells.  Engagement by TLR8 agonists evokes a distinct cytokine profile which favors the development of type 1 helper T cells.  Crystal structures of the ectodomain of hTLR8 cocrystd. with two regioisomers of a dual TLR7/8-agonistic N1-substituted imidazoquinolines showed subtle differences in their interactions in the binding site of hTLR8.  The authors hypothesized that the potency of a previously reported best-in-class pure TLR8 agonist, 3-pentylquinoline-2-amine, could be further enhanced by "designing in" functional groups that would mimic key intermol. interactions that the authors had obsd. in the crystal structures.  The authors performed a focused exploration of decorating the quinoline core with alkylamino groups at all possible positions.  These studies have led to the identification of a novel TLR8 agonist that was ∼20-fold more potent than the parent compd. and displays prominent adjuvantic activity in a rabbit model of immunization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_vD5opmBVbrVg90H21EOLACvtfcHk0liqZ3AH8EF3Rg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVyhu7fN&md5=799d7d25cd9819e46b9a1086025587e1</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01087&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01087%26sid%3Dliteratum%253Aachs%26aulast%3DBeesu%26aufirst%3DM.%26aulast%3DCaruso%26aufirst%3DG.%26aulast%3DSalyer%26aufirst%3DA.%2BC.%2BD.%26aulast%3DKhetani%26aufirst%3DK.%2BK.%26aulast%3DSil%26aufirst%3DD.%26aulast%3DWeerasinghe%26aufirst%3DM.%26aulast%3DTanji%26aufirst%3DH.%26aulast%3DOhto%26aufirst%3DU.%26aulast%3DShimizu%26aufirst%3DT.%26aulast%3DDavid%26aufirst%3DS.%2BA.%26atitle%3DStructure-Based%2520Design%2520of%2520Human%2520TLR8-Specific%2520Agonists%2520with%2520Augmented%2520Potency%2520and%2520Adjuvanticity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D7833%26epage%3D7849%26doi%3D10.1021%2Facs.jmedchem.5b01087" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beesu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salyer, A. C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trautman, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">David, S. A.</span></span> <span> </span><span class="NLM_article-title">Human Toll-like Receptor (TLR) 8-Specific Agonistic Activity in Substituted Pyrimidine-2,4-diamines</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">8082</span>– <span class="NLM_lpage">8093</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00872</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00872" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhtlamt7vI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=8082-8093&author=M.+Beesuauthor=A.+C.+D.+Salyerauthor=K.+L.+Trautmanauthor=J.+K.+Hillauthor=S.+A.+David&title=Human+Toll-like+Receptor+%28TLR%29+8-Specific+Agonistic+Activity+in+Substituted+Pyrimidine-2%2C4-diamines&doi=10.1021%2Facs.jmedchem.6b00872"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Human Toll-like Receptor (TLR) 8-Specific Agonistic Activity in Substituted Pyrimidine-2,4-diamines</span></div><div class="casAuthors">Beesu, Mallesh; Salyer, Alex C. D.; Trautman, Kathryn L.; Hill, Justin K.; David, Sunil A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">8082-8093</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Activation of human toll-like receptor-8 (TLR8) evokes a distinct cytokine profile favoring the generation of Type 1 helper T cells.  A multiplexed high-throughput screen had led to the identification of N4-butyl-5-iodo-6-methylpyrimidine-2,4-diamine as a pure TLR8 agonist, and a detailed SAR study of this chemotype was undertaken.  A Bu substituent at N4 was optimal, and replacement of the 5-iodo group with chloro, bromo, or fluoro groups led to losses in potency, as did the introduction of arom. bulk.  Drawing from the previous structure-based design, several 5-alkylamino derivs. were evaluated.  Significant enhancement of potency was achieved in 5-(4-aminobutyl)-N4-butyl-6-methylpyrimidine-2,4-diamine.  This compd. potently induced Th1-biasing IFN-γ and IL-12 in human blood, but lower levels of the proinflammatory cytokines IL-1β, IL-6 and IL-8.  These results suggest that the inflammatory and reactogenic propensities of this compd. could be considerably more favorable than other TLR8 agonists under evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDCMECaTCj-bVg90H21EOLACvtfcHk0liqZ3AH8EF3Rg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhtlamt7vI&md5=3632c71b22857ff6f3561dc372b5e52f</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00872&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00872%26sid%3Dliteratum%253Aachs%26aulast%3DBeesu%26aufirst%3DM.%26aulast%3DSalyer%26aufirst%3DA.%2BC.%2BD.%26aulast%3DTrautman%26aufirst%3DK.%2BL.%26aulast%3DHill%26aufirst%3DJ.%2BK.%26aulast%3DDavid%26aufirst%3DS.%2BA.%26atitle%3DHuman%2520Toll-like%2520Receptor%2520%2528TLR%2529%25208-Specific%2520Agonistic%2520Activity%2520in%2520Substituted%2520Pyrimidine-2%252C4-diamines%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D8082%26epage%3D8093%26doi%3D10.1021%2Facs.jmedchem.6b00872" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McGowan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herschke, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pauwels, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoops, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Last, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pieters, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scholliers, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thoné, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Schoubroeck, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Pooter, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mostmans, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khamlichi, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Embrechts, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhuyvetter, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smyej, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnoult, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borghys, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fanning, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vlach, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raboisson, P.</span></span> <span> </span><span class="NLM_article-title">Novel Pyrimidine Toll-Like Receptor 7 and 8 Dual Agonists to Treat Hepatitis B Virus</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">7936</span>– <span class="NLM_lpage">7949</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00747</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00747" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhtlamt7vF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=7936-7949&author=D.+McGowanauthor=F.+Herschkeauthor=F.+Pauwelsauthor=B.+Stoopsauthor=S.+Lastauthor=S.+Pietersauthor=A.+Scholliersauthor=T.+Thon%C3%A9author=B.+Van+Schoubroeckauthor=D.+D.+De+Pooterauthor=W.+Mostmansauthor=M.+D.+Khamlichiauthor=W.+Embrechtsauthor=D.+Dhuyvetterauthor=I.+Smyejauthor=E.+Arnoultauthor=S.+Deminauthor=H.+Borghysauthor=G.+Fanningauthor=J.+Vlachauthor=P.+Raboisson&title=Novel+Pyrimidine+Toll-Like+Receptor+7+and+8+Dual+Agonists+to+Treat+Hepatitis+B+Virus&doi=10.1021%2Facs.jmedchem.6b00747"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Pyrimidine Toll-like Receptor 7 and 8 Dual Agonists to Treat Hepatitis B Virus</span></div><div class="casAuthors">McGowan, David; Herschke, Florence; Pauwels, Frederik; Stoops, Bart; Last, Stefaan; Pieters, Serge; Scholliers, Annick; Thone, Tine; Van Schoubroeck, Bertrand; De Pooter, Dorien; Mostmans, Wendy; Khamlichi, Mourad Daoubi; Embrechts, Werner; Dhuyvetter, Deborah; Smyej, Ilham; Arnoult, Eric; Demin, Samuel; Borghys, Herman; Fanning, Gregory; Vlach, Jaromir; Raboisson, Pierre</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7936-7949</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Toll-like receptor (TLR) 7 and 8 agonists can potentially be used in the treatment of viral infections and are particularly promising for chronic hepatitis B virus (HBV) infection.  An internal screening effort identified a pyrimidine Toll-like receptor 7 and 8 dual agonist.  This provided a novel alternative over the previously reported adenine and pteridone type of agonists.  Structure-activity relationship, lead optimization, in silico docking, pharmacokinetics, and demonstration of ex vivo and in vivo cytokine prodn. of the lead compd. are presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-fRW7IJ3nZ7Vg90H21EOLACvtfcHk0liqZ3AH8EF3Rg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhtlamt7vF&md5=f98f5bf04418de548b34463b3ebf2c2e</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00747&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00747%26sid%3Dliteratum%253Aachs%26aulast%3DMcGowan%26aufirst%3DD.%26aulast%3DHerschke%26aufirst%3DF.%26aulast%3DPauwels%26aufirst%3DF.%26aulast%3DStoops%26aufirst%3DB.%26aulast%3DLast%26aufirst%3DS.%26aulast%3DPieters%26aufirst%3DS.%26aulast%3DScholliers%26aufirst%3DA.%26aulast%3DThon%25C3%25A9%26aufirst%3DT.%26aulast%3DVan%2BSchoubroeck%26aufirst%3DB.%26aulast%3DDe%2BPooter%26aufirst%3DD.%2BD.%26aulast%3DMostmans%26aufirst%3DW.%26aulast%3DKhamlichi%26aufirst%3DM.%2BD.%26aulast%3DEmbrechts%26aufirst%3DW.%26aulast%3DDhuyvetter%26aufirst%3DD.%26aulast%3DSmyej%26aufirst%3DI.%26aulast%3DArnoult%26aufirst%3DE.%26aulast%3DDemin%26aufirst%3DS.%26aulast%3DBorghys%26aufirst%3DH.%26aulast%3DFanning%26aufirst%3DG.%26aulast%3DVlach%26aufirst%3DJ.%26aulast%3DRaboisson%26aufirst%3DP.%26atitle%3DNovel%2520Pyrimidine%2520Toll-Like%2520Receptor%25207%2520and%25208%2520Dual%2520Agonists%2520to%2520Treat%2520Hepatitis%2520B%2520Virus%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D7936%26epage%3D7949%26doi%3D10.1021%2Facs.jmedchem.6b00747" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bondy, S.</span>; <span class="NLM_string-name">Chou, C.-H.</span>; <span class="NLM_string-name">Watkins, W. J.</span>; <span class="NLM_string-name">Chong, L. S.</span>; <span class="NLM_string-name">Zhang, J. R.</span>; <span class="NLM_string-name">Mishra, R.</span></span> <span> </span><span class="NLM_article-title">Pyrido(3,2-<i>d</i>)pyrimidines Useful For Treating Viral Infections</span>. WO <span class="NLM_patent">WO2008/077651 A1</span>, <span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=S.+Bondy&author=C.-H.+Chou&author=W.+J.+Watkins&author=L.+S.+Chong&author=J.+R.+Zhang&author=R.+Mishra&title=Pyrido%283%2C2-d%29pyrimidines+Useful+For+Treating+Viral+Infections"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBondy%26aufirst%3DS.%26atitle%3DPyrido%25283%252C2-d%2529pyrimidines%2520Useful%2520For%2520Treating%2520Viral%2520Infections%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Daffis, S.</span>; <span class="NLM_string-name">Balsitis, S.</span>; <span class="NLM_string-name">Chamberlain, J.</span>; <span class="NLM_string-name">Zheng, J.</span>; <span class="NLM_string-name">Santos, R.</span>; <span class="NLM_string-name">Rowe, W.</span>; <span class="NLM_string-name">Ramakrishnan, D.</span>; <span class="NLM_string-name">Pattabiraman, D.</span>; <span class="NLM_string-name">Spurlock, S.</span>; <span class="NLM_string-name">Chu, R.</span>; <span class="NLM_string-name">Kang, D.</span>; <span class="NLM_string-name">Mish, M.</span>; <span class="NLM_string-name">Ramirez, R.</span>; <span class="NLM_string-name">Li, L.</span>; <span class="NLM_string-name">Li, B.</span>; <span class="NLM_string-name">Ma, S.</span>; <span class="NLM_string-name">Hung, M.</span>; <span class="NLM_string-name">Voitenleitner, C.</span>; <span class="NLM_string-name">Yon, C.</span>; <span class="NLM_string-name">Suresh, M.</span>; <span class="NLM_string-name">Menne, S.</span>; <span class="NLM_string-name">Cote, P.</span>; <span class="NLM_string-name">Delaney, W. E.,  IV</span>; <span class="NLM_string-name">Mackman, R.</span>; <span class="NLM_string-name">Fletcher, S. P.</span></span> <span> </span><span class="NLM_article-title">Toll-Like Receptor 8 Agonist GS-9688 Induces Sustained Efficacy in the Woodchuck Model of Chronic Hepatitis B</span>.  <i>Hepatology</i> <span class="NLM_year" style="font-weight: bold;">2020</span> <span class="refDoi"> DOI: 10.1002/hep.31255</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=10.1002%2Fhep.31255" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=32246499" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=S.+Daffis&author=S.+Balsitis&author=J.+Chamberlain&author=J.+Zheng&author=R.+Santos&author=W.+Rowe&author=D.+Ramakrishnan&author=D.+Pattabiraman&author=S.+Spurlock&author=R.+Chu&author=D.+Kang&author=M.+Mish&author=R.+Ramirez&author=L.+Li&author=B.+Li&author=S.+Ma&author=M.+Hung&author=C.+Voitenleitner&author=C.+Yon&author=M.+Suresh&author=S.+Menne&author=P.+Cote&author=W.+E.+Delaney&author=R.+Mackman&author=S.+P.+Fletcher&title=Toll-Like+Receptor+8+Agonist+GS-9688+Induces+Sustained+Efficacy+in+the+Woodchuck+Model+of+Chronic+Hepatitis+B&doi=10.1002%2Fhep.31255"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1002%2Fhep.31255&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.31255%26sid%3Dliteratum%253Aachs%26aulast%3DDaffis%26aufirst%3DS.%26atitle%3DToll-Like%2520Receptor%25208%2520Agonist%2520GS-9688%2520Induces%2520Sustained%2520Efficacy%2520in%2520the%2520Woodchuck%2520Model%2520of%2520Chronic%2520Hepatitis%2520B%26jtitle%3DHepatology%26date%3D2020%26doi%3D10.1002%2Fhep.31255" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohto, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shibata, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taoka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamauchi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shukla, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">David, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isobe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyake, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimizu, T.</span></span> <span> </span><span class="NLM_article-title">Structural Analyses of Toll-like Receptor 7 Reveal Detailed RNA Sequence Specificity and Recognition Mechanism of Agonistic Ligands</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">3371</span>– <span class="NLM_lpage">3381</span>, <span class="refDoi"> DOI: 10.1016/j.celrep.2018.11.081</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=10.1016%2Fj.celrep.2018.11.081" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=30566863" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFKhsbvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2018&pages=3371-3381&author=Z.+Zhangauthor=U.+Ohtoauthor=T.+Shibataauthor=M.+Taokaauthor=Y.+Yamauchiauthor=R.+Satoauthor=N.+M.+Shuklaauthor=S.+A.+Davidauthor=T.+Isobeauthor=K.+Miyakeauthor=T.+Shimizu&title=Structural+Analyses+of+Toll-like+Receptor+7+Reveal+Detailed+RNA+Sequence+Specificity+and+Recognition+Mechanism+of+Agonistic+Ligands&doi=10.1016%2Fj.celrep.2018.11.081"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Analyses of Toll-like Receptor 7 Reveal Detailed RNA Sequence Specificity and Recognition Mechanism of Agonistic Ligands</span></div><div class="casAuthors">Zhang, Zhikuan; Ohto, Umeharu; Shibata, Takuma; Taoka, Masato; Yamauchi, Yoshio; Sato, Ryota; Shukla, Nikunj M.; David, Sunil A.; Isobe, Toshiaki; Miyake, Kensuke; Shimizu, Toshiyuki</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3371-3381.e5</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Toll-like receptor 7 (TLR7) is an innate immune receptor for single-stranded RNA (ssRNA) and has important roles in infectious diseases.  We previously reported that TLR7 shows synergistic activation in response to two ligands, guanosine and ssRNA.  However, the specific ssRNA sequence preference, detailed recognition mode of TLR7 and its ligand, and mol. determinants of TLR7 and TLR8 selectivity remain unknown.  Here, we report on TLR7 from a large-scale crystallog. study combined with a multifaceted approach.  We reveal that successive uridine-contg. ssRNAs fully or moderately bind TLR7, whereas single uridine-contg. ssRNAs have reduced affinities.  We also reveal the detailed relationships between the chem. structures of ligands and their binding to TLR7.  We demonstrate that an engineered TLR8 mutant alters its responsiveness to TLR7-specific ligands.  Finally, we identify guanosine 2',3'-cyclic phosphate (2',3'-cGMP) as a possible endogenous ligand for TLR7 with greater affinity than guanosine.  The abundant structural information will facilitate future development of treatments targeting TLR7.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSfIvVPXG7NbVg90H21EOLACvtfcHk0ljE2IWpJbZSNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFKhsbvK&md5=2b8c37cd45a96e9298540bd87fb77faa</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2018.11.081&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2018.11.081%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DOhto%26aufirst%3DU.%26aulast%3DShibata%26aufirst%3DT.%26aulast%3DTaoka%26aufirst%3DM.%26aulast%3DYamauchi%26aufirst%3DY.%26aulast%3DSato%26aufirst%3DR.%26aulast%3DShukla%26aufirst%3DN.%2BM.%26aulast%3DDavid%26aufirst%3DS.%2BA.%26aulast%3DIsobe%26aufirst%3DT.%26aulast%3DMiyake%26aufirst%3DK.%26aulast%3DShimizu%26aufirst%3DT.%26atitle%3DStructural%2520Analyses%2520of%2520Toll-like%2520Receptor%25207%2520Reveal%2520Detailed%2520RNA%2520Sequence%2520Specificity%2520and%2520Recognition%2520Mechanism%2520of%2520Agonistic%2520Ligands%26jtitle%3DCell%2520Rep.%26date%3D2018%26volume%3D25%26spage%3D3371%26epage%3D3381%26doi%3D10.1016%2Fj.celrep.2018.11.081" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Embrechts, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herschke, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pauwels, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoops, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Last, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pieters, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pande, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pille, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amssoms, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smyej, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhuyvetter, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scholliers, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mostmans, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Dijck, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Schoubroeck, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thone, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Pooter, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fanning, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jonckers, T. H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horton, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raboisson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGowan, D.</span></span> <span> </span><span class="NLM_article-title">2,4-Diaminoquinazolines as Dual Toll-like Receptor (TLR) 7/8 Modulators for the Treatment of Hepatitis B Virus</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">6236</span>– <span class="NLM_lpage">6246</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00643</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00643" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1CqurvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=6236-6246&author=W.+Embrechtsauthor=F.+Herschkeauthor=F.+Pauwelsauthor=B.+Stoopsauthor=S.+Lastauthor=S.+Pietersauthor=V.+Pandeauthor=G.+Pilleauthor=K.+Amssomsauthor=I.+Smyejauthor=D.+Dhuyvetterauthor=A.+Scholliersauthor=W.+Mostmansauthor=K.+Van+Dijckauthor=B.+Van+Schoubroeckauthor=T.+Thoneauthor=D.+De+Pooterauthor=G.+Fanningauthor=T.+H.+M.+Jonckersauthor=H.+Hortonauthor=P.+Raboissonauthor=D.+McGowan&title=2%2C4-Diaminoquinazolines+as+Dual+Toll-like+Receptor+%28TLR%29+7%2F8+Modulators+for+the+Treatment+of+Hepatitis+B+Virus&doi=10.1021%2Facs.jmedchem.8b00643"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">2,4-Diaminoquinazolines as Dual Toll-like Receptor (TLR) 7/8 Modulators for the Treatment of Hepatitis B Virus</span></div><div class="casAuthors">Embrechts, Werner; Herschke, Florence; Pauwels, Frederik; Stoops, Bart; Last, Stefaan; Pieters, Serge; Pande, Vineet; Pille, Geert; Amssoms, Katie; Smyej, Ilham; Dhuyvetter, Deborah; Scholliers, Annick; Mostmans, Wendy; Van Dijck, Kris; Van Schoubroeck, Bertrand; Thone, Tine; De Pooter, Dorien; Fanning, Gregory; Jonckers, Tim H. M.; Horton, Helen; Raboisson, Pierre; McGowan, David</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6236-6246</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel series of 2,4-diaminoquinazolines was identified as potent dual Toll-like receptor (TLR) 7 and 8 agonists with reduced off-target activity.  The stereochem. of the amino alc. was found to influence the TLR7/8 selectivity with the (R) isomer resulting in selective TLR8 agonism.  Lead optimization toward a dual agonist afforded (S)-3-((2-amino-8-fluoroquinazolin-4-yl)amino)hexanol 31 as a potent analog, being structurally different from previously described dual agonists (McGowan J. Med. Chem. 2016, 59, 7936).  Pharmacokinetic and pharmacodynamic (PK/PD) studies revealed the desired high first pass profile aimed at limiting systemic cytokine activation.  In vivo pharmacodynamic studies with lead compd. 31 demonstrated prodn. of cytokines consistent with TLR7/8 activation in mice and cynomolgus monkeys and ex vivo inhibition of hepatitis B virus (HBV).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIZ2UOyVhderVg90H21EOLACvtfcHk0ljE2IWpJbZSNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1CqurvM&md5=7cc741c6b341d318798e26150ce7856c</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00643&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00643%26sid%3Dliteratum%253Aachs%26aulast%3DEmbrechts%26aufirst%3DW.%26aulast%3DHerschke%26aufirst%3DF.%26aulast%3DPauwels%26aufirst%3DF.%26aulast%3DStoops%26aufirst%3DB.%26aulast%3DLast%26aufirst%3DS.%26aulast%3DPieters%26aufirst%3DS.%26aulast%3DPande%26aufirst%3DV.%26aulast%3DPille%26aufirst%3DG.%26aulast%3DAmssoms%26aufirst%3DK.%26aulast%3DSmyej%26aufirst%3DI.%26aulast%3DDhuyvetter%26aufirst%3DD.%26aulast%3DScholliers%26aufirst%3DA.%26aulast%3DMostmans%26aufirst%3DW.%26aulast%3DVan%2BDijck%26aufirst%3DK.%26aulast%3DVan%2BSchoubroeck%26aufirst%3DB.%26aulast%3DThone%26aufirst%3DT.%26aulast%3DDe%2BPooter%26aufirst%3DD.%26aulast%3DFanning%26aufirst%3DG.%26aulast%3DJonckers%26aufirst%3DT.%2BH.%2BM.%26aulast%3DHorton%26aufirst%3DH.%26aulast%3DRaboisson%26aufirst%3DP.%26aulast%3DMcGowan%26aufirst%3DD.%26atitle%3D2%252C4-Diaminoquinazolines%2520as%2520Dual%2520Toll-like%2520Receptor%2520%2528TLR%2529%25207%252F8%2520Modulators%2520for%2520the%2520Treatment%2520of%2520Hepatitis%2520B%2520Virus%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D6236%26epage%3D6246%26doi%3D10.1021%2Facs.jmedchem.8b00643" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span> <i>pKa Calculator</i>; <span class="NLM_publisher-name">ACD Labs</span>, <span class="NLM_year">2020</span>; <a href="https://www.acdlabs.com/products/percepta/predictors/pka/index.php" class="extLink">https://www.acdlabs.com/products/percepta/predictors/pka/index.php</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+pKa+Calculator%3B+ACD+Labs%2C+2020%3B+https%3A%2F%2Fwww.acdlabs.com%2Fproducts%2Fpercepta%2Fpredictors%2Fpka%2Findex.php."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DpKa%2520Calculator%26pub%3DACD%2520Labs%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harwood, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vines, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drew, M. G. B.</span></span> <span> </span><span class="NLM_article-title">Synthesis of Homochiral α-Substituted Alanine Derivatives by Daistereocontrolled Alkylation of (5R)-5-Phenyl-3-methyl-3,4-dehydromorpholinones</span>. <i>Synlett</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>1996</i></span>,  <span class="NLM_fpage">1051</span>– <span class="NLM_lpage">1053</span>, <span class="refDoi"> DOI: 10.1055/s-1996-5682</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=10.1055%2Fs-1996-5682" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1996&publication_year=1996&pages=1051-1053&author=L.+M.+Harwoodauthor=K.+J.+Vinesauthor=M.+G.+B.+Drew&title=Synthesis+of+Homochiral+%CE%B1-Substituted+Alanine+Derivatives+by+Daistereocontrolled+Alkylation+of+%285R%29-5-Phenyl-3-methyl-3%2C4-dehydromorpholinones&doi=10.1055%2Fs-1996-5682"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1055%2Fs-1996-5682&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-1996-5682%26sid%3Dliteratum%253Aachs%26aulast%3DHarwood%26aufirst%3DL.%2BM.%26aulast%3DVines%26aufirst%3DK.%2BJ.%26aulast%3DDrew%26aufirst%3DM.%2BG.%2BB.%26atitle%3DSynthesis%2520of%2520Homochiral%2520%25CE%25B1-Substituted%2520Alanine%2520Derivatives%2520by%2520Daistereocontrolled%2520Alkylation%2520of%2520%25285R%2529-5-Phenyl-3-methyl-3%252C4-dehydromorpholinones%26jtitle%3DSynlett%26date%3D1996%26volume%3D1996%26spage%3D1051%26epage%3D1053%26doi%3D10.1055%2Fs-1996-5682" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Menne, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tumas, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thampi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">AlDeghaither, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baldwin, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellezza, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cote, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halcomb, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fosdick, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daffis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yue, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolfgang, G. H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tennant, B. C.</span></span> <span> </span><span class="NLM_article-title">Sustained Efficacy and Serconversion with the Toll-like Receptor 7 Agonist GS-9620 in the Woodchuck Model of Chronic Hepatitis B</span>. <i>J. Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1237</span>– <span class="NLM_lpage">1245</span>, <span class="refDoi"> DOI: 10.1016/j.jhep.2014.12.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=10.1016%2Fj.jhep.2014.12.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=25559326" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmtFSju74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2015&pages=1237-1245&issue=6&author=S.+Menneauthor=D.+B.+Tumasauthor=K.+H.+Liuauthor=L.+Thampiauthor=D.+AlDeghaitherauthor=B.+H.+Baldwinauthor=C.+A.+Bellezzaauthor=P.+J.+Coteauthor=J.+Zhengauthor=R.+Halcombauthor=A.+Fosdickauthor=S.+P.+Fletcherauthor=S.+Daffisauthor=L.+Liauthor=P.+Yueauthor=G.+H.+I.+Wolfgangauthor=B.+C.+Tennant&title=Sustained+Efficacy+and+Serconversion+with+the+Toll-like+Receptor+7+Agonist+GS-9620+in+the+Woodchuck+Model+of+Chronic+Hepatitis+B&doi=10.1016%2Fj.jhep.2014.12.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Sustained efficacy and seroconversion with the Toll-like receptor 7 agonist GS-9620 in the Woodchuck model of chronic hepatitis B</span></div><div class="casAuthors">Menne, Stephan; Tumas, Daniel B.; Liu, Katherine H.; Thampi, Linta; AlDeghaither, Dalal; Baldwin, Betty H.; Bellezza, Christine A.; Cote, Paul J.; Zheng, Jim; Halcomb, Randall; Fosdick, Abigail; Fletcher, Simon P.; Daffis, Stephane; Li, Li; Yue, Peng; Wolfgang, Grushenka H. I.; Tennant, Bud C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hepatology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1237-1245</span>CODEN:
                <span class="NLM_cas:coden">JOHEEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-8278</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">New therapies for chronic hepatitis B (CHB) are urgently needed since current treatments rarely lead to cure.  We evaluated whether the oral small mol. toll-like receptor (TLR7) agonist GS-9620 could induce durable antiviral efficacy in woodchucks chronically infected with woodchuck hepatitis virus (WHV), a hepadnavirus closely related to human hepatitis B virus (HBV).  After evaluating the pharmacokinetics, pharmacodynamics and tolerability of oral GS-9620 in uninfected woodchucks, adult woodchucks chronically infected with WHV (n = 7 per group) were dosed with GS-9620 or placebo for 4 or 8 wk with different treatment schedules.  GS-9620 treatment induced rapid, marked and sustained redn. in serum viral DNA (mean maximal 6.2 log10 redn.), and hepatic WHV DNA replicative intermediates, WHV cccDNA and WHV RNA, as well as loss of detectable serum WHV surface antigen (WHsAg).  GS-9620 treatment also induced a sustained antibody response against WHsAg in a subset of animals.  Strikingly, treatment reduced the incidence of hepatocellular carcinoma (HCC) from 71% in the placebo group to 8% in GS-9620-treated woodchucks with sustained viral load redn.  GS-9620 treatment was assocd. with reversible increases in serum liver enzymes and thrombocytopenia, and induced intrahepatic CD8+ T cell, NK cell, B cell and interferon response transcriptional signatures.  The data demonstrate that short duration, finite treatment with the oral TLR7 agonist GS-9620 can induce a sustained antiviral response in the woodchuck model of CHB, and support investigation of this compd. as a therapeutic approach to attain a functional cure in CHB patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpH0B6F10zhw7Vg90H21EOLACvtfcHk0lj5qsdD3Q0Xig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmtFSju74%253D&md5=65d5f40b523dfedca5146e0bfbc54baf</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2014.12.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2014.12.026%26sid%3Dliteratum%253Aachs%26aulast%3DMenne%26aufirst%3DS.%26aulast%3DTumas%26aufirst%3DD.%2BB.%26aulast%3DLiu%26aufirst%3DK.%2BH.%26aulast%3DThampi%26aufirst%3DL.%26aulast%3DAlDeghaither%26aufirst%3DD.%26aulast%3DBaldwin%26aufirst%3DB.%2BH.%26aulast%3DBellezza%26aufirst%3DC.%2BA.%26aulast%3DCote%26aufirst%3DP.%2BJ.%26aulast%3DZheng%26aufirst%3DJ.%26aulast%3DHalcomb%26aufirst%3DR.%26aulast%3DFosdick%26aufirst%3DA.%26aulast%3DFletcher%26aufirst%3DS.%2BP.%26aulast%3DDaffis%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DYue%26aufirst%3DP.%26aulast%3DWolfgang%26aufirst%3DG.%2BH.%2BI.%26aulast%3DTennant%26aufirst%3DB.%2BC.%26atitle%3DSustained%2520Efficacy%2520and%2520Serconversion%2520with%2520the%2520Toll-like%2520Receptor%25207%2520Agonist%2520GS-9620%2520in%2520the%2520Woodchuck%2520Model%2520of%2520Chronic%2520Hepatitis%2520B%26jtitle%3DJ.%2520Hepatol.%26date%3D2015%26volume%3D62%26issue%3D6%26spage%3D1237%26epage%3D1245%26doi%3D10.1016%2Fj.jhep.2014.12.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tikad, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akssira, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massip, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Léger, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarry, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guillaumet, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Routier, S.</span></span> <span> </span><span class="NLM_article-title">Regiocontroled S<sub>N</sub>Ar and Palladium Cross-Coupling Reactions of 2,4,7-Trichloropyrido[3,2-<i>d</i>]pyrimidine</span>. <i>Eur. J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>2012</i></span>,  <span class="NLM_fpage">4523</span>– <span class="NLM_lpage">4532</span>, <span class="refDoi"> DOI: 10.1002/ejoc.201200521</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=10.1002%2Fejoc.201200521" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=1%3ACAS%3A528%3ADC%252BC38Xps1Ors70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2012&publication_year=2012&pages=4523-4532&author=A.+Tikadauthor=M.+Akssiraauthor=S.+Massipauthor=J.-M.+L%C3%A9gerauthor=C.+Jarryauthor=G.+Guillaumetauthor=S.+Routier&title=Regiocontroled+SNAr+and+Palladium+Cross-Coupling+Reactions+of+2%2C4%2C7-Trichloropyrido%5B3%2C2-d%5Dpyrimidine&doi=10.1002%2Fejoc.201200521"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Regiocontroled SNAr and Palladium Cross-Coupling Reactions of 2,4,7-Trichloropyrido[3,2-d]pyrimidine</span></div><div class="casAuthors">Tikad, Abdellatif; Akssira, Mohamed; Massip, Stephane; Leger, Jean-Michel; Jarry, Christian; Guillaumet, Gerald; Routier, Sylvain</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">2012</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">4523-4532, S4523/1-S4523/53</span>CODEN:
                <span class="NLM_cas:coden">EJOCFK</span>;
        ISSN:<span class="NLM_cas:issn">1099-0690</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">An efficient and original synthesis of various 2,4,7-trisubstituted pyrido[3,2-d]pyrimidines is reported.  The first access to and the chem. interest of 2,4,7-trichloropyrido[3,2-d]pyrimidine is described.  Double arylations and SNAr reactions occurred selectively at the C4 and C2 positions of 2,4,7-trichloropyrido[3,2-d]pyrimidine.  The reactions at the C7 position were achieved under microwave irradn. in a few minutes.  A one-step synthesis of a 2,4,7-tris(aminated) deriv. was achieved as a highly efficient alternative.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIDfMAffPqqbVg90H21EOLACvtfcHk0lj5qsdD3Q0Xig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xps1Ors70%253D&md5=1fb02978d762657dc5284d74a8483bd9</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1002%2Fejoc.201200521&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fejoc.201200521%26sid%3Dliteratum%253Aachs%26aulast%3DTikad%26aufirst%3DA.%26aulast%3DAkssira%26aufirst%3DM.%26aulast%3DMassip%26aufirst%3DS.%26aulast%3DL%25C3%25A9ger%26aufirst%3DJ.-M.%26aulast%3DJarry%26aufirst%3DC.%26aulast%3DGuillaumet%26aufirst%3DG.%26aulast%3DRoutier%26aufirst%3DS.%26atitle%3DRegiocontroled%2520SNAr%2520and%2520Palladium%2520Cross-Coupling%2520Reactions%2520of%25202%252C4%252C7-Trichloropyrido%255B3%252C2-d%255Dpyrimidine%26jtitle%3DEur.%2520J.%2520Org.%2520Chem.%26date%3D2012%26volume%3D2012%26spage%3D4523%26epage%3D4532%26doi%3D10.1002%2Fejoc.201200521" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Niu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daffis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucifora, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maadadi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salas, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramos, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Livingston, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beran, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garg, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balsitis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durantel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoulim, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delaney, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, S. P.</span></span> <span> </span><span class="NLM_article-title">Toll-like Receptor 7 Agonist GS-9620 Induces Prolonged Inhibition of HBV Via a Type I Interferon-Dependent Mechanism</span>. <i>J. Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">922</span>– <span class="NLM_lpage">931</span>, <span class="refDoi"> DOI: 10.1016/j.jhep.2017.12.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=10.1016%2Fj.jhep.2017.12.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=29247725" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVent7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2018&pages=922-931&author=C.+Niuauthor=L.+Liauthor=S.+Daffisauthor=J.+Luciforaauthor=M.+Bonninauthor=S.+Maadadiauthor=E.+Salasauthor=R.+Chuauthor=H.+Ramosauthor=C.+M.+Livingstonauthor=R.+K.+Beranauthor=A.+V.+Gargauthor=S.+Balsitisauthor=D.+Durantelauthor=F.+Zoulimauthor=W.+E.+Delaneyauthor=S.+P.+Fletcher&title=Toll-like+Receptor+7+Agonist+GS-9620+Induces+Prolonged+Inhibition+of+HBV+Via+a+Type+I+Interferon-Dependent+Mechanism&doi=10.1016%2Fj.jhep.2017.12.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Toll-like receptor 7 agonist GS-9620 induces prolonged inhibition of HBV via a type I interferon-dependent mechanism</span></div><div class="casAuthors">Niu, Congrong; Li, Li; Daffis, Stephane; Lucifora, Julie; Bonnin, Marc; Maadadi, Sarah; Salas, Eduardo; Chu, Ruth; Ramos, Hilario; Livingston, Christine M.; Beran, Rudolf K.; Garg, Abhishek V.; Balsitis, Scott; Durantel, David; Zoulim, Fabien; Delaney, William E., IV; Fletcher, Simon P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hepatology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">922-931</span>CODEN:
                <span class="NLM_cas:coden">JOHEEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-8278</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">GS-9620, an oral agonist of toll-like receptor 7 (TLR7), is in clin. development for the treatment of chronic hepatitis B (CHB).  GS-9620 was previously shown to induce prolonged suppression of serum viral DNA and antigens in the woodchuck and chimpanzee models of CHB.  Herein, we investigated the mol. mechanisms that contribute to the antiviral response to GS-9620 using in vitro models of hepatitis B virus (HBV) infection.  Cryopreserved primary human hepatocytes (PHH) and differentiated HepaRG (dHepaRG) cells were infected with HBV and treated with GS-9620, conditioned media from human peripheral blood mononuclear cells treated with GS-9620 (GS-9620 conditioned media [GS-9620-CM]), or other innate immune stimuli.  The antiviral and transcriptional response to these agents was detd.  GS-9620 had no antiviral activity in HBV-infected PHH, consistent with low level TLR7 mRNA expression in human hepatocytes.  In contrast, GS-9620-CM induced prolonged redn. of HBV DNA, RNA, and antigen levels in PHH and dHepaRG cells via a type I interferon (IFN)-dependent mechanism.  GS-9620-CM did not reduce covalently closed circular DNA (cccDNA) levels in either cell type.  Transcriptional profiling demonstrated that GS-9620-CM strongly induced various HBV restriction factors - although not APOBEC3A or the Smc5/6 complex - and indicated that established HBV infection does not modulate innate immune sensing or signaling in cryopreserved PHH.  GS-9620-CM also induced expression of immunoproteasome subunits and enhanced presentation of an immunodominant viral peptide in HBV-infected PHH.  Type I IFN induced by GS-9620 durably suppressed HBV in human hepatocytes without reducing cccDNA levels.  Moreover, HBV antigen presentation was enhanced, suggesting addnl. components of the TLR7-induced immune response played a role in the antiviral response to GS-9620 in animal models of CHB.GS-9620 is a drug currently being tested in clin. trials for the treatment of chronic hepatitis B virus (HBV) infection.  GS-9620 has previously been shown to suppress HBV in various animal models, but the underlying antiviral mechanisms were not completely understood.  In this study, we detd. that GS-9620 does not directly activate antiviral pathways in human liver cells, but can induce prolonged suppression of HBV via induction of an antiviral cytokine called interferon.  However, interferon did not destroy the HBV genome, suggesting that other parts of the immune response (e.g. activation of immune cells that kill infected cells) also play an important role in the antiviral response to GS-9620.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVwmNAOC2M67Vg90H21EOLACvtfcHk0ljYeh1pHtQ45A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVent7g%253D&md5=e1a6a4ca710eb312e36f9d84e7f0f29d</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2017.12.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2017.12.007%26sid%3Dliteratum%253Aachs%26aulast%3DNiu%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DDaffis%26aufirst%3DS.%26aulast%3DLucifora%26aufirst%3DJ.%26aulast%3DBonnin%26aufirst%3DM.%26aulast%3DMaadadi%26aufirst%3DS.%26aulast%3DSalas%26aufirst%3DE.%26aulast%3DChu%26aufirst%3DR.%26aulast%3DRamos%26aufirst%3DH.%26aulast%3DLivingston%26aufirst%3DC.%2BM.%26aulast%3DBeran%26aufirst%3DR.%2BK.%26aulast%3DGarg%26aufirst%3DA.%2BV.%26aulast%3DBalsitis%26aufirst%3DS.%26aulast%3DDurantel%26aufirst%3DD.%26aulast%3DZoulim%26aufirst%3DF.%26aulast%3DDelaney%26aufirst%3DW.%2BE.%26aulast%3DFletcher%26aufirst%3DS.%2BP.%26atitle%3DToll-like%2520Receptor%25207%2520Agonist%2520GS-9620%2520Induces%2520Prolonged%2520Inhibition%2520of%2520HBV%2520Via%2520a%2520Type%2520I%2520Interferon-Dependent%2520Mechanism%26jtitle%3DJ.%2520Hepatol.%26date%3D2018%26volume%3D68%26spage%3D922%26epage%3D931%26doi%3D10.1016%2Fj.jhep.2017.12.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3W3M" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3W3M','PDB','3W3M'); return false;">PDB: 3W3M</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6WML" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6WML','PDB','6WML'); return false;">PDB: 6WML</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i49"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00100">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_53721"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c00100?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00100</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Pharmacokinetic methods, cell-based assays, preparation of amines, molecular modeling/single crystal x-ray diffraction methods, appendix of final compound HPLC and NMR spectra (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00100/suppl_file/jm0c00100_si_002.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00100/suppl_file/jm0c00100_si_001.csv">CSV</a>)</p></li><li><p class="inline">TLR8 <b>6a</b> model (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00100/suppl_file/jm0c00100_si_003.pdb">PDB</a>)</p></li><li><p class="inline">TLR8 (<i>R</i>)-<b>6d</b> model (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00100/suppl_file/jm0c00100_si_004.pdb">PDB</a>)</p></li><li><p class="inline">TLR8 (<i>R</i>)-<b>6d</b> no H<sub>2</sub>O model (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00100/suppl_file/jm0c00100_si_005.pdb">PDB</a>)</p></li><li><p class="inline">TLR8 (<i>S</i>)-<b>6d</b> model (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00100/suppl_file/jm0c00100_si_006.pdb">PDB</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00100/suppl_file/jm0c00100_si_001.csv">jm0c00100_si_001.csv (3.41 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00100/suppl_file/jm0c00100_si_002.pdf">jm0c00100_si_002.pdf (1.9 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00100/suppl_file/jm0c00100_si_003.pdb">jm0c00100_si_003.pdb (1.98 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00100/suppl_file/jm0c00100_si_004.pdb">jm0c00100_si_004.pdb (1.99 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00100/suppl_file/jm0c00100_si_005.pdb">jm0c00100_si_005.pdb (1.98 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00100/suppl_file/jm0c00100_si_006.pdb">jm0c00100_si_006.pdb (1.99 MB)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">The PDB code for the TLR8 X-ray structure of (<i>R</i>)-<b>7</b> is <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6WML">6WML</a>. Authors will release the atomic coordinates upon article publication. Homology models: PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3W3M">3W3M</a> structure was used for the models of <b>6a</b>, (<i>R</i>)-<b>6d</b>, and (<i>S</i>)-<b>6d</b>.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c00100%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-18%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c00100" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799927f6ca62332","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
